An investigation into the influence of substituents and extended π-conjugation on the substitution reactions of bifunctional platinum (II) complexes. by Khusi, Bongumusa Bucus.
 
An investigation into the influence of 
substituents and extended π-conjugation on 






Bongumusa Bucus Khusi 
BSc. (Hons.) (UKZN) 
 
A thesis submitted in the fulfillment of the academic requirements for the 
degree of  
Master of Science 




School of Chemistry and Physics 





I, Bongumusa Bucus Khusi declare that this thesis reports on research results of my 
own work carried out in the School of Chemistry and Physics, University of KwaZulu-
Natal, Pietermaritzburg campus. Where use of work of others has been made, it is duly 
accredited through reference citation.  This thesis has not been submitted for the award 
of a qualification award at any University.     
 
……………………… 
B.B. Khusi        
We, hereby certify that this statement is correct, and as the supervisors of the candidate, 
we have approved the submission of this thesis. 
 
……………………… 





































You never know how strong you are, until being strong is 






















First and foremost, I would like to deeply thank my supervisors, Dr. A. Mambanda and 
Prof. D. Jaganyi for their guidance and help throughout this MSc work. Special thanks 
to Dr. A. Mambanda for the discussions on Pt(II) complexes which were synthesized 
and kinetically studied in this work, his trust in me on the execution of this project and 
allowing me to work independently. I thank him for fruitful discussions, helpful 
comments and unreserved advice on the write-up and arrangement of this thesis.   
I also wish to express my sincere gratitude to: 
o My parents, Mrs. N.V. Khusi and Mr. B.R. Khusi and my dear sisters, Zibuyile, 
Sethembile, Ntandokazi and Mandisa Khusi, for their love and motivation.  
o Thandeka A. Tshabalala for her assistance and encouragement. 
o All the members of the kinetic research group, Meshack Sitati, Asman Panyako 
and Mthandi Mthiyane.  
o All technical staff in the school of chemistry and physics for their support. With 
special thanks to Mr. Craig Grimmer for his help with the NMR analysis and 
Mrs. Caryl Rensburg for her assistance with MS and elemental analysis. 









Conference and publication contributions 
Publication 
Bongumusa B. Khusi, Allen Mambanda and Deogratius Jaganyi, The role of substituents 
in a bidentate N,N-chelating ligand on the substitution of aqua ligands from mononuclear Pt(II) 
complexes. 
This work has been accepted to Transition Metal Chemistry. 
Manuscript ID: TMCH-D-15-00429 
 
Bongumusa B. Khusi, Allen Mambanda and Deogratius Jaganyi, The role of substituents 
and extended π-conjugation in a bidentate N,N-chelate on the substitution kinetics of aqua 
ligands from platinum(II) complexes. 
This work is on its final stage of preparation for publication. 
 
Poster presentation 
SACI postgraduate colloquium 2014, University of KwaZulu-Natal, Pietermatzburg 
campus, entitled: Kinetic and Thermodynamic Studies on Stepwise Substitution of Aqua 









List of Abbreviations 
Å    Angstrøm  
T    temperature 
K    Kelvin 
kJ    kilojoule 
g    gram 
L    liter 
mL    milliliter 
M    molar, mol/L 
R    gas constant, 8.3145 J K-1 mol-1 
h    Planck constant, 6.6261 x 10-34 J s 
kB    Boltzmann constant, 1.3807 x 10-23 J K-1 
ΔH≠               activation enthalpy 
ΔS≠   activation entropy 
ΔV≠   activation volume 
I    ionic strength 
DFT    density functional theory 
DNA   deoxyribose nucleic acid 
NMR    nuclear magnetic resonance 
s, d, t, m (NMR)  singlet, doublet, triplet, multiplet 
δ    chemical shift 
ppm (NMR)   parts per million 
MS    mass spectrometry 
UV/vis   ultraviolet–visible 
λ    wavelength 
HOMO  highest occupied molecular orbital 
LUMO  lowest unoccupied molecular orbital 
NBO   natural bond orbital 
viii 
 
List of Figures and Schemes 
Figure 1.1 Selected metal-based therapeutics and diagnostics that are used 
in the medical field. Cisplatin (a), sodium nitroprusside (b), 
auranofin (c) and cardiolite (d). 
1 
Figure 1.2 Schematic representation of the stages of cellular activation of 
cisplatin and possible biological consequences.  
6 
Figure 1.3 Different adducts formed from the interaction of cisplatin with 
DNA. 
7 
Figure 1.4 Second- and third-generation of anticancer drugs that have been 
approved for clinical use. Carboplatin (a), nedaplatin (b), 
heptaplatin (c), laboplatin (d) and  oxaliplatin (e). 
10 
Figure 1.5 Mononuclear platinum(II) complexes with a trans geometry (a-e) 
and octahedral Pt(IV) complexes (f-g) that display anticancer 
activity.  
12 
Figure 1.6 Selected multinuclear platinum complexes that have promising 
anticancer agents.  
14 
Figure 1.7 Antitumour Ru(III) agents,  KP1019 (a) and NAMI-A (b)  with 
promising cytostatic properties.  
16 
Figure 1.8 Structures of pyrazole derivatives of cisplatin evaluated for 
anticancer activity.  
18 
Figure 1.9 Formulae of biologically active complexes evaluated against 
Hela cancer cell line. These compounds hold promise for 
anticancer treatment. 
19 
Figure 1.10 Platinum(II) terpy complexes studied by Jaganyi and co-
workers.  
21 
Figure 1.11 Structures of bifunctional Pt(II) complexes with N,N-bidentate 
chelate and the nucleophiles used for kinetic investigations. The 
counter anions of the complexes are omitted for simplicity. 
24 
Figure 2.1 A representation of the direct attack by the entering ligand at the 
square planar Pt(II) centre below or above the plane. The 
nucleophile (Y) coordinates to give the trigonal bipyramidal 
intermediate species which loses the leaving group (X) with the 
retention of the stereochemistry. 
33 
Figure 2.2 The reaction-energy profile for the associative (A), associative 





Scheme 2.1 Synthesis of the cis and trans isomers of [Pt(NH3)2Cl2]. 43 
Scheme 2.2 Synthesis of the cis and trans isomers of [Pt(NH3)(NO2)Cl2]−. 44 
Figure 2.3 Charge distribution and induced dipoles in the T−Pt−X 
coordinate.   
44 
Figure 2.4 The trigonal bipyramidal geometry of the transition state and 
the π-back-bonding of the trans ligand. 
45 
Figure 2.5 Molecular orbital diagram of [PtCl4]
2−. 47 
Figure 2.6 Trigonal bipyramidal transition state of the cis and trans isomers. 50 
Figure 3.1 Schematic presentation of the fundamental approach in kinetic 
and mechanistic studies. 
54 
Figure 3.2 Schematic representation of a UV/Visible spectrophotometer. 66 
Figure 3.3 Schematic representation of a stopped-flow spectrophotometric 
technique. 
69 
Figure 4.1 Chemical structures of the bifunctional Pt(II) complexes. The 
perchlorate (ClO4
−) counter ions are omitted for clarity. 
74 
Scheme 4.1 Synthesis of the (pyrazolylmethyl)pyridine ligands. 75 
Figure 4.2 UV/visible spectra for the titration of 0.06 mM Pt(dCH3Py) with 
NaOH in the pH range 2-10 at T = 298.15 K. Insert:  Boltzmann 
fit of the pH data at 305 nm. 
81 
Scheme 4.2 Proposed stepwise deprotonation of the diaqua Pt(II) complexes.  
 
82 
Figure 4.3 DFT-calculated HOMO and LUMO frontier molecular orbitals of 
Pt(II) complexes. 
86 
Figure 4.4 The effect of substituents on the pyrazole ring in the energies of 
HOMO and LUMO orbitals and the resultant LUMO-HOMO 
energy gap. 
86 
Scheme 4.3 The proposed stepwise substitution of aqua ligands from 
bifunctional Pt(II) complexes by thiourea nucleophiles.        
87 
Figure 4.5 typical kinetic trace for the first substitution step in a two-step 
reaction between Pt(dCF3Py) (0.133 mM) and TU (5.32mM) 
recorded at 310 nm, T = 298 K, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4) on the stopped-flow spectrophotometer. 
88 
Figure 4.6 Pseudo-first-order rate constants, kobs1 and kobs2, plotted as a 
function of thiourea nucleophile concentration for the 
substitution of the first (a) and second (b) aqua ligand from 





Figure 4.7 Plots of ln⁡(𝑘2⁡/𝑇) versus (1/𝑇) for the substitution of the first (a) 
and second (b) aqua ligand from Pt(dCH3Py) by thiourea 
nucleophiles at varying temperatures. 
91 
Figure 4.8 1H NMR spectral arrays acquired during the reaction of 
[Pt(H2Py)Cl2] and 2 equiv. of TU in DMSO-d6 at 303 K. 
93 
Scheme 4.4 Numbering scheme employed for the protons in [Pt(H2Py)Cl2]. 93 
Figure 4.9 195Pt NMR spectra acquired during the reaction of [Pt(H2Py)Cl2] 
and 2 equiv. of TU in DMSO-d6 at 303 K. Insert: 195Pt NMR 
spectrum of [Pt(H2Py)Cl2] before the reaction.   
95 
Figure SI 4.1a 1H NMR spectrum of 2-(pyrazol-1-ylmethyl)pyridine (H2Py) in 
CDCl3.  
108 
Figure SI 4.1b 13C NMR spectrum of 2-(pyrazol-1-ylmethyl)pyridine (H2Py) in 
CDCl3 
108 
Figure SI 4.1c Low resolution ESI+ mass spectrum of 2-(pyrazol-1-ylmethyl)- 
Pyridine (H2Py).  
109 
Figure SI 4.2a 1H NMR spectrum of [Pt{2-(3,5-dimethylpyrazol-1-ylmethyl)- 
Pyridine}Cl2], [Pt(dCH3Py)Cl2], in DMSO-d6. 
109 
Figure SI 4.2b 13C NMR spectrum of [Pt{2-(3,5-dimethylpyrazol-1-ylmethyl)- 
Pyridine}Cl2], [Pt(dCH3Py)Cl2], in DMSO-d6. 
110 
Figure SI 4.2c 195Pt  NMR spectrum of [Pt{2-(3,5-dimethylpyrazol-1-ylmethyl)- 
Pyridine}Cl2], [Pt(dCH3Py)Cl2], in DMSO-d6. 
110 
Figure SI 4.3 UV/Visible spectra for the titration of 0.054 mM Pt(dCF3Py) 
with NaOH in the pH range 2-10 at T = 298.15 K. Inset: 
Absorbance versus pH plot at 295 nm for Pt(dCF3Py) complex. 
111 
Figure SI 4.4 Concentration dependence of plots of kobs1, s-1, for the 
displacementof the first aqua ligand of Pt(H2Py) (a) and 
Pt(dCH3Py) (b) by thiourea nucleophiles, pH = 2.0, T = 298 K, 
and I = 0.1 M (HClO4/NaClO4). 
115 
Figure SI 4.5 Erying plots for the substitution of the first aqua ligand of 
Pt(H2Py) (a) and Pt(dCF3Py) (b) by thiourea nucleophiles, pH = 
2.0, and I = 0.1 M (HClO4/NaClO4). 
115 
Figure SI 4.6 1H NMR spectrum of [Pt{2-[(3,5-bis(trifluoromethyl)pyrazoly-1-
ylmethyl]pyridine}Cl2], [Pt(dCF3Py)Cl2] in DMSO-d6. 
116 
Figure SI 4.7 13C NMR spectrum of [Pt{2-[(3,5-bis(trifluoromethyl)pyrazoly-1-
ylmethyl]pyridine}Cl2], [Pt(dCF3Py)Cl2] in DMSO-d6. 
116 
Figure 5.1 Chemical structures of the bifunctional Pt(II) complexes. 




Scheme 5.1 Proposed stepwise deprotonation for the pH dependence of 
mononuclear bifunctional Pt(II) system of complexes with 
different donors. 
126 
Figure 5.2 UV/Visible spectra for the titration of 0.050 mM Pt(dCF3Qn) 
with NaOH in the pH range 2-9 at T = 298.15 K. Insert: 
Boltzmann fit of Absorbance vs. pH at 275 nm for Pt(dCF3Qn) 
complex. 
127 
Figure 5.3 DFT-calculated HOMO and LUMO frontier molecular orbitals of 
Pt(II) complexes. 
130 
Scheme 5.2 The proposed stepwise substitution of diaqua ligand from 
bifunctional Pt(II) complexes by thiourea nucleophiles.        
131 
Figure 5.4 A typical kinetic trace for the first substitution step in a two-step 
reaction between Pt(dCH3Qn) (0.15 mM) and TU (6.0 mM) 
recorded at 290 nm, T = 298 K, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4) on the stopped-flow spectrophotometer. 
132 
Figure 5.5 UV/visible spectra recorded during a two-step reaction of 0.22 
mM Pt(H2Quin) and 4.4 mM TU recorded at pH = 2, T = 298 K 
and I = 0.1 M (HClO4/ NaClO4). Insert: kinetic trace for the 
substitution of the second aqua ligand recorded at 293 nm. 
133 
Figure 5.6 Pseudo-first-order rate constants, 𝑘obs⁡1/2, plotted as a function of 
nucleophile concentration for the substitution of the first (a) and 
second (b) labile aqua ligand from Pt(dCF3Qn) at pH = 2.0, T = 
298 K and I = 0.1 M (HClO4/ NaClO4). 
135 
Figure 5.7 Plots of ln(k2/T) versus (1/T) for the substitution of the first (a) 
and second (b) labile aqua ligand from Pt(dCF3Qn) by thiourea 
nucleophiles at varying temperatures. 
136 
Figure SI 5.1a 1H NMR spectrum of 2-(pyrazol-1-ylmethyl)quinoline (H2Qn) in 
CDCl3 
148 
Figure SI 5.1b 13C NMR spectrum of 2-[3,5-bis(trifluoromethyl)pyrazol-1-
ylmethyl]quinoline, dCF3Qn in CDCl3.  
148 
Figure SI 5.1c Low resolution ESI+ mass spectrum of 2-(pyrazol-1-
ylmethyl)quinoline (H2Qn).  
149 
Figure SI 5.1d 1H NMR spectrum of [Pt{2-[(3,5-bis(trifluoromethyl)-pyrazol-1-
ylmethyl]quinoline}Cl2], [Pt(dCF3Qn)Cl2] in DMSO-d6.  
149 
Figure SI 5.1e 13C NMR spectrum [Pt{2-[(3,5-bis(trifluoromethyl)-pyrazol-1-
ylmethyl]quinoline}Cl2], [Pt(dCF3Qn)Cl2] in DMSO-d6.  
150 
Figure SI 5.1f 1H NMR spectrum of [Pt{2-[(3,5-bis(trifluoromethyl)pyrazoly-1- 150 
xii 
 
ylmethyl]quinoline}Cl2], [Pt(dCF3Qn)Cl2] in DMSO-d6 
Figure SI 5.1g 1H NMR spectrum of [Pt{(2-pyrazoly-1-ylmethyl)quinoline}Cl2], 
[Pt(H2Qn)Cl2] in DMSO-d6. 
151 
Figure SI 5.2 UV/visible scan for a trial run of the reaction between Pt(H2Qn) 
(written as PtL3) and 60-fold DMTU at different times. 
151 
Figure SI 5.3 UV/Visible spectra for the titration of 0.054 mM Pt(dCH3Qn) 
with NaOH in the pH range 2-10 at T = 298.15 K. Insert: 
Absorbance versus pH plot at 295 nm for Pt(dCF3Qn) complex. 
152 
Figure SI 5.4 Concentration dependence plots of kobs1, s-1, for the displacement 
of the first aqua ligand of Pt(H2Qn) (a) and Pt(dCH3Qn) (b) by 
thiourea nucleophiles, pH = 2.0, T = 298 K, and I = 0.1 M 
(HClO4/NaClO4). 
157 
Figure SI 5.5 Erying plot for the substitution of the first aqua ligand of 
Pt(H2Qn) (a) and Pt(dCH3Qn) (b) by thiourea nucleophiles, pH 












List of Tables 
Table 2.1 The effect of different leaving groups on the rate of substitution of 
X in [Pt(dien)X]+ complexes at 25°C. 
38 
Table 2.2 Solvent effect on chloride substitution (Equation 2.5) at 25 °C. 40 
Table 2.3 cis/trans steric effects on the rate of chloride ligand substitution by 
pyridine in [Pt(PEt3)2(L)Cl]. 
49 
Table 4.1 Summary of pKa data for the deprotonation of Pt-bound aqua 
ligands in the bifunctional Pt(II) complexes. 
84 
Table 4.2 DFT-calculated data for the bifunctional Pt(II) complexes. 87 
Table 4.3 Summary of the second-order rate constants for the stepwise 
substitution of the aqua ligands by thiourea nucleophiles from 
diaqua Pt(II) complexes. 
92 
Table 4.4 Summary of the activation parameters for the stepwise 
substitution of aqua ligands from the diaqua Pt(II) complexes. 
94 
Table SI 4.1a  Summary of wavelengths (nm) used for monitoring the first 
substitution reactions between a series of bifunctional Pt(II) 
complexes and thiourea nucleophiles. 
107 
Table SI 4.1b Summary of wavelengths (nm) used for monitoring the second 
substitution reactions between a series of bifunctional Pt(II) 
complexes and thiourea nucleophiles. 
107 
Table SI 4.2a. Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(H2Py) by thiourea nucleophiles, pH = 2.0, T 
= 298 K, I = 0.1 M (HClO4/NaClO4). 
111 
Table SI 4.2b Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCH3Py) by thiourea nucleophiles, pH = 
2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
111 
Table SI 4.2c Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, 
T = 298 K, I = 0.1 M (HClO4/NaClO4). 
112 
Table SI 4.2d Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(H2Py) by thiourea nucleophiles, pH = 
2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
112 
Table SI 4.2e Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCH3Py) by thiourea nucleophiles, pH = 




Table SI 4.2f Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCF3Py) by thiourea nucleophiles, pH = 
2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
112 
Table SI 4.3a Temperature dependence of the second-order rate constants, 
𝑘2⁡(1𝑠𝑡), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(H2Py) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4).   
113 
Table SI 4.3b Temperature dependence of the second-order rate constants, 
𝑘2⁡(1𝑠𝑡), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(dCH3Py) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
113 
Table SI 4.3c Temperature dependence of the second-order rate constants, 
𝑘2⁡(1𝑠𝑡), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
113 
Table SI 4.3d Temperature dependence of the second-order rate constants, 
𝑘2⁡(2𝑛𝑑), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(H2Py) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
114 
Table SI 4.3e Temperature dependence of the second-order rate constants, 
𝑘2⁡(2𝑛𝑑), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(dCH3Py) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
114 
Table SI 4.3f Temperature dependence of the second-order rate constants, 
𝑘2⁡(2𝑛𝑑), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
114 
Table 5.1 Summary of pKa values for the deprotonation of Pt-bound aqua 
ligands in bifunctional Pt(II) complexes studied. 
127 
Table 5.2 DFT-calculated data for bifunctional Pt(II) complexes. 129 
Table 5.3 Summary of the second-order rate constants for the stepwise 
substitution of labile aqua ligands by thiourea nucleophiles in 
diaqua Pt(II) complexes. 
134 
Table 5.4 Summary of the activation parameters for the stepwise 
substitution of labile aqua ligands from the diaqua Pt(II) 
complexes. 
137 
Table SI 5.1 Summary of wavelength (nm) used for monitoring the first 147 
xv 
 
substitution reactions between a series of bifunctional Pt(II) 
complexes and thiourea nucleophiles. 
Table SI 5.1b Summary of wavelength (nm) used for monitoring the second 
substitution reactions between a series of bifunctional Pt(II) 
complexes and thiourea nucleophiles 
147 
Table SI 5.2a Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(H2Qn) by thiourea nucleophiles, pH = 2.0, 
T = 298 K, I = 0.1 M (HClO4/NaClO4). 
152 
Table SI 5.2b Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCH3Qn) by thiourea nucleophiles, pH = 
2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
152 
Table SI 5.2c Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCF3Qn) by thiourea nucleophiles, pH = 
2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
153 
Table SI 5.2d Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, 
T = 298 K, I = 0.1 M (HClO4/NaClO4). 
153 
Table SI 5.2e. Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(H2Qn) by thiourea nucleophiles, pH = 
2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
153 
Table SI 5.2f Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCH3Qn) by thiourea nucleophiles, pH 
= 2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
153 
Table SI 5.2g Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCF3Qn) by thiourea nucleophiles, pH = 
2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
154 
Table SI 5.2h Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCF3Py) by thiourea nucleophiles, pH = 
2.0, T = 298 K, I = 0.1 M (HClO4/NaClO4). 
154 
Table SI 5.3a Temperature dependence of the second-order rate constants, 
𝑘2⁡(1𝑠𝑡), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(H2Qn) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
154 
Table SI 5.3b Temperature dependence of the second-order rate constants, 
𝑘2⁡(1𝑠𝑡), M
−1⁡s−1 for the displacement of the first aqua ligand in 





Table SI 5.3c Temperature dependence of the second-order rate constants, 
𝑘2⁡(1𝑠𝑡), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(dCF3Qn) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
155 
Table SI 5.3d Temperature dependence of the second-order rate constants, 
𝑘2⁡(1𝑠𝑡), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
155 
Table SI 5.3e Temperature dependence of the second-order rate constants, 
𝑘2⁡(2𝑛𝑑), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(H2Qn) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
155 
Table SI 5.3f Temperature dependence of the second-order rate constants, 
𝑘2⁡(2𝑛𝑑), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(dCH3Qn) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
156 
Table SI 5.3g Temperature dependence of the second-order rate constants, 
𝑘2⁡(2𝑛𝑑), M
−1⁡s−1 for the displacement of the first aqua ligand in 
Pt(dCF3Qn) by thiourea nucleophiles, pH = 2.0, I = 0.1 M 
(HClO4/NaClO4). 
156 
Table SI 5.3h Temperature dependence of the second-order rate constants, 
𝑘2⁡(2𝑛𝑑), M
−1⁡s−1 for the displacement of the first aqua ligand in 










Table of Contents 
Chapter 1: The use of platinum and ruthenium complexes as anticancer 
therapeutic agents  
 
1 
1.0 Metal complexes as potential therapeutics 1 
1.1 Cancer and its treatment 2 
1.2 Prospects of platinum and ruthenium complexes in cancer chemotherapy  3 
1.2.1 The first generation of platinum anticancer drugs 3 
1.2.2 Biochemical mechanism of action and resistance of cisplatin 
1.2.2.1 The mechanism of action of cisplatin 




1.2.3 General considerations for the development of new platinum         
anticancer drugs 
8 
1.2.4 The development of second and third generations of ciplatin. 
1.2.5 New approaches in platinum drug development 




1.3 Platinum(IV) complexes as prodrugs 
1.4 Development of polynuclear platinum complexes as anticancer agents  
1.5 The anticancer activity of other metal complexes   
1.6 Platinum(II) complexes with pyrazole-based ligands 
1.6.1 Medical potential of pyrazole-based Pt(II) complexes  
1.6.2 Cytotoxic studies of (pyrazolylmethyl)pyridine Pt(II) 
complexes 
1.7 Mechanistic studies of Pt(II) complexes 
1.7.1 The effect of substituents of a polydentate ligand on the rate of 
substitution  
1.7.2 The role of an extended π-conjugation in the ligand core on 
the rate of substitution 
1.8 Role of  kinetic data in the development of drugs 
1.9 Aims and objectives of the research 
1.9.1 Pt(II) complexes with flexible (pyrazolylmethyl)pyridine and 

























Chapter 2: Theoretical aspects on the substitution reactions in 
inorganic compounds focusing on platinum (II) complexes 
 
31 
 2.0 Introduction 
 2.1 Classification of Inorganic reaction mechanisms 
                  2.1.1 Dissociative mechanism (D-mechanism) 
                  2.1.2 Associative mechanism (A-mechanism)   






2.2 Influence of the coordinated ligands around the metal centre on the 
mechanism of substitution 
2.3 Ligand-exchange reactions at square-planar Pt(II) metal centre 
2.4 Factors affecting the reactivity of square planar Pt(II) complexes 
                  2.4.1 Effect of the leaving group 
                  2.4.2 Effect of the entering ligand 
                  2.4.3 Effect of the solvent 
                  2.4.4 Effect of the non-leaving ligand 
                             2.4.4.1 The trans-effect 
                             2.4.4.2 The electrostatic polarization theory 
                             2.4.4.3 The π-bonding theory 
                             2.4.4.4 The molecular orbital theory 
























3.2 The rate law 
3.3 Integrated rate laws 
                 3.3.1 First-order reactions     
                             3.3.1.1 Irreversible first-order reactions  
                             3.3.1.2 Reversible first-order reactions 
                  3.3.2 second-order reactions 
3.4 Measurements of activation parameters 
3.5 Measurement of the activation volume 













                  3.6.1 UV/visible spectrophotometric technique     






Chapter 4: The role of substituents in a bidentate N,N-chelate on the 






               4.2.1 Chemicals 
               4.2.2 Synthesis of the ligands 
               4.2.3 Synthesis of Pt(II) complexes 
               4.2.4 Preparation of diaqua Pt(II) complexes 
               4.2.5 Instrumentation and physical measurements    
               4.2.6 Measurements of pKa values of the diaqua Pt(II) complexes 
               4.2.7 Kinetic measurements 
               4.2.8 Computational calculations 
4.3 Results  
               4.3.1 Acid-base equilibrium of diaqua Pt(II) complexes  
               4.3.2 DFT-calculated optimised structures 
               4.3.3 Ligand substitution kinetics of the diaqua Pt(II) complexes  
               4.3.4 Activation parameters 
4.4 NMR studies 
4.5 Discussion 
               4.5.1 First substitution step 
               4.5.2 Second substitution step 
               4.5.3 Activation parameters and reactivity of the nucleophiles 
4.6 Conclusion 
4.7 References   



























Chapter 5: The influence of substituents and extended π-conjugation 
in bidentate N,N-chelate on the substitution kinetics of aqua ligands 











               5.2.1 Chemicals and reagents 
               5.2.2 Preparation of the ligands 
               5.2.3 Synthesis of the platinum complexes 
               5.2.4 Preparation of diaqua Pt(II) complex and nucleophile solutions 
               5.2.5 Instrumentation and physical measurements    
               5.2.6 Kinetic measurements 
               5.2.7 Computational details 
5.3 Results  
               5.3.1 Acidity of diaqua Pt(II) complexes 
               5.3.3   Kinetics of the substitution reactions with thiourea nucleophiles  
5.4 Discussion 
                5.4.1 Acid-base equilibrium of diaqua Pt(II) complexes  
                5.4.2 DFT calculated optimised structures 
                5.4.3 Kinetic studies 
                           5.4.3.1 First substitution 
                           5.4.3.2 Second substitution 
                5.4.4 Activation parameters and reactivity of the nucleophiles 
5.5 Conclusion 
5.6 References 


































The substitution rates of aqua ligands from bifunctional Pt(II) complexes were studied 
using biologically relevant thiourea nucleophiles viz., thiourea (TU), N,N-
dimethylthiourea (DMTU) and N,N,N’,N’-tetramethylthiourea (TMTU). The reactions 
were studied in aqueous acidic media (pH 2) under pseudo first-order conditions as a 
function of nucleophile concentration and temperature, using conventional stopped-
flow and UV/Visible spectrophotometric techniques.  
Three of the Pt(II) complexes had a flexible (pyrazolylmethyl)pyridine core, differing on 
the 3,5-substituents (−H, −CH3, −CF3) on the pyrazole ring. The other three complexes 
were structurally similar to the first but had a (pyrazolylmethyl)quinoline as the non-
leaving ligand. Through a comparative approach, the two sets of Pt(II) complexes were 
designed to quantify the effect on the rate of substitution at the square-planar geometry 
when the substituents (electronic and steric properties) of the coordinated pyrazole ring 
are changed or when the strong π-acceptor pyridine ring  is replaced with quinoline in 
the (pyrazolylmethyl)quinoline bidentate core.  
The 3,5-substituents on the pyrazole ring as well as the replacement of a pyridine with a 
quinoline ring in the N,N-bidentate chelate both affected the electrophilicity of the Pt(II) 
centre. This in turn controlled the lability of the coordinated aqua ligands and hence the 
reactivity of the complexes. The inductive electron-donating groups (−CH3) on the 
pyrazole ring decreased the rate of substitution, whereas the inductive electron-
withdrawing groups ( −CF3)  increased the rate of substitution. This is supported by the 
order of reactivity of Pt(dCF3Py) > Pt(H2Py)⁡> Pt(dCH3Py) for the substitution of the 
aqua ligand trans to the pyrazole ring in the first series of the complexes. On the other 
hand, the lability of the aqua ligand cis to the pyrazole ring followed the order: Pt(H2Py) 
≈⁡Pt(dCF3Py) > Pt(dCH3Py). This indicates that 3-substituent on the pyrazole ring 
causes a steric retardation on the lability of the aqua ligand in a cis position. In the 
second series of complexes, the complete order of reactivity for the first substitution 
was found to be Pt(dCF3Py) > Pt(H2Qn)⁡> Pt(dCF3Qn) > Pt(dCH3Qn) and indicates an 
xxii 
 
interplay between steric and electronic effects, with the dominant factor controlling the 
rate. However, the reactivity trend for the substitution of the second aqua did not 
follow that of the first, and pointed out a steric retardation to the approach of the 
second incoming nucleophile due to the cis-positioned 3-substituent { either ( −CH3)  or 
( −CF3)}  on the pyrazole ring. 
Further, the reactivity trends confirms that the quinoline substructure in the 
(pyrazolylmethyl)quinoline ligands acts as an apparent donor of electron density 
towards the metal centre rather than being a π-acceptor. This is contrary to what would 
be expected given its stabilized extended molecular orbitals, which should delocalise 
electron better than those of pyridine. The DFT and pKa data both support the 
experimentally obtained kinetic data. The mechanism of substitution remains 
ass ociative throughout.               
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Chapter 1 
The use of platinum and ruthenium complexes as anticancer 
therapeutic agents  
1.0 Metal complexes as potential therapeutics 
The roles of metal ions in biological systems have stimulated the development of 
metal-based therapeutics. In particular coordination compounds of transition metals 
are important due to their enzymatic, homeostasis and transporting functions (e.g. 
oxygen transportation in the blood system by heme complexes which has four Fe2+ 
ions). The biochemical reactions of some inorganic compounds have long been 
known to treat certain diseases. For example complexes of platinum(II) are used for 
treating cancer, while gold(I) and iron(III) compounds are used  to treat arthritis and 
cardiovascular diseases, respectively.1,2 Furthermore, some coordination compounds 
have been used in biological systems as clinical diagnostics. Examples include 
radioactive technetium (99mTc) tracers and complexes carrying fluorescent groups.1,2 
Some selected metal complexes that are currently used in clinical treatment and 






Figure 1.1: Selected metal-based therapeutic and diagnostic agents that are used in 
the medical field.2 Cisplatin (a), sodium nitroprusside (b), auranofin (c) and 
cardiolite (d). 
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Knowledge of coordination and redox properties of metal ions also plays an 
important role in the development of modern medicinal inorganic chemistry.2 
Positively charged metal ions have a strong affinity for negatively charged 
biomolecules (e.g. constituents of proteins and nucleic acids) that provide perfect 
ligands for coordinative binding.2 The pharmaceutical and medicinal applications of 
metals have an excellent future potential. As a result, the biological activities of 
numerous metal complexes have been investigated.2,3 It is clear that mechanistic 
understanding of how metal complexes achieve their biological activities is essential 
for the design of new metal-based compounds with high efficiency and wide 
spectrum of activity.  
1.1 Cancer and its treatment 
Cancer can be described as a group of diseases in which one or more cells display 
uncontrolled and accelerated cell growth leading to the formation of tumours.4 The 
majority of cancers are stimulated by the mutation of specific genes.5,6 The mutations 
may cause accelerated cell division or deactivation of important processes that 
control cell division in the cell cycle.6,7,8 Uncontrolled and accelerated cell growth 
may ultimately cause benign or malignant tumour.9 The latter is characterised by 
invasion of neighbouring tissues or other parts of the body. This creates a life-
threatening condition since normal cells in the neighbourhood of the tumours are 
transformed to cancerous cells.10 
Cancer can be treated by surgery, chemotherapy, radiotherapy, photodynamic 
therapy and biochemical therapies (e.g. immunotherapy and gene therapy). The 
treatment of localised solid tumours may primarily involve surgical removal of the 
tumour and nearby affected tissues. Modern clinical procedures generally combine 
several types of treatment (e.g. surgery and chemotherapy) for better effects. What 
makes cancer more complex is that each type of cancer has its own specific 
characteristics which are different from other types of cancers e.g. lung cancer is 
biologically different from colon cancer. As a result, there is no single treatment for 
cancer; the combination of clinical protocols used is based on the biological 
properties of a particular type of cancer. Radiation treatment and chemotherapy are 
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more effective against small tumours and leukaemia although treatment is 
associated with side effects such as hair loss, induced anaemia, as well as nausea and 
vomiting.11  
1.2 Prospects of platinum and ruthenium complexes in cancer 
chemotherapy  
1.2.1 The first generation of platinum anticancer drugs 
The use of inorganic complexes in the treatment of cancer was unknown until the 
discovery of cis-diamminedichloroplatinum(II), commonly known as cisplatin 
(Figure 1.1a). This compound was first synthesized by Michele Pyrone in 1844. 
However its biological activity was serendipitously discovered by Barnett 
Rosenburg in 1969.12 During his study on the effect of the electric field on the growth 
of E.coli bacteria using inert platinum electrodes, he observed that bacteria grew into 
long filaments, an indication that the division and replication of cells had been 
adversely affected by the electric field with no concomitant inhibition of bacterial cell 
growth. It was rationalised that ammonium chloride (NH4Cl) electrolyte had reacted 
with platinum ions from the inert electrode to form soluble platinum complexes. The 
two compounds which were capable of inducing filamentous growth in the absence 
of an electric field are cis-[Pt(NH3)2Cl2] (cisplatin) and cis-[Pt(NH3)2Cl4]. Subsequent 
evaluation of these compounds against the fast growing tumourous cells gave 
positive results leading to cis-Pt(NH3)2Cl2 being registered as an anticancer drug in 
1978.13,14       
Cisplatin is currently the most established and valuable anticancer drug used to treat 
a number of cancers including; ovarian, testicular, skin, lung and blood cancer. 13,14 
In a bid to better understand the mechanism of action of this new drug, its analogues 
were synthesised and forwarded for screening. These studies focussed on 
establishing the empirical relationship between the structure of a compound and its 
antitumour activity. Cleare and Hoeschele15 came up with laid-down rules which 
they termed the structure-activity relationships (SARs) for anticancer activity of 
platinum complexes. They postulated that for a metal complex to have antitumor 
activity: 
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 it should have a cis-geometry and a general structural formula cis-[Pt(N)2X2], 
where N is an N-donor amine ligand and X is a labile leaving group. 
Transplatin, an isomer which has a trans-geometry was observed to be 
inactive against cancer cells propelling them to this conclusion.15    
 its non-leaving ligand should have at least one N-H moiety, which was 
thought to be crucial for hydrogen bonding interactions with DNA. This 
would stabilize the Pt-DNA adducts.16   
 its leaving group, X, should be an anionic ligand of moderate binding 
strength to the platinum metal ion (e.g. Cl- or SO42-). Such ligand would 
exhibit weak trans-effect to avoid labilization of the amine ligands.17 Other 
leaving groups were found to be either highly toxic or inactive.  
 it should be neutral so that it can easily pass through the cell membrane. 
Neutral compounds are found to be more lipophilic than charged species.18 
A large number of new complexes that obeyed the empirical structure-activity rules 
were later synthesized.19 Most of the platinum complexes that have entered clinical 
trials and practice adhere to a set of these empirical SAR rules. Later on, active 
complexes which did not obey the rules were synthesized, notably being the 
complexes of trans-geometry.20 
1.2.2 Biochemical mechanism of action and resistance of cisplatin 
1.2.2.1 The mechanism of action of cisplatin  
A wide range of low-molecular weight compounds of biological importance interact 
with DNA. The biological effect of these compounds may be associated with the 
alterations they cause in DNA and with the recognition of these changes by cellular 
constituents.21,22 These compounds may therefore be used as probes in the studies of 
DNA properties and interactions. Some of these compounds are effective cross-
linking agents that can form DNA-DNA or DNA-protein interactions showing 
remarkable antitumor and antiviral effects.21,22,23 Platinum coordination complexes 
represent one class of such compounds. Several studies on cisplatin unravelled the 
mechanism of Pt(II) compounds and how they kill the cancer cells in the human 
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body. Consequently, it is widely accepted that the main target of cisplatin is the 
genomic DNA.24,25  
Understanding the actual mechanism of cisplatin, and other platinum drugs has 
been essential for the development of improved anticancer drugs. Yet the actual 
mechanism of its biological activity is not fully understood, in spite of the large 
number of research initiatives in the past few decades.26,27 However, considerable 
amount of data on how the drug induces the killing of certain cancers and how 
resistance develops have been reported. Compared to other metal complexes {e.g. 
Pd(II) and Ni(II)}, cisplatin is relatively kinetically inert. The substitution of its labile 
leaving groups follows an associative mechanism in many cases and is characterised 
by two independent reaction pathways i.e. solvent-assisted stepwise hydrolysis and 
direct attack by a nucleophile.17 
The two labile halide ligands are not susceptible to hydrolysis outside the cell due to 
elevated extracellular concentration of chloride ions (104 mM), thus cisplatin 
remains neutral before active uptake unto the cells.17,28 This is important in 
ameliorating toxicity. The neutral platinum compound diffuses across the cell 
membrane through active uptake, where it is gradually activated by a step-wise 
hydrolysis to generate positively charged aqua species, [Pt(NH3)2(H2O)Cl]+and 
[Pt(NH3)(H2O)2]2+.  The first aquation step, for which the rate of DNA binding to 
form platinated-DNA adducts is dependent on, is very rapid due to low 
concentration of chloride (4 mM) inside the cell (Figure 1.2).11,29 Upon hydrolysis, the 
platinum compound binds rapidly to DNA, since the water ligand is a better leaving 
group than the chloride ligand, and the resulting positively charged species are more 
reactive towards biomolecules.11,29     
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Figure 1.2: Schematic representation of the stages of cellular activation of cisplatin 
and possible biological consequences.28  
DNA provides several nucleophilic sites in which the active [Pt(NH3)2(H2O)2]2+ can 
bind especially the nitrogen atoms of nucleobases. This form of complex can bind to 
DNA forming various intrastrand, interstrand and also DNA-proteins cross-links 
(Figure 1.3).28,30 The cytostatic effect of this drug is widely accepted to occur through 
its interaction with the DNA in the nucleus of the cell, generating Pt-N adducts.31,32  
The major adducts produced are the 1,2-intrastrand cross-links between the adjacent 
N-7 atoms of guanine (G) residues.32,33 Other nucleophilic sites of DNA e.g. N-7 
atom of adenine and N-3 atom of cytosine are engaged in hydrogen bonding with 
the DNA framework, making G-N7 the most electron rich site. The binding of 
cisplatin to DNA induces significant distortions on the DNA helical structure and 
results in the inhibition of DNA replication and/or transcription.32,33,34  
Subsequently, this further persuades cell death though apoptosis and/or necrosis 
within the cancerous cells that form a tumoural mass.    
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Alternatively, active platinum complexes may interact with sulfur donors either in 
the blood plasma or inside the cell, since the sulphur atoms have high affinity for 
Pt(II) centres,35 yielding kinetically inert or stable Pt-S adducts.36 The presence of 
sulfur-containing amino acids or proteins may lead to potential deactivation of the 
platinum drug, which affects its pharmacokinetics or biodistribution.24,37 Not only 
does this reduce the required platinated-DNA adducts and active drug 
accumulation, but also leads to toxic side effects.24,37,38 Upon coordination to the 
Pt(II) complex, the trans-influence of the biological sulfur donors, can potentially de-
coordinate the non-leaving amine groups, thereby suppressing the drug’s actual 
mechanism of action that leads to cytotoxicity. This leads to the development of drug 
resistance.24 
 
Figure 1.3: Different adducts formed from the interaction of cisplatin with DNA.39  
1.2.2.2 The mechanism of resistance of cisplatin 
Cisplatin has several drawbacks that restrict its use as an anticancer agent. It is 
applicable to narrow range of tumours and some sensitive ones develop 
resistance.40,41 The resistance can either be intrinsic (i.e. when the tumours do not 
respond naturally to the drug) or acquired ( i.e. when tumours develop resistance to 
a drug which they were previously sensitive to its activity).40,42,43 Drug resistance is 
closely related to the drug’s bio-transformational pathways that compete for the bio-
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availability of the drug to its target, DNA. Cross-resistance may develop between 
two or more drugs that exhibit similar inhibitory profiles.  At least four biochemical 
pathways are thought to be responsible for the underlying mechanism of resistance 
to the cisplatin chemotherapy:44 
a) reduced active transport across the cell membrane.  
b) increased deactivation by plasma proteins in the extracellular bio-domain. 
c) intracellular irreversible binding to inactivating thiolates e.g. glutathione 
(GSH) and/or metallothionein (MT). 
d) enzymatic repair of platinated-DNA lesions (e.g excision repair).  
Approximately 1% of the total intracellular platinum complex binds to DNA. The 
major causes for inadequate drug concentration reaching DNA include; the 
reduction in platinum drug uptake or its intracellular accumulation and increased 
cytoplasmic inactivation by GSH and MT. The resistance mechanisms that occur 
once the drug has bound to DNA include increased enzymatic repair of Pt-DNA 
adducts, and increased tolerance to high levels of DNA damage without 
simultaneously triggering downstream cellular mechanism that lead to programmed 
cell death.45 The clarification of these major biochemical mechanisms of action and 
resistance is critical in the development of new platinum-based drugs with high 
efficiency and capability to evade drug resistance.   
1.2.3 General considerations for the development of new platinum anticancer 
drugs 
In the past few decades, considerable amount of effort has been dedicated to 
establishing factors related to cytotoxicity properties of different platinum drugs. It 
has been shown that the development of new platinum drugs can be achieved by the 
variation of the carrier ligands and/or the leaving group. The carrier ligands are 
known to influence drug uptake, the reactivity of the metal centre and ultimate 
target selection. Lipophilic carrier ligands enhance the drug uptake, since the 
hydrophobic cell membrane is the first barrier that the drug encounters.28 Several 
metal complexes with planar and intercalatory ligands have been shown to possess 
high affinity for DNA.27   
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Therefore, future development of platinum-based drugs should be informed by the 
following points: 
 reactive platinum complexes may quickly bind to other biomolecules other 
than the targeted genomic DNA, causing severe toxic effects. 
 the toxic side effects can be lowered using less labile leaving groups. 
 replacing the non-leaving amine (NH3) ligand may also change the 
anticancer properties of the complexes through the formation of structurally 
different adducts with DNA.  
 stable platinum complexes are less toxic, however, their tumour inhibiting 
properties are also reduced.  
 lipophilic complexes diffuse quickly through the cell membrane and thus 
increase the intracellular drug uptake.  
 
1.2.4 The development of second and third generations of ciplatin.  
The applicability and effectiveness of cisplatin in cancer therapy has been 
thoroughly documented since its entry to clinical trials in the late 1970’s.46 The 
clinical success of cisplatin stimulated development of other new platinum 
complexes. This was necessitated because cisplatin was found to be highly toxic 
especially when administered in high dosage concentration despite its effectiveness 
in a variety of cancers.47 The drug is also shrouded by intrinsic and acquired drug 
resistance.46,47 In addition to these limitations, the use of cisplatin was noted to be 
accompanied by dose-limiting side effects including vomiting, nausea, hair loss and 
anaemia.47 The side effects and systemic toxicities of cisplatin are, in part, associated 
with its poor specificity. 
The limited efficiency and applicability of cisplatin caused a sustained momentum 
for the development of platinum-based anticancer drugs, with a common goal of 
finding new drugs with higher efficacy, lower toxicological profile and broader 
spectrum of anticancer activity. As a result, thousands of platinum complexes were 
synthesized and screened for anticancer activity.48,49,50 However, only a few entered 
clinical trials, and most of these encountered pharmacokinetic difficulties.51,52,53 Some 
examples of second and third generation of cisplatin derivatives that have been 
- 10 - 
 
prepared and approved for clinical use are shown in Figure 1.4. Today, carboplatin 
and oxaliplatin are commonly used anticancer drugs.52,53 The structural 
modifications on the second- and third-generation of cisplatin analogues are based 
on replacing the halide leaving groups or changing the amine ligand, respectively. 
For example, carboplatin (second generation) has the chloride leaving group of 
cisplatin replaced by a less labile (or more kinetically inert) bidentate chelating 
dicarboxylate. This increases the intracellular and tissue distribution of the platinum 
drug due to limited susceptibility to deactivation. Therefore the drug may be 
administered at moderate to high dose concentration with no adverse effects. As a 
result, carboplatin has been widely used as a complementary drug to ciplatin in 
treating cancer.54  
For oxaliplatin (third generation), the non-leaving amine ligands of cisplatin were 
replaced by a bulky diaminocyclohexane. This leads to the formation of stable Pt-
DNA adducts which are believed to circumvent the recognition by repairing cellular 
proteins, thereby sustaining the activity of oxaliplatin in cisplatin resistant tumours. 







Figure 1.4: Second- and third-generation of anticancer drugs that have been 
approved for clinical use.52 Carboplatin (a), nedaplatin (b), heptaplatin (c), laboplatin 
(d) and oxaliplatin (e). 
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1.2.5 New approaches in platinum drug development 
 One of the main challenges in the rational design of metal-based chemotherapeutic 
agents is to enhance their cytotoxic activity while concurrently reducing toxicity.55 
Crucial progress includes the elucidation of drug resistance mechanisms, the 
development of combination therapeutic scheme and novel targeting strategies (e.g. 
nano-delivered drugs) and introduction of new platinum (IV) agents (e.g. satraplatin 
and picoplatin). Based on substantial expertise acquired on metal-based anticancer 
drugs in the past few decades, it is clear that carefully designed metal complexes 
structurally different from cisplatin and its related drugs (2nd and 3rd generation 
analogues) are prone to display an altered spectrum of clinical activity and toxicity, 
due to differences in biochemical mechanism for drug response.54  
1.2.5.1 Active platinum(II) complexes with a trans geometry 
The early structure-activity relationship rules of Cleare and Hoeschele had 
stipulated that trans-diamminedichloroplatinum(II), transplatin and other trans 
platinum complexes lacked antitumour activity.56 However, it was later shown that 
certain types of trans-Pt(II) complexes have antitumor activity comparable to that of 
ciplatin both  in vitro  and in vivo. It is known that the inactivity of transplatin is due 
to its kinetic instability or fast ligand kinetics and subsequent susceptibility to 
deactivation. Therefore new approaches have focused on the development of 
transplatin complexes using bulky ligands to reduce their kinetic reactivity. The 
hindering ligands retard the reactivity, thereby slowing down their inactivation by 
cellular components through ligand exchange reactions. Thus, higher concentration 
levels of the activated complex could reach its target, genomic DNA. The subclasses 
of trans-Pt(II) complexes that have shown significant in vitro antitumour activity 
include; trans-Pt(II) complexes bearing planar heterocyclic ligands such as pyridine, 
quinoline, isoquinoline, benzothiazole and thiazole (Figure 1.5; a-e).56           
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Figure 1.5: Mononuclear platinum(II) complexes with a trans geometry (a-e) and 
octahedral Pt(IV) complexes (f-g) that display anticancer activity.56  
The cytotoxicity of the trans platinum complexes with bulky aromatic non-leaving 
groups were in some cases shown to be superior to cisplatin, and often better than 
the cytotoxicity of their respective cis analogues.56 The trans-geometry complexes are 
characterised by a spectrum of activity different from cisplatin and often overcome 
resistance encountered by cisplatin. This is probably because these complexes 
generate different Pt-DNA adducts compared to cisplatin. 
1.3 Platinum(IV) complexes as prodrugs 
Most recently, kinetically inert Pt(IV) complexes have received much interest.57,58 
The structures of some of these complexes developed for anticancer activity are 
shown in Figure 1.5 f-g. Some of these complexes have lipophilic groups at the axial 
positions which facilitate the intestinal absorption of the drug, therefore making the 
oral administration possible.59 The reduction of Pt(IV) to Pt(II) by extracellular or 
intracellular agents is necessary for the activation of the drug. Therefore these 
compounds are pro-drugs since chemical conversion by metabolic processes is 
required before the pharmacological agent reaches its site of action.  
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One of the most successful Pt(IV) complexes is bis(acetate)-amminedichlorido-
(cyclohexylamine)platinum(IV), also known as satraplatin or JM216 (Figure 1.5 f). 
JM216 showed a great potential in phase I and II clinical stages of development.59 It 
also represents the first platinum drug that was found to be suitable for oral 
administration due to its favourable pharmacokinetic properties. The phase II trial of 
this drug has been completed in hormone-refractory prostate cancer (HRPC), small 
lung cancer and ovarian cancer.60 However, it was abandoned in phase III clinical 
trials due to variability in the drug uptake.58 It has been suggested that the loss of 
lipophilic axial groups as a result of the reduction of the drug from Pt(IV) to Pt(II) in 
the bloodstream, accounts for the disparity in the activity between in vitro and in vivo 
systems.61 JM216 also shows anticancer activity against various murine and human 
subcutaneous tumours comparable to the activity of cisplatin. It has a relatively low 
toxicological profile, being myellosuppression instead of dose-limiting 
nephrotoxicity in cisplatin.60 Its analogous platinum(IV) complex with trans chloro 
labile groups (JM335, Figure 1.5 g) has shown similar and promising cytotoxic 
activity to that of JM216. Upon reduction, JM216 and JM335 form Pt(II) complexes 
with cis- and trans-geometry respectively. The specific activity of these compounds is 
thought to be associated with their ability to produce DNA-interstrand adducts that 
cannot be recognised or repaired by gene-specific repair enzymes.62 
1.4 Development of polynuclear platinum complexes as anticancer agents  
Polynuclear platinum complexes represent a new and distinct class of anticancer 
agents, in terms of their DNA binding features and antitumour activity from their 
mononuclear counterparts, particularly cisplatin. Several polynuclear platinum 
complexes with two or more linked platinum centers have been developed in order 
to improve their DNA binding ability (Figure1. 6).63,64,65 These compounds are 
characterised by innovative DNA interactions, producing additional long-range 
inter- and intra-strand crosslinks (e.g. 1,4-inter-strand and 1,6-inter-strand CLs) 
which are not available in conventional mononuclear platinum complexes. In 
general, polynuclear compounds display high cytotoxicity on both cisplatin sensitive 
and resistant cancer strains. The diversified nature of the DNA cross links of these 
agents is more likely to be responsible for their remarkable cytotoxicity.  
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Figure 1.6: Selected multinuclear platinum complexes that have promising 
anticancer agents.  
A multinuclear platinum complex that has been shown to improve cross-resistance 
to cisplatin is an analogous trinuclear platinum(II) complex,65 BBR3464 (Figure 1.6). 
This complex can bind to DNA with its two terminal monofunctional [trans-
Pt(NH3)2] platinum units. The tetra-amine platinum linker also contributes to DNA 
interactions through electrostatic and H-bonding. BBR3464 represents the first 
polynuclear platinum complex to enter the clinical trials. It has shown good 
cytostatic effects more so in several ciplatin-resistant cancers. The latter compound 
has recently undergone phase II clinical stage of development.63,64,65 The activity of 
BBR3464 and other multinuclear platinum complexes against cisplatin-resistant 
cancer strains may be attributed to a distinctly different mode of binding to DNA. 
The HMG-protein domain that triggers DNA repair enzymes which shield Pt-DNA 
adducts of cisplatin cannot recognise Pt-DNA adducts of BBR3464 and other 
polynuclear platinum complexes.65 Therefore, the resistance mechanism based on 
DNA-damage recognition and DNA repair by enzymes can be excluded. When 
compared to conventional platinum chemotherapeutics, polynuclear compounds 
show an increased cellular uptake and rapid formation of DNA adducts.66 This is 
most likely due to their amphiphilic nature (lipophilic linker and hydrophilic 
platinum-amine terminal) which enhances their membrane permeability compared 
to cisplatin or oxaliplatin.66 As a result, preclinical and clinical tests have shown that 
polynuclear complexes are indeed more active than mononuclear analogues. 
However, their remarkable efficacy was found to be also tainted by acute toxicity as 
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was the problem with several mononuclear counterparts, prohibiting any further 
clinical tests on some of these potential candidate drugs.67  
1.5 The anticancer activity of other metal complexes   
Preclinical and clinical studies have shown that the development of new metal 
complexes with improved biological and pharmacological properties is possible.68 A 
few other metal complexes (including Fe, Co and Au) have been shown to exhibit 
promising cytostatic properties in preclinical studies, while those of Ti, Ru, and Ga 
were even evaluated in phase I and II clinical stage of development.68 Metallocenes 
of Re, Mo, and Ni have also shown promising cytostatic properties in vitro and in 
vivo.68 Although some of these compounds have been tested and proven to display 
anticancer activities, cisplatin and its analogues have by far displayed the best 
chemotherapeutic results.68 
1.5.1 Ruthenium complexes as anticancer agents 
This review will be limited to ruthenium-based anticancer chemotherapy, although a 
wide variety of other non-platinum containing metal complexes has been 
investigated for anticancer activities. Ruthenium(II) and ruthenium(III) exhibit 
relatively slow substitution reactions comparable to those of platinum(II) complexes. 
The slow ligand-exchange rates may prevent the deactivation of the drug, ensuring 
that the drug reaches its target without being modified. Under physiological 
conditions, various oxidation states (I, II and III) of ruthenium are accessible. Ru(II) 
complexes are usually less inert than their corresponding  Ru(III) counterparts. As a 
result, Ru(III) complexes are thought to be prodrugs that undergo activation through 
reduction in vivo. The reduction of Ru(III) to Ru(II) is more favoured in tumours than 
in normal tissue, due to low oxygen content and low pH in tumour cells. 
Furthermore, extracellular reducing agents (such as glutathione (GSH)), and 
intracellular redox proteins may also enhance the reduction of Ru(III) to Ru(II).69   
Various ruthenium complexes with monodentate heterocyclic ligands, amine or 
ammine have been synthesized for evaluation as anticancer agents.70 Ru(III) 
complexes with the general formula [RuCl4L2](HL), where L is imidazole (im) or 
indazole (ind), have emerged as promising anticancer compounds.71 The lead 
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compound, [RuCl4(ind)2](Hind) (KP1019; ind = indazole; Figure 1.7 a) displays 
anticancer activity against a number of cancer cell lines.71,72 KP1019 has entered 
phase I clinical trial for anticancer activity, and is completely devoid of side effects.73 
KP1019 induces lethality at small dosages and has a higher therapeutic index than 
the imidazole derivative. Phase I clinical trial results have shown that the transferrin 
bound KP1019, as well as the apotransferrin modified [RuCl4(im)2](Him) exhibit 
superior anticancer activity compared to protein-free complexes.74  
 
Figure 1.7: Antitumour Ru(III) agents,  KP1019 (a) and NAMI-A (b)  with promising 
cytostatic properties.  
Another example is (trans-(Him)[RuCl4(DMSO)(H2im)] (NAMI-A; Figure 1.7 b), 
which is the first Ru complex to accomplish phase I clinical trials and a recent 
evaluation candidate in phase II clinical trials.69,75 Although this drug is inactive 
against tumour cells in vitro, it has shown significant efficiency against lung 
metastasis in vivo. NAMI-A is easily reduced to Ru(II) by bio-reducing agents under 
physiological conditions due to the labile S-bonded DMSO ligand.69 Even though 
NAMI-A interacts with DNA in vitro, its anticancer activity does not appear to be 
related to DNA binding.76 Instead, the anti-metastatic activity of this drug is related 
to its interaction with fibrous collagen of the lung and with the basement membrane 
of collagen type IV.76 This significantly increases the thickness of the connective 
tissue around the tumour capsule and blood vessels, thereby blocking the blood flow 
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1.6 Platinum(II) complexes with pyrazole-based ligands 
1.6.1 Medical potential of pyrazole-based Pt(II) complexes  
Complexes of pyrazole-based ligands are potential therapeutic agents and hold 
promise in medicine.77 In particular, platinum complexes bearing N-donors have 
shown interesting biological activities in a wide range of diseases ranging from 
cancer to bacterial, viral and parasitic infections.77 Pyrazole-metal based complexes 
have not been used extensively in medicine, compared to other metal complexes 
with N-donor atoms. A replacement of the inert amine non-leaving group (NH3) of 
cisplatin by N-containing heterocyclic ligands (e.g. pyridine and pyrazole) has been 
reported to afford complexes of decreased reactivity, leading to reduced toxicity.77 
Moreover, replacing the NH3 group(s) of cisplatin with planar N-containing 
heterocyclic ligands does not considerably affect the DNA-binding ability of the 
complex and the formation of platinum-modified DNA.77  
Thus, the rationale behind the improvement of the Pt-based drugs lies on the 
designing of kinetically inert platinum complexes, which have limited sensitivity 
towards deactivation by intracellular thiols, since this is thought to be responsible 
for the most severe side effects.41 Ciesielka et al.78 synthesized analogues of cisplatin 
in which the amine ligands of cisplatin were replaced with pyrazole. The cytotoxicity 
of the platinum complexes was evaluated against murine Leukemia cancer cell lines. 
The structures of the pyrazole Pt(II) complexes are shown in Figure 1.8. The 
cytotoxic properties of pyrazole-bearing analogues as well as their damages and 
modifications on DNA were compared to their respective parent compound, since 
DNA has been considered the major pharmacological target of cisplatin.   
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Figure 1.8: Structures of pyrazole derivatives of cisplatin evaluated for anticancer 
activity.78  
The complexes displayed significant anticancer activity higher than the one for 
carboplatin, in terms of the IC50 values, but relatively lower compared to the one for 
cisplatin. The cytotoxicity was dependent on the substituents introduced on the 
pyrazole ring. While complex (2) is an active anticancer agent, Sakai et al.79 showed 
that its 3,5-dipyrazolecarboxylic acid analogue was inactive against human 
colorectal cancer cell line AGS and DLD-1. The carboxylic acids are known to be 
strong electron-withdrawing groups and would result in a diminished electron 
density on the coordinated pyrazole ring, which may be a possible explanation for 
the poor activity, since the complex may be pharmacokinetically unstable due to 
enhanced reactivity with other cellular nucleophiles. In spite of increased steric 
hindrance by substituents on the ligand system, complexes 1-4 (Figure 1.8) have the 
same electron density on the coordinated pyrazole moieties, and this accounts for 
similar cytotoxic properties.  
1.6.2 Cytotoxic studies of (pyrazolylmethyl)pyridine Pt(II) complexes 
Since the discovery of the medical potential of pyrazole complexes, there has been a 
rapid growth in the synthesis of pyrazole derivatives for applications as anticancer, 
antiviral and anti-inflammatory agents.77 Pyrazolyl ligands are easily modulated or 
fine-tuned to achieve the desired electronic and steric effects, which are necessary in 
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controlling the thermodynamic and kinetic properties of their respective metal 
complexes.  
The (pyrazolylmethyl)pyridine Pt(II) complexes with bidentate ligands are more 
stable than their monodentate counterparts, because of the chelate effect. The 
(pyrazolymethyl)pyridine coordinate to the metal centre via N-donors of pyrazole 
and pyridine forming a stable six-membered chelate ring. The methylene linker of 
the two rings confers moderate flexibility at the (pyrazolylmethyl)pyridine ligand. 
Segapelo et al.80 evaluated the cytotoxicity of (pyrazolylmethyl)pyridine ligands and 
their respective Pt(II) and Au(III) complexes (Figure 1.9). All the complexes were 
active against Hela cancer cell line. The activities of the Pt(II) and Au(III) complexes 
were within the range of 10-20 times lower than cisplatin and also exhibited low 
tumor specificity. Growth inhibition of normal human lymphocytes cells (PBMC) 
were tested under the same experimental conditions. It was found that the 
complexes exhibit poor selectivity, indiscriminately killing both normal and 
cancerous cells. However, these complexes have superior activity than carboplatin, a 
widely used anticancer drug. Compared to platinum complexes, gold complexes 
displayed even lower cytotoxicity when tested against Hela cancer cell line. The low 
cytotoxicity of gold complexes is probably due to low stability of Au(III) which is 
usually reduced to Au(I).   
 
Figure 1.9: Formulae of biologically active complexes evaluated against Hela cancer 
cell line.80 These compounds hold promise for anticancer treatment.  
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1.7 Mechanistic studies of Pt(II) complexes 
1.7.1 The effect of substituents of a polydentate ligand on the rate of substitution  
The influence of chelate substituents on the ligand substitution reactions was 
extensively studied by Jaganyi et al.81,82,83 A series of platinum(II) complexes (Figure 
1.10) were studied using neutral and ionic nucleophiles, viz. TU, DMTU, TMTU and 
I−and SCN−, respectively. The results have shown that the chloride ligand 
substitution is controlled by the electrophilicity of the Pt(II) centre, which is in turn 
dependent on the electronic properties of the non-leaving terpy ligand. The electron-
donating groups decelerated the substitution reaction by reducing the π-back-
bonding ability of the terpy fragment. On the other hand, electron-withdrawing 
groups increased the reactivity by enhancing the extent of π-back-bonding of the 
terpy fragment.81,82 These observations are true when the substitution rate constants 
for [Pt{tBu3-terpy)}Cl]+ and [Pt(terpy)Cl]+ are compared.81b The slower reactivity of 
the former complex is due to the electron-donating tert-butyl groups on the terpy 
ligand, which reduce the π-acceptibility of the ligand and hence reduce the 
electrophilicity of the metal centre. The same is true for [Pt{4’-phenyl-terpy}Cl]+ with 
the electron-donating phenyl ring at the 4’ position of terpy, reducing the reactivity 
of the complex compared to [Pt(terpy)Cl]+.  
The presence of ancillary substituents on the ortho position of the 4’-phenyl ring 
attached to the terpy ligand also control the reactivity of the complexes by either 
reducing or enhancing the π-back-bonding of the terpy, depending on the electronic 
properties of the ancillary substituent. The presence of an electron-withdrawing 
trifluoromethyl (−CF3) group on the ortho position of the 4’-phenyl ring in [Pt{4’-(o-
CF3-phenyl)-terpy}Cl]+ increases the π-back-bonding ability of the terpy ring. This 
increases the electrophilicity of the metal centre which in turn increases the rate of 
substitution compared to [Pt{4’-phenyl-terpy}Cl]+. The opposite is true for [Pt{4’-(o-
CH3-phenyl)-terpy}Cl]+, which has an electron-donating methyl (−CH3) group on 
the ortho position of the 4’-phenyl ring. The reactivity of the complexes is therefore 
dependent on the electron-donating or electron-withdrawing strength of the 
substituents. The complexes with the strongest electron-withdrawing substituents 
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are more reactive, whereas those with the best electron-donating substituents are 
less reactive.  
 
Figure 1.10: Platinum(II) terpy complexes studied by Jaganyi and co-workers.81,82,83  
 
1.7.2 The role of an extended π-conjugation in the ligand core on the rate of 
substitution 
Most recently, the π-acceptor effect of N-donor tridentate ligands on the reactivity of 
platinum(II) complexes has been studied.81,82,83 The extended π-conjugation in which 
pyridine formed part of the aromatic ring system has been shown to enhance the 
extent of π-back-bonding due to a favourable overlap of ligand π*-orbitals with dπ-
orbitals of the metal.84 Jaganyi and Ongoma83 studied a series of mononuclear Pt(II) 
complexes bearing isoquinolyl and phenanthrolyl groups as part of the tridentate 
ligand. Their structures are labeled as CH3PhisoqPtCl) and PyPhenPtCl, 
respectively, in Figure 1.10. 
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It was found that the increase in the π-conjugation at the cis/trans position as in 
PyPhenPtCl (when compared to PtCl) strengthen the extent of π-back-bonding of 
the chelate backbone making the platinum centre more electrophilic. This accelerates 
the rate of chloride ligand substitution.  However, the extended π-conjugation in the 
cis position as in CH3PhisoqPtCl (when compared to CH3PhPtCl) retards the 
substitution process, contrary to what was expected. The increase in the number of 
fused rings around the metal centre was expected to be accompanied by an efficient 
transfer of electron density from the d-orbitals of the metal ion into the extended and 
easily accessible molecular orbitals of the fused rings, leading to rapid substitution of 
the leaving group. The decreased rate of substitution was due to a more dominant cis 
σ-effect of the isoquinoline ring that facilitates the accumulation of the electron 
density on the Pt(II) center,  reducing its electrophilicity.  
1.8  Role of  kinetic data in the development of drugs 
While cisplatin is one of the most developed inorganic compounds and successful 
anticancer agent, it shows limited activity against the most common and recalcitrant 
forms of cancers such as those of the colon and breast. The clinical success of 
cisplatin is also limited by significant side effects, drug resistance (intrinsic and 
acquired), poor water solubility and intravenous administration. Therefore, much 
attention is still directed towards the designing of new platinum compounds with 
carrier groups that target tumour cells with high specificity, improving and 
expanding the range of antitumor activity spectrum. Recent cytotoxicity studies 
came up with new platinum complexes which exhibit remarkable anticancer activity 
against many cancer cell lines.77-80 Some of these Pt(II) complexes are endowed with 
superior anticancer activity compared to cisplatin.  
Since the understanding of the mechanistic pathways and the reactivity of metal 
complexes both in vitro and in vivo is vital for the rational design of new compounds 
with improved potency, kinetic studies on these new and improved potential drugs 
should be carefully undertaken. It is known that the reactivity of platinum 
complexes can be systematically tuned through steric and electronic properties to 
achieve the desired thermodynamic and kinetic properties. The data from such 
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studies is crucial in understanding drug metabolism, chemo-protection as well as the 
influence of intrinsic reactivity on the mechanism of action. Kinetic data including 
mechanism of product formation from the substitution reactions of Pt(II) and  model 
nucleophiles such as iodides, bromides, thiocyanate as well as nitrogen- and 
sulphur-donor nucleophiles such as azoles and thioureas are important in 
understanding the fate of the drug after administration.  
1.9 Aims and objectives of the research 
Recent work by Jaganyi et al.81,83,85 has concentrated on the modification of the 
tridentate N-donor ligands by either varying the number of π-accepting pyridine 
rings and through direct substitution of the pyridine ring with an electron-donating 
or electron-withdrawing group, in order to modulate the reactivity of the Pt(II) 
centre by controlling the extent of π-back-bonding. The anomalous decrease in the 
rate of substitution with an increase in the π-conjugation has caught our interest in 
this study.83,84,86 Jaganyi and Kinunda87 have most recently reported the effect of the 
extended π-conjugation of a quinoline ring positioned cis to the leaving group on the 
reactivity of the tridentate Pt(II) complexes. The observed trend in the reactivity was 
contrary to the expected higher reactivity based on the increase in π-conjugation as 
reported elsewhere in the literature.81,84,85  
There is a limited information on the influence of the π-conjugation of a coordinated 
bidentate ligand on the reactivity of bifunctional Pt(II) complexes. In order to extend 
our understanding of the role of substituents on the core ligand in controlling the 
extent of π-back-bonding, part of this study was to look into the effect of introducing 
electron-donating and electron-withdrawing groups in the 3,5-positions of the 
pyrazole ligand in bifunctional Pt(II) complexes endowed with N,N-
(pyrazolylmethyl)pyridine/quinoline chelates. Therefore this work enables the 
investigation of the competing effect of the σ-donor or π-acceptor strength of the 
pyrazole ligand positioned cis or trans to the aqua leaving groups, on the rate of 
substitution reaction in a series of bifunctional Pt(II) complexes. The structures of the 
Pt(II) complexes and the nucleophiles studied are shown in Figure 1.11. It will also 
report on the effect of the π-conjugation incorporated into the (pyrazolylmethyl)-
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Figure 1.11: Structures of bifunctional Pt(II) complexes with N,N-bidentate chelate 
and the nucleophiles used for kinetic investigations. The counter anions of the 
complexes are omitted for simplicity.  
Sulphur-containing bio-relevant nucleophiles i.e. thiourea (TU), N,N’-
dimethylthiourea (DMTU), and N,N.N’N’-tetramethylthiourea (TMTU) will be used 
as substituting nucleophiles. The choice of nucleophiles was made based on their 
difference in nucleophilicity, steric hindrance and binding properties. TU and its 
derivatives have a combination of thiolates (π-donor) and thioether (σ-donor and π-
acceptor) ligand properties similar to those found in biological nucleophiles.88 In 
addition, TU and other sulphur-containing molecules (e.g. cysteine and glutathione) 
are used as protective agents against nephro- and neuro-toxicity following cisplatin 
administration.88 Therefore understanding how Pt(II) complexes interact with S-
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containing bio-relevant molecules is of vital importance from the medicinal and 
biological point of view.          
1.9.1 Pt(II) complexes with flexible (pyrazolylmethyl)pyridine and 
(pyrazolylmethyl)quinoline bidentate chelates  
This study was divided into two parts with different but interrelated aims and 
specific objectives. This thesis will report on the: 
 synthesis and characterization of dichloro bifunctional Pt(II) complexes 
with flexible and versatile 2-(3,5-disubstituted-pyrazolylmethyl)quinoline 
and 2-(3,5-disubstituted-pyrazolylmethyl)pyridine chelates as well as their 
respective unsubstituted analogues .  
 preparation of their respective diaqua complexes in solution and 
determination of the pKa values of the coordinated aqua ligands as a 
measure of their electrophilicity and hence the reactivity of the Pt(II) 
centre. 
 effect of replacing the π-acceptor pyridine ring with a quinoline in a 
flexible bidentate chelate on the reactivity of the complex by following the 
substitution of the coordinated aqua ligands by S-containing nucleophiles 
viz. TU, DMTU and TMTU.  
  effect of modulating the donicity of the substituted pyrazole ring on the 
reactivity of the complex by bringing in electron donating or withdrawing 
ancillary groups on the ring, while maintaining the pyridine or quinoline 
ring constant.  
  data from computational modelling of the diaqua complexes to 
understand the low energy structural geometries of the complexes and 
how it supports observed trends in reactivity. 
  on how electronic and steric properties of the synthesised complexes can 
be used to modulate their reactivity.  
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Chapter 2 
Theoretical aspects on the substitution reactions of inorganic 
compounds focusing on platinum (II) complexes 
2.0 Introduction 
Substitution reactions are single-replacement reactions of a functional group by 
another group. Inorganic substitution reactions include the displacement of the 
ligand from a coordination complex by another. The substitution reactions in 
inorganic chemistry can be classified as Lewis acid-base reactions in which a 
positively charged metal ion can act as a Lewis acid and the coordinated ligand acts 
as a Lewis base. Mechanisms for such reactions have been studied for d8 Pt(II) square 
planar complexes as well as for complexes of other metal ions such as Pd(II), Au(II), 
Ni(II), Ir(I) and Rh(I).3,4 Ligand substitution reactions involving complexes of these 
metal ions play a fundamental role in homeostasis, anticancer therapy and 
homogeneous catalysis. For example, in the treatment of tumours, metallo-drugs 
such as cisplatin are designed to inhibit tumour growth by replacing the chloride 
ligand with guanosine base of DNA.1,2 
This chapter covers the general mechanistic pathways for substitution reactions of d8 
square-planar Pt(II) complexes i.e. classification of reaction mechanisms as well as 
other factors that affect the reactivity of these complexes.     
2.1 Classification of Inorganic reaction mechanisms 
In an attempt to classify inorganic substitution reactions based on their mechanistic 
schemes, Langford and Grey5 introduced the stoichiometric mechanism of 
substitution which exists in three forms; associative, dissociative and interchange 
mechanism. 
2.1.1 Dissociative mechanism (D-mechanism) 
This reaction pathway involves the formation of an intermediate with a reduced 
coordination number as the reaction proceeds. The intermediate is generated 
through the bond breaking of the leaving group (X) prior to the attachment of the 
- 32 - 
 
entering group (Y) to the coordination sphere (M). The reaction scheme for this 





+ X - Y
+ Y
 
The rate of the reaction is dependent on the bond breaking step and is insensitive to 
the nature of the entering group. Since the breaking of the bond between the metal 
and the leaving group also affects the rate determining step; the nature of the leaving 
group affects the rate of its substitution from the metal ion.  
D-mechanism of substitution is common in octahedral metal complexes of the first 
transition metal series because they are coordinatively saturated i.e. they have 
reached their maximum stable coordination number of six. In square-planar 
complexes, the D-mechanistic pathway leads to the formation of a 14-electron, T-
shaped transition state. For square planar complexes, the dissociative mechanism 
will only occur when very bulky spectator ligands or good leaving groups are 
coordinated to the metal centre in the presence of a strongly coordinating solvent.6 
Bulky ligands will destabilise the ground state energy as well as obstruct the 
approach of a nucleophile. On the other hand, a good leaving group will enhance the 
bond breaking between itself and the metal centre. When this dominates over the 
approach of an incoming nucleophile, the dissociative mechanism is favoured.  
2.1.2 Associative mechanism (A-mechanism)   
This reaction pathway is characterised by the formation of an intermediate with an 
increase in the coordination number.7 The intermediate is formed between the metal 
centre and the entering group prior to the displacement of the leaving group. The 
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The bond formation between the metal centre and the entering group is the rate-
determining step, and therefore the rate of the reaction is dependent on the entering 
group. The rate of the reaction is not very sensitive to the leaving group. The 
associative mechanism of substitution is the most common mechanism for 
coordinatively unsaturated metal complexes especially for d8 square-planar 
complexes. The mechanism usually proceeds via the formation of a 5-coordinate 
transition state intermediate with a trigonal bipyramidal geometry (Figure 2.1).  In 
the transition state, the entering nucleophile (Y), the leaving group (X) and the 
ligand trans to the leaving group (L2) occupy the trigonal plane, while the other two 
non-labile groups (L1 and L3) that were formerly coordinated in a cis position to the 
leaving group occupy the axial positions. Throughout the substitution, the spatial 
arrangement of the groups in the transition state is maintained, thus leading to the 
substitution process with a retained configuration. Associative mechanistic 
pathways are also characterised by an increase in the micro-static order of 
arrangement of species in the transition state. This is because A-mechanism proceeds 
via a contracted transition state with a greater extent of bond making. 
 
Figure 2.1:  A representation of the direct attack by the entering ligand at the square 
planar Pt(II) centre below or above the plane. The nucleophile (Y) coordinates to give 
the trigonal bipyramidal intermediate species which loses the leaving group (X) with 
the retention of the stereochemistry.  
- 34 - 
 
This corresponds to a decrease in both volume and entropy of activation of the 
activated complex compared to the ground states of the reactants. Thus, the change 
in the volume of activation (∆V≠) is negative since the coordinative partial volume of 
the transition state is smaller compared to the volume of the complex and the 
nucleophile before the substitution reaction. The change in entropy of activation 
(∆S≠) is also negative, indicative of the more ordered microstates for the substitution 
process at the transition state.8      
2.1.3 Interchange mechanism (I-mechanism)   
For this reaction pathway, bond formation between the metal centre and the entering 
group as well as the bond breaking between the metal centre and the leaving group 
occur at the same time.9 As a result, there is no observable intermediate during the 
reaction. The reaction scheme for this mechanism can be summarised as follows;  
+ X (2.3)[XLnM] X...[LnM]...Y [YLnM]+ Y  
The energy-reaction coordinate diagrams illustrating dissociative, associative and 
interchange processes and respective intermediates formed are shown in Figure 2.2, 
where X= leaving group and Y= entering group.  
 
Figure 2.2: The reaction-energy profiles for the associative (A), associative 
interchange (Ia), dissociative interchange (Id) and dissociative mechanism (D).5  
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The interchange reaction mechanism maybe divided into two other reaction 
pathways according to various transition states formed:5 
 associatively activated interchange reaction mechanism (Ia-mechanism) is 
the one in which the transition state consist of substantial bonding of the 
metal centre to both the leaving and the entering group. Usually the bond 
formation between the incoming ligand and the metal centre dominates over 
the bond breaking with the leaving group, and the rate of the reaction shows 
sensitivity on the nature and concentration of the entering ligand. The rate of 
this reaction is insensitive to the concentration of leaving group. 
 
 dissociatively activated interchange mechanism (Id-mechanism) is the one 
in which a transition state consists only of very week bonding from the metal 
centre to both the leaving and the entering group. On the other hand, if the 
bond breaking dominates over bond formation, and the rate of the reaction is 
influenced by the leaving group, the mode of activation becomes 
dissociatively interchange mechanism (Id). The rate of this reaction is not 
affected by the nature and concentration of the entering group. 
2.2 Influence of the coordinated ligands around the metal centre on the 
mechanism of substitution  
Both ground and transition state geometries of the coordination compounds are 
controlled by electronic and steric factors of the coordinated ligands around the 
central atom. Various factors determine the changes from the ground state to the 
transition state. For example, the observed mechanism of substitution may be 
dependent on the number of ligands coordinated around the central atom. The more 
ligands surrounding the central atom, the more difficult it is for the next ligand to 
attach on the metal centre. Logically, metal centres with large number of ligands 
coordinated should favour a dissociative mechanism, while centres with few ligands 
coordinated should favour an associative mechanism.  
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2.3 Ligand-exchange reactions at square-planar Pt(II) metal centre 
Theoretically, substitution reactions of square-planar complexes would be expected 
to proceed most readily by an increase in the coordination number due to the 
attachment of the entering group to the coordination sphere.10,11 For electronic and 
steric reasons, these reactions are also expected to favour biomolecular nucleophilic 
substitution or an associative reaction mechanism. The metal complex is susceptible 
to nucleophilic attack above and below its plane as there is no obstruction of the 
incoming ligand in both positions (Figure 2.3). The expansion of the coordination 
number readily occurs as complexes of more than four coordinated groups around 
the central atom are common. Furthermore, the low-spin d8 system of a central atom 
comprises a vacant 𝑝𝑧-orbital of relatively low energy that may accommodate a pair 
of electrons donated by the incoming ligand.     
Pt(II) complexes are favoured when studying square-planar substitution reactions 
because they are generally thermodynamically stable and insensitive to oxidative 
addition.11 Moreover, they also display moderate to slow kinetic lability (slow 
reactivity) in their ligand-exchange reactions.12 In contrast to Pt(II) complexes, 
analogous complexes derived from metal ions with +2 oxidation state {e.g. Pd(II) or 
Ni(II)} or other d8 metal ions {e.g. Ir(I), Rd(I) or Ru(III)} are thermodynamically 
unstable, sensitive to oxidative addition and undergo rapid ligand-exchange 
reactions.13,14 A relatively low reactivity or kinetic stability and stable redox 
behaviour of Pt(II) complexes lead to simple, easily monitored and interpreted 
kinetics. As a result, extensive research has been done on mechanistic and kinetic 
behaviour of ligand-exchange reactions on Pt(II) complexes.12-14 
In spite of their differences in kinetic stability and redox behaviour, data gathered 
for Pt(II) complexes can also be applied to analogous square-planar complexes due 
to similarities in their reaction mechanism.10,15 For example, ligand-exchange 
behaviour of Pd(II) complexes is known to be very similar to that of Pt(II) complexes 
often with reaction rates of five orders of magnitude faster than Pt(II) analogue.11,15 
Like Pt(II) complexes, analogous Au(III) complexes are also effective as anticancer 
agents, however, they are usually thermodynamically unstable and are readily 
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reduced to Au(I) and Au(0).15,16 This analysis indicates that a continued study on 
ligand-exchange reactions of Pt(II) complexes remains an essential area in rational 
drug design and synthesis. Parameters such as electronic and steric effects may be 
used to modulate the reactivity and solubility of the metal complexes. Particularly 
for platinum-based anticancer drugs, these parameters may be used to ameliorate 
the drug potency as well as widen the anticancer activity spectrum.   
Ligand substitution reaction kinetics on square-planar Pt(II) complexes and 
mechanistic investigations are important in understanding how Pt-based drugs 
achieve their desired anticancer activity. Structural attributes using model 
compounds could be systematically investigated both thermodynamically and 
kinetically to unveil the underlying mechanism for the interaction of these drugs 
with their target material viz. genomic DNA and bio-competing deactivating species 
such as plasma proteins (cysteine and methionine) and other intracellular bio-
regulating thiols such as glutathione.  
2.4 Factors affecting the reactivity of square-planar Pt(II) complexes 
2.4.1 Effect of the leaving group 
The effect of the leaving group is more significant in the substitution reactions that 
follow dissociative pathway compared to the ones in which the reaction pathway is 
associative.  The type and nature of the leaving group has a remarkable influence on 
the rates of ligand-exchange reactions on square planar complexes.  
The extent of this influence is determined by the degree in which bond breaking 
between the metal centre and the leaving group occurs. A classic example 
elaborating on the influence of the leaving group on the square planar substitution 
reactions is the reaction of [Pt(dien)X]+ with pyridine (Equation 2.4).17,18 The kinetic 
data is reproduced in Table 2.1.   
[Pt(dien)X]+  +  Py [Pt(dien)Py]2+ + X- (2.4) 
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Table 2.1   The effect of different leaving groups on the rate of substitution of X in 
[Pt(dien)X]+ complexes at 25°C.17,18 
Ligand X  𝒌𝒐𝒃𝒔 / 𝟏𝟎
𝟔 𝐬−𝟏 
NO3












It was found that the rate of substitution reaction increased in the order; 
                        CN− <  NO2
− < SCN− <  N3
− < I− < Br− < Cl− < H2O < NO3
−   
for the displacement of X by the pyridine ligand. Generally, it is much easier to 
displace the ligands which are less nucleophilic than those which are more 
nucleophilic. Although the reactivity of square-planar complexes strongly depends 
on the nature on the incoming group, this data shows a clear dependence of the rate 
of substitution on the leaving group.17,18 This shows that the strength of the Pt−X 
bond influence the rate of dissociation in the transition state. Further insight on the 
effect of the leaving group on the reactivity of square planar complexes could be 
obtained from the activation parameters e.g. activation volume, enthalpy and 
entropy. This could provide evidence for the extent of bond breaking in the 
transition state.     
2.4.2 Effect of the entering ligand 
The incoming ligand is markedly important when dealing with the substitution 
reactions that follow an associative pathway. The magnitude of the second-order 
rate constants (𝑘2) quantifies the rate at which the incoming ligand substitutes the 
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leaving group. The rate of the substitution reaction is dependent on the 
nucleophilicity of the incoming ligand. The nucleophilicity is a measure of how 
readily the nucleophile is able to attack an electron deficient centre (Pt(II) metal 
centre). Therefore, the stronger the nucleophile the faster the rate of substitution of a 
particular Pt(II) complex. The nucleophilicity of the ligand is usually characterised 
by the following several factors:7,10,16 
a) basicity The basicity of the ligand is usually characterised by its pKa 
values and is directly proportional to the nucleophilicity of the 
ligand towards the metal centre. 
b) oxidizability Ligands that are strongly oxidized (strong reducing agents) are 
considered good nucleophiles. The oxidizability of the ligand can 
be identified from their electron reduction potential.   
c) polarizability 
 
The polarization of the ligand is better explained by the Pearson’s 
Hard Soft Acid Base (HSAB) theory which stated that hard acidsI 
prefer hard bases and soft acids prefer soft bases. An increase in 
the polarizability increases the effectiveness of the entering group 
in attacking the metal centre by increasing its electron donor 
ability.    
d) solvation 
energy  
Ligands that are strongly solvated are considered weak 
nucleophiles because energy is required to remove the bound 
solvent molecules or to free the ligand before it coordinate to the 
metal centre. 
e) metal centre  An increase in the polarizability of the metal centre also increases 
the effectiveness of the attacking nucleophile. Heavier metals are 
better polarised in the transition state, therefore the 
corresponding rate of substitution follow the trend Ni(II)>> 
Pd(II)>> Pt(II). 
 
                                                          
I Hard acids are metal ions that are highly charged and bear the valence electron shell that is not 
easily distorted (Li+ & Mg2+). Similarly, soft acids are metal ions that have a low charge, and bear a 
valence electron shell that easily distorted (Pt2+ & Pd2+).     
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2.4.3 Effect of the solvent 
Since the solvent is the medium in which the reaction takes place and is usually 
provided in excess, it can potentially substitute the labile group rendering a rate law 
that is independent on the entering nucleophile. The established two-term rate law 
common for an associative pathway for the substitution of square-planar complexes, 
consists of a term that is independent of the concentration of the nucleophile.19 This 
may be ascribed to the parallel solvolysis pathway i.e. the mechanism in which the 
solvent displaces the leaving group prior to substitution by the entering nucleophile. 
The contribution of the solvent to the overall rate of the reaction depends on its 
coordinating ability.20 For this process, the bond formation between the metal and 
the solvent in the transition state is imperative and the rate of substitution can be 
expected to increase proportionally with the coordinating ability of the solvent.  Data 
showing the solvent effect on the substitution is shown in Table 2.2 for the reaction 
of trans-Pt(Py)2Cl2 and 36Cl- (Equation 2.5).7,10,19    
trans-Pt(Py)2Cl2
36Cl- Cl- (2.5)trans-Pt(Py)2Cl (
36Cl)  






















































The results show that for strongly coordinating solvents, the reaction proceeds 
predominantly through the solvolytic pathway which is independent of the chloride 
concentration, while the opposite is true for weakly coordinating (or non-
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coordinating) solvents. The values of 𝑘−2 (measuring the solvolytic pathway) were 
found to decrease in the order of the coordinating strength of the solvent;  
DMSO > H2O ~ CH3NO2 > EtOH > PrOH 
where DMSO is the strongest coordinating solvent and PrOH the weakest. The 
second-order rate constants (𝑘2) for the direct nucleophilic substitution were found 
to be higher in non-polar solvents (e.g. CCl4) than in polar solvents (e.g. DMF) 
because of poor solvating abilities of the non-polar solvents. Linear free energy 
relationships between a number of common parameters that are used to describe the 
Lewis acidity of the solvent and the reactivity were found to depend strongly on the 
solvation of the anionic nucleophile.      
2.4.4 Effect of the non-leaving ligand 
Apart from the influence of the entering and leaving ligand, the substitution 
reactions on square planar Pt(II) complexes are also affected by the nature of the 
non-leaving group. The penta-coordinate transition state of an associative 
mechanism typical for square-planar Pt(II) complexes comprises of a trigonal 
bipyramidal intermediate with the trans ligand, the leaving group and the entering 
group in a trigonal plane and the two cis ligands in the axial positions.3,4 The effect 
exerted by the trans ligand on the leaving group is different from the one of the cis 
ligand. Numerous studies have reported on the effect of the non-leaving ligands cis 
and trans to the leaving group, on the reactivity of the Pt(II) complexes.21,22 The effect 
that the non-leaving ligand has on  the coordinated labile ligand in a trans and cis 
positions is referred to as the trans- and cis-effect respectively. The effect on the 
reactivity of Pt(II) complexes from the non-leaving ligand trans to the labile leaving 
group is more prominent compared to the one in the cis  position23 i.e. the trans-effect 
is stronger than the cis-effect. 
2.4.4.1 The trans-effect 
The trans-effect is the effect exerted by the non-leaving ligand on the rate of 
substitution of the labile ligand trans to it.4,20 Kinetic data reported on the ability of 
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the non-leaving ligand to directing an entering group on a position trans to it using 
several nucleophiles has established a general order of labilization to be:4,10,16 
CN−, CO ,  C2H4 , NO >  R3P, H
− > CH3
− >  C6H5
− > SCN− > NO2
− > I− >  Br−  >  Cl−
> NH3 > OH
− > H2O. 
A ligand high up in the trans-effect series (strong trans-ligand) enhances the rate of 
substitution of the leaving group trans to itself e.g. CN− has a stronger trans-effect 
than SCN−. This is due to the fact that CN− has both σ-donor and π-acceptor 
properties, which contribute to the ground state destabilization and transition state 
stabilization, respectively. Thus, the relative stabilities of both ground state and 
transition state are relevant in determining the overall magnitude of the trans-effect. 
These two factors accelerate the rate of substitution by reducing the activation 
energy barrier necessary to activate the reactants to the transition state. Therefore, 
the trans-effect is a kinetic phenomenon. 
A characteristically different but closely related concept to the trans-effect is the 
trans-influence. This is the influence of the non-leaving ligand on the strength of the 
metal-to-ligand bond trans to it. Therefore, the trans-influence is a thermodynamic 
effect that affects the ground state properties of the metal complex. Experimental 
evidence of the trans-influence has been shown through the use of X-ray analysis, 
nuclear magnetic resonances and infrared spectroscopy confirming the elongation of 
the bond between the metal and the leaving group.10,20  
The trans-effect plays a significant role in the synthesis of desired Pt(II) complexes 
with a specific geometry.4,23 Examples showing the role of the trans-effect rule in the 
synthesis of geometric isomers of [Pt(NH3)2Cl2] are shown in Scheme 2.1. 
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Scheme 2.1: Synthesis of the cis and trans isomers of [Pt(NH3)2Cl2]. 
Theoretically, cis-[Pt(NH3)2Cl2] can be prepared by a stepwise reaction of [PtCl4]2− 
with two mole equivalents of ammonia (NH3). The success of this reaction is 
dependent on the strong trans-directing effect of the chloride ion compared to 
ammonia, which ensures that the second ammonia coordinates at the cis position. 
Therefore, the least reactive chloride ligand in the [Pt(NH3)Cl3]− intermediate is the 
one trans to the ammonia ligand. On one hand, trans-[Pt(NH3)2Cl2] is prepared by a 
stepwise reaction of the tetraamine Pt(II) complex, [Pt(NH3)4]2+, with two mole 
equivalents of a chloride (Cl−) ligand. Upon the coordination of the first chloride 
ligand, the second chloride ligand replaces the most labile ammonia ligand from 
[Pt(NH3)3Cl]+, in a trans position. Therefore, the strong trans-effect of the chloride 
ligand directs the substitution of the ammonia ligand trans to it. 
Another example is shown in Scheme 2.2 for the stepwise synthesis of cis- and trans-
[Pt(NH3)(NO2)Cl2]−. Reversing the order at which the ligands are introduced to 
[PtCl4]2− results into the formation of different isomers.4,24  The trans-directing effect 
of nitrite is greater than that of chloride, thus directs the incoming NH3 group to the 
position trans to itself. Therefore, the trans-labilizing effect of the ligands follow the 
order NO2 > Cl > NH3.4,24 
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Scheme 2.2: Synthesis of the cis and trans isomers of [Pt(NH3)(NO2)Cl2]−. 
Several theories have been used to explain the trans-effect. The three most prominent 
ones include the electrostatic polarization, π-bonding and molecular orbital (MO) 
theory.   
2.4.4.2 The electrostatic polarization theory 
This theory was first proposed by Grinberg25 using the charge distributions of 
induced dipoles along the T−Pt−X coordinate within a square-planar complex, 
where T is a trans ligand and X is the leaving group (Figure 2.3).  
 
Figure 2.3: Charge distribution and induced dipoles in the T−Pt−X coordinate.   
The charge on the Pt(II) metal ion induces the  primary dipole in the trans ligand (T), 
which in turn induces the secondary dipole to the metal ion. The orientation of the 
secondary dipole on the Pt(II) metal ion repels the negative charge on the leaving 
group (X), thereby weakening or lengthening the Pt−X bond.  
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2.4.4.3 The π-bonding theory 
This theory suggests that the π-bonding ligands such as CO, C2H2, and R3P are able 
to stabilise the transition state and therefore are high in the trans-effect series.3,10 The 
π-bond is formed when the filled d-orbitals of the Pt(II) metal overlap with the empty 
π*-orbitals of the ligand. On the other hand, the σ-bond is formed from the donation 
of a pair of electrons from the ligand to the metal centre. It would appear that 
withdrawal of electrons from the metal centre through π-back-bonding would 
strengthen the bond between the Pt(II) metal and the trans ligand in the ground 
state, instead of weakening the bond between the metal centre and the leaving 
group.20 Therefore, the destabilization of the trans bond in the ground state cannot  
be used to adequately account for the effect of good trans activators.3,10,20 As a result, 
Chatt et al.26 and Orgel et al.27,28 proposed that the explanation of the trans-effect has 
to involve the stabilization of the transition state. The intermediate is assumed to 
have a trigonal bipyramidal geometry as shown in Figure 2.4.  
 
Figure 2.4: The trigonal bipyramidal geometry of the transition state and the π-back-
bonding of the trans ligand.  
Chatt et al.26 highlighted that the removal of electrons from the metal centre through 
π-back-bonding of the trans ligand (T) will enhance the addition of the entering 
ligand (Y), thus increasing the rate of substitution. Orgel et al.27 highlighted that the 
observed higher substitution rate is due to the stabilization of the transition state 
because of the reduced accumulation of the electron density in the T−Pt and Pt−X 
coordinate, through π-back-bonding.    
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2.4.4.4 The molecular orbital theory 
The σ/π-trans effect is also supported by the molecular orbital (MO) theory.    
a) The σ-trans effect  
A simplified MO diagram for an exemplary square planar [PtCl4]2− complex is 
shown in Figure 2.5. It can be seen from the diagram that the most stable orbitals are 
the σ-bonding atomic orbitals which are primarily located on the chloride ligands. 






∗ , which are relatively stable. These orbitals are derived 
from the 5d atomic orbitals of the Pt(II) metal. The 𝜎𝑥2−𝑦2
∗  orbitals are located at a 




∗ as well as the valence 𝑝𝑧 orbital which is not involved in the σ-
bonding, are the least stable.  
Considering the geometry of the four valence atomic orbitals of the Pt(II) metal 
(𝑑𝑥2−𝑦2 , 𝑠, 𝑝𝑥 and 𝑝𝑦) which are used for σ-bonding in the square planar complex, 
only 𝑝𝑥 and 𝑝𝑦 orbitals have the trans directional properties.20,24 Therefore, in trans-
PtL2TX, the trans ligand (T) and  leaving group  (X), must share the same 𝜎𝑥 orbital 
in the overall MO arrangement.20 When strong σ-donor ligands such as H− and CH3
− 
are positioned trans to the leaving group, they contribute a greater share of the 
electron density to the 𝜎𝑥 orbital of the metal, thereby increasing the σ-bond strength. 
This will repel the electrons of the leaving group leading to the weakening of the 
Pt−X bond. This leads to an increase in the rate of displacement of the leaving group 
irrespective of the mechanism of substitution. This is true for the reactions in which 
ground state destabilization of the trans bond is operational in the reactivity of the 
complex. However, for the associative mode of action, the strong σ-donating ligand 
may result in the destabilization of the electron-rich penta-coordinate transition 
state, resulting into a decrease in the rate of substitution.22  
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Figure 2.5: Molecular orbital diagram of [PtCl4]
2−.20,24 
b) The π-trans effect 
Good trans activators such as C2H4, CN
− and CO, stabilize the square planar complex 
through strong π-back-donation from the filled 𝑑-orbitals of the metal with an 
appropriate π-symmetry, to the π*-orbitals of the ligand.20 Out of five 𝑑-orbitals in the 




Upon the coordination of the entering ligand and the formation of a trigonal 
bipyramidal intermediate, the number of molecular orbitals with the appropriate π-
symmetry increases to four (including 𝜋𝑥2−𝑦2
∗ ). These orbitals are shared in the π-
interaction with the trans ligand, T, the entering group, Y, and the leaving group, X, 
in the trigonal plane. Therefore, the trigonal bipyramidal transition state will be 
stabilised more by the trans ligand with low energy lying vacant π-orbitals since their 
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interaction with the 𝑑-orbitals of the metal centre delocalises the excess electron 
density on the metal centre donated by the other three coordinated ligands thereby 
lowering the activation energy. The transition state is stabilised relative to the 
ground state, since it has more π*-orbitals. Thus, strong π-acceptor ligands occupying 
a trans position enhance the addition of the entering group, leading to an accelerated 
rate of substitution. Consequently, facile substitution kinetics have been reported for 
Pt(II) complexes with good π-acceptor ligands.22 
2.4.4.5 The steric and electronic cis-effect 
Steric effect is one of the most widely used concepts in chemistry.29 It originates from 
the fact that each atom in a free molecule has a specific spatial size. It is a space-
filling effect categorised as steric hindrance or steric bulk. When atoms are brought 
closer together, mutual repulsion between bonded and non-bonded electrons occurs. 
If an atom is bonded to bulk groups, its accessibility to attack by other groups is 
limited due to steric hindrance. In ligand substitution reactions, steric hindrance 
refers to the shielding of the central metal atom from the direct attack by the entering 
nucleophile. The magnitude of the resulting steric effect is directly proportional to 
the space occupied by the substituents that causes it. Therefore, the steric effect 
depends on:10,16,29 
a) the spatial size or space occupied by the bonded atoms and substituents.  
b) relative spatial configuration or orientation of the bonded substituents 
with respect to the targeted metal centre. 
c) the spatial position of steric imparting substituents with respect to the 
leaving group.  
Since and associative pathway’s transition state is characterised by an increase in the 
coordination number, due to bond formation between the metal centre and the 
incoming ligand, steric effects due to substituent (non-leaving) hindrance is 
increased in the transition state. This destabilises the transition state, thereby 
slowing down the rate of substitution. The steric influence on the rate of the 
substitution reaction can be either due to the steric bulk in the spectator ligand or in 
the incoming nucleophile. Generally, the larger the incoming ligand the slower is the 
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rate of a reaction. It is also rationalised that an increase in the steric bulk of the 
spectator ligand usually decrease the rate of the reaction.  
The steric effects of spectator ligands may influence the lability of the leaving group 
in trans or cis position differently. When the steric imparting substituent is located in 
a cis position to the leaving group, the retardation on the rate of substitution on 
square-planar complexes is more prominent rather than in the trans position.3,7,10  
This was demonstrated in the chloride substitution from cis/trans-[Pt(Et3P)(L)Cl] by 
pyridine (Equation 2.6). The reported data is reproduced in Table 2.3. 
cis/trans-[Pt(Et3P)2(L)Py]  +  Cl
- cis/trans-[Pt(Et3P)2(L)Cl]  +  Py (2.6)   
Table 2.3   cis/trans steric effects on the rate of chloride ligand substitution by 









8.0 × 10−2 
 




2.0 × 10−4 
 




1.0 × 10−6 (25 °C) 
 
3.4 × 10−6 
 
The introduction of one or more methyl substituents on the coordinated phenyl ring 
retards the reactivity of the complex.  The retardation in the rate of substitution due 
to cis steric effect was more prominent than the corresponding trans steric effect. The 
larger decrease in the substitution rates for the cis complexes can be explained in 
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terms of their trigonal bipyramid transition state with both the leaving group and the 










Figure 2.6: Trigonal bipyramidal transition state of the cis and trans isomers.7   
In the transition state of the cis-isomer, the o-tolyl group occupies an axial position 
and interacts with the leaving group at the angle of 90°. This causes greater 
repulsion between the ortho-methyl substituent, the leaving group and the entering 
ligand. In the trans-isomer, the o-tolyl group is in the equatorial position and 
interacts with the leaving group at 120 ° angle which is further apart. As a result, the 
repulsions between the ortho-methyl substituent, the leaving group and the entering 
ligand are reduced.  
A distinctive cis-electronic effect similar in effect to the steric effect occurs for 
substitution reactions on a square planar complex.  The presence of the σ-donor 
ligand cis to the leaving group usually retards the reactivity of the Pt(II) complexes 
through the accumulation of electron density on the metal centre thereby decreasing 
its electrophilicity.30,31 This further repel the approach of a nucleophile through 
transition state destabilization thereby decreasing the rate of susbtitution.30,31 This 





L = phenyl, o-tolyl, mesityl
Y = pyridine
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electronic σ cis-effect have the same net effect on the reactivity of the Pt(II) 
complexes. On the other hand, the presence of the strong π-accepting ligand in a cis 
position suppresses the transition state destabilization by withdrawing the π-
electron density from the metal centre. This leads to a more electropositive metal 
centre and a simultaneous increase in its reactivity. This effect is called the π-cis 
effect. Therefore, the σ-cis effect and the the π-cis effect have the opposite net effect 
on the rate of substitution. 
2.5 Dissociative mechanism in square planar Pt(II) complexes 
Dissociative mechanism of substitution is not very common for square planar Pt(II) 
complexes, owing to the instability of the 14-electron three coordinate transition 
state. However, some studies have reported the mechanistic changeover from 
associative to dissociative mode of action for square planar Pt(II).3,6,32 Dissociative 
mechanism has also been reported for some Pt(II) complexes with strong cis σ-donor 
atoms such as carbon, sulfur or phosphorous.33-35 Some examples of the complexes 
that undergo the mechanistic changeover are cis-[Pt(Me)2R2] and cis-[Pt(Ph)2R2], 
where R = DMSO or thioether.35 However, when one of the thioether groups is 
replaced by a strong π-accepting CO ligand, the substitution reaction followed an 
associative mode of action. The strong π-accepting ligand reduces the electron 
density on the metal centre and hence favours the formation of an 18-electron-rich 5-
coordinate transition state. It will also destabilize the formation of the 14-electron 3-
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Chapter 3 
Kinetic theory and relevant techniques used for kinetic 
measurements 
3.0 Introduction 
The reactivity of metal complexes can only be quantified by a kinetic approach. It is 
important to gather as much as possible information from the empirical rate law, 
activation parameters, evidence of intermediates from the studied systems, and the 
theoretical analysis of the suggested mechanism and proposed transition states, in 
order to come as  close as possible to the “real” mechanism. Figure 3.1 depicts 
schematic presentation of the fundamental approach in kinetic-mechanistic studies. 
The application of thermodynamic and kinetic techniques can reveal crucial 
information of the assignment of mechanism for ligand exchange reactions.  
Reaction Kinetics







Empirecal Rate Law Suggested Mechanism




Figure 3.1: Schematic presentation of the fundamental approach in kinetic and 
mechanistic studies.1 
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In addition to proper knowledge of electronic and geometrical structures, a detailed 
knowledge of thermodynamics and kinetics is essential to address issues of 
structure, reactivity and stability in metal coordination compounds. In some cases, a 
ligand is displaced at a faster rate from metal compexes whose M-L bonds are of the 
same thermodynamic strength.2 Therefore the kinetic stability of molecules must be 
considered in addition to their thermodynamic stability.      
In this chapter, a brief summary of relevant rate laws and experimental techniques 
used in the kinetic measurements will be given.  
3.2 The rate law 
The rate of a reaction can be expressed as the change in the concentration of 
reactants or products per unit time (Equation. 3.1).3,4 
                   







The negative sign in the above equation signifies that the rate of a reactant decreases 
with time. The rate of a chemical reaction can therefore be expressed  in mol dm-3 s-
1.5 On the other hand, the rate law is an expression based on the experimentally 
measured data, which shows the relationship between the rate of a chemical reaction 
and the concentrations of all species involved in the turnover of the reactants to 
products.   Considering the following chemical reaction; 
                   aA bB cCdD  (3.2) 
where the chemical compounds are represented by capital letters and the 
stoichiometric coefficients are represented by lower case letters. Using the 
concentrations of all the components of the reaction, the rate can be expressed as;3  
                


















Rate    
(3.3) 
Alternatively, the rate law can be written as; 
               Rate = -k∏i[Ai]αi[Xj]βj  (3.4) 
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where k is a rate constant, Ai is a reactant and Xj is any other species such as a 
catalyst that may affect the rate of the reaction, while α and β are the rate orders with 
respect to Ai and Xj, respectively, which are determined experimentally and are 
independent on the stoichiometric coefficients. The magnitude of the rate constant 
(k) is a direct measure of how fast or slow a chemical reaction is. The sum of α and β 
represent the overall order of the reaction.      
3.3 Integrated rate laws 
Integrated rate laws are used to determine how the concentrations of reactants (or 
products) are related with time. A brief overview of the theory underlying the 
integrated rate law will be discussed in the following sub-headings.  
3.3.1 First-order reactions      
For first-order reactions, only one species is involved in the rate determining step. 
The concentration profiles of such reactions follow an exponential decay or growth. 
These reactions can either be reversible or irreversible, depending on the factors that 
affect the rate of a reaction. 
3.3.1.1 Irreversible first-order reactions 
For an irreversible first-order reaction below (Equation. 3.5), 
                    
k1 BA    
(3.5) 
the rate law can be written as; 
                    𝑅𝑎𝑡𝑒 = −
𝑑[𝐴]
𝑑𝑡
=  𝑘[𝐴]      (3.6) 
rearranging Equation 3.6 gives; 
 
                 −
𝑑[𝐴]
𝑑𝑡
= 𝑘1𝑑𝑡                                                                                                                  (3.7) 
Integrating from 𝑡 = 0 ([𝐴]0) to 𝑡 = 𝑡 ([𝐴]𝑡) gives;  





= −𝑘1 ∫ 𝑑𝑡
𝑡
0
                                                                                                     (3.8) 
            ln
[𝐴]𝑡
[𝐴]0
= −𝑘1𝑡                                                                                                                      (3.9) 
  or 
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                  ln[𝐴]𝑡 = −𝑘1𝑡 + ln[𝐴]0                                                                                             (3.10) 
where [𝐴]𝑡  and [𝐴]0 are concentrations of a reactant at time 𝑡 = 𝑡 and 𝑡 = 0, 
respectively.  
From Equation 3.10, a plot of  ln[𝐴]𝑡 against time (𝑡), yields a straight line which 
passes through the intercept, ln[𝐴]0, and has a negative slope from which the first-
order rate constant (𝑘1) is obtained.  
Equation 3.10 can also be written as; 
                  
[𝐴]𝑡
[𝐴]0
= 𝑒−𝑘1𝑡                                                                                                                  (3.11) 
which rearranges to 
                  [𝐴]𝑡 = [𝐴]0𝑒
−𝑘1𝑡                                                                                                           (3.12)  
The above equations indicate that the plot of  [𝐴]𝑡 against time (𝑡) follows an 
exponential decay or growth.  
3.3.1.2 Reversible first-order reactions 
Reversible first-order reactions that attain equilibrium can be represented by the 




                                                                      (3.13) 
with the rate law; 






= −𝑘1[𝐴]𝑡 − 𝑘−1[𝐵]𝑡                                                       (3.14) 
At time 𝑡 = 0, [𝐵]0 = 0 and [𝐴]𝑡  = [𝐴]0, the concentration of B at time 𝑡 ([𝐵]𝑡) can be 
written as;  
                            [𝐵]𝑡 = [𝐴]0 − [𝐴]𝑡                                                                                                              (3.15) 
 Substitution of Equation 3.15 into Equation 3.14 gives;  
                           
−𝑑[𝐴]
𝑑𝑡
= 𝑘1[𝐴]𝑡 − 𝑘−1([𝐴]0 − [𝐴]𝑡)                                                                             (3.16) 
At equilibrium, there is no overall reaction, thus 
                            
−𝑑[𝐴]
𝑑𝑡
= 0                                                                                                                            (3.17) 
Therefore applying Equation 3.17 to Equation 3.14 gives;  
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              𝑘1[𝐴]𝑒𝑞 =  𝑘−1[𝐵]𝑒𝑞 =   𝑘−1([𝐴]0 −  [𝐴]𝑒𝑞)                                                        (3.18) 
or 
                          [𝐴]0 =
𝑘1 + 𝑘−1
𝑘−1
[𝐴]𝑒𝑞                                                                                          (3.19) 
Substituting [𝐴]0 from Equation 3.19 to Equation 3.16 yields;  
                      −
𝑑[𝐴]
𝑑𝑡
= (𝑘1 + 𝑘−1)[𝐴] − (𝑘1 + 𝑘−1)[𝐴]𝑒𝑞                                                      (3.20) 
Seperations of variables and integrating from time 𝑡 = 0 ([𝐴]0) to 𝑡 = 𝑡 ([𝐴]𝑡) leads to; 





= −(𝑘1 + 𝑘−1) ∫ 𝑑𝑡
𝑡
0
                                                    (3.21) 
 or 
                            ln
[𝐴]0 − [𝐴]𝑒𝑞
[𝐴]𝑡 − [𝐴]𝑒𝑞
= −(𝑘1 + 𝑘−1)𝑡                                                                      (3.22) 
Rearranging Equation 3.22 affords;  
                           ln([𝐴]𝑡 − [𝐴]𝑒𝑞) = −(𝑘1 + 𝑘−1)𝑡 + ln([𝐴]0 − [𝐴]𝑒𝑞)                               (3.23) 
A plot of ln([𝐴]𝑡 − [𝐴]𝑒𝑞)against time (t) will produce a straight line with a slope of 
−(𝑘1 +  𝑘−1). Experimentally, the observed rate constant, 𝑘𝑜𝑏𝑠 , can be used to 
determine the individual rate constants, 𝑘1 and 𝑘−1, for the forwad and backward 
reaction using Equation 3.24.  
                         𝑘𝑜𝑏𝑠 = 𝑘1 + 𝑘−1                                                                                                     (3.24) 
 It is crucial to also consider the equilibrium constant, 𝐾𝑒𝑞, since the above equation 
has two unknowns. Thus, Equations 3.24 and 3.25 can be solved simultaneously to 
determine the individual rate constants of the forward and backward reaction.3,6  






                                                                                                            (3.25) 
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3.3.2 second-order reactions 
For second-order reactions, the rate of the reaction depends on both reactant species, 
i.e. both reactant species are involved in the rate-determining step. Depending on the 
contribution of the reverse reaction, second-order reactions can be either reversible 
or irreversible.7 The reaction is irreversible when there is no significant contribution 
from the reverse reaction, otherwise it is reversible as shown in Equation 3.26.     





                                                                                            (3.26) 
The rate law of this reaction can be written as; 
                            − 
𝑑[𝐴]
𝑑𝑡






=  𝑘2 [𝐴]𝑡[𝐵]𝑡 −  𝑘−2 [𝐶]𝑡                           (3.27) 
Assuming that the stoichiometric ratio of all species involved in a reaction is 1:1:1, 
application of the mass balance at time, 𝑡, affords; 
                        [𝐴]𝑡 =  [𝐴]0 − [𝐶]𝑡  and  [𝐵]𝑡 =  [𝐵]0 −  [𝐶]𝑡                                            (3.28) 
At equilibrium, the above expressions can be written as; 
                           [𝐴]𝑒𝑞 =  [𝐴]0 −  [𝐶]𝑒𝑞   and  [𝐵]𝑒𝑞 =  [𝐵]0 −  [𝐶]𝑒𝑞                                  (3.29)  
At equilibrium, the rate of a forward reaction is equal to the one for a reverse 
reaction, as shown in Equation 3.30. 
                                − 
𝑑[𝐴]
𝑑𝑡
=  𝑘2 [𝐴]𝑒𝑞[𝐵]𝑒𝑞 −  𝑘−2 [𝐶]𝑒𝑞 = 0                                              (3.30) 
Hence, 
                                  𝑘2 [𝐴]𝑒𝑞[𝐵]𝑒𝑞 =  𝑘−2 [𝐶]𝑒𝑞                                                                         (3.31) 
Substituting the expression of [𝐶]𝑒𝑞 from Equation 3.29 into Equation 3.31 yield; 
                              𝑘2 [𝐴]𝑒𝑞[𝐵]𝑒𝑞 =  𝑘−2 ([𝐴]𝑒𝑞 − [𝐴]0)                                                            (3.32) 
This simplifies to;  
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                        𝑘−2 [𝐴]0  =     𝑘2 [𝐴]𝑒𝑞[𝐵]𝑒𝑞 +  𝑘−2 [𝐴]𝑒𝑞                                                       (3.33) 
Substituting the expression of [𝐶]𝑡 from Equation 3.28 into Equation 3.27 gives; 
                              − 
𝑑[𝐴]
𝑑𝑡
=  𝑘2 [𝐴]𝑡[𝐵]𝑡 −  𝑘−2 ([𝐴]0 −  [𝐴]𝑡)                                            (3.34) 
This simplifies to; 
                              𝑘2 [𝐴]𝑡[𝐵]𝑡 −  𝑘−2[𝐴]0𝑘2 [𝐴]𝑡                                                                        (3.35)  
Combining Equation 3.35 and Equation 3.33 affords;  
                           − 
𝑑[𝐴]
𝑑𝑡
=  𝑘2 [𝐴]𝑡[𝐵]𝑡 − 𝑘2 [𝐴]𝑒𝑞[𝐵]𝑒𝑞 −  𝑘−2 [𝐴]𝑒𝑞 +  𝑘−2[𝐴]𝑡            (3.36) 
Under pseudo-first order conditions,3,6 where [𝐵]0 ≫  [𝐴]0, Equation 3.36 becomes; 
                                 − 
𝑑[𝐴]
𝑑𝑡
=  𝑘2 [𝐴]𝑡[𝐵]0 − 𝑘2 [𝐴]𝑒𝑞[𝐵]0 −  𝑘−2[𝐴]𝑒𝑞 +  𝑘−2[𝐴]𝑡 
                                                = (𝑘2[𝐵]0 +  𝑘−2)([𝐴]𝑡 −  [𝐴]𝑒𝑞)                                               (3.37) 
Separation of variable and integrating from time = 0 ([𝐴]0) to time = 𝑡 ([𝐴]𝑡) gives;  
                                   ∫
𝑑[𝐴]
([𝐴]𝑡 −  [𝐴]𝑒𝑞)
[𝐴]𝑡
[𝐴]0
=  −(𝑘2 [𝐵]0 +  𝑘−2) ∫ 𝑑𝑡   
𝑡
0
                                (3.38) 
This results in; 
                                   In ( 
[𝐴]𝑡 − [𝐴]𝑒𝑞
[𝐴]0 −  [𝐴]𝑒𝑞
 ) =  −( 𝑘2 [𝐵]0 +   𝑘−2)𝑡 =  − 𝑘𝑜𝑏𝑠𝑡                  (3.39) 
where  
                                     𝑘𝑜𝑏𝑠  = 𝑘2 [𝐵]0 + 𝑘−2                                                                             (3.40) 
A plot of  𝑘𝑜𝑏𝑠 vs. [𝐵]0 is linear with a slope of 𝑘2 and the y-intercept of 𝑘−2. 
According to the above Equation, second-order rate constants, 𝑘2, can be determined 
by measuring the observed pseudo-first order rate constants, 𝑘𝑜𝑏𝑠 , as a function of 
nucleophile concentration (in this case [𝐵]0).    
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Some reactions do not establish equilibrium between the reactants and the formed 
products but instead go to completion. These reactions are known as irreversible 




                                                                    (3.41) 
The rate law of this reaction can be written as;  
𝑅𝑎𝑡𝑒 =  
𝑑[𝐶]
𝑑𝑡
=  − 
𝑑[𝐴]
𝑑𝑡
=  − 
𝑑[𝐵]
𝑑𝑡
=  𝑘 [𝐴]𝑡[𝐵]𝑡                                     (3.42) 
Considering the initial concentrations of reactants at time 𝑡 = 0 as [𝐴]0 and [𝐵]0, after 
a particular time, 𝑡, the concentration of reactants will be reduced to ([𝐴]0 − 𝑥) and 
([𝐵]0 − 𝑥), respectively, where x is the amount of reactants that has reacted to form 




=  𝑘2([𝐴]0 − 𝑥)([𝐵]0 − 𝑥)                                                                 (3.43) 
Since [𝐴]𝑡 = [𝐴]0 − 𝑥, it follows that − 
𝑑𝑥
𝑑𝑡
=  − 
𝑑[𝐴]
𝑑𝑡
, thus the rate law in Equation 
3.43 can be written as;  
𝑑𝑥
𝑑𝑡
=  𝑘2([𝐴]0 − 𝑥)([𝐵]0 − 𝑥)                                                                         (3.44) 
Seperation of variable and intergrating from x = 0 to x = x and t = 0 to t = t, yields;  
                         ∫
𝑑𝑥
([𝐴]0 − 𝑥)([𝐵]0 − 𝑥)  
𝑥
0
=  𝑘2 ∫ 𝑑𝑡          
𝑡
0
                                                      (3.45) 
Provided [𝐴]0 ≠ [𝐵]0 Equation 3.45 can also be written as;  
1
[𝐴]0 −   [𝐵]0
ln 
[𝐵]0 ([𝐴]0 − 𝑥)
[𝐴]0 ([𝐵]0 − 𝑥)
=  𝑘2𝑡                                                         (3.46) 
This expression can be simplified to;  
                           
1




=  𝑘2𝑡                                                                     (3.47) 
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From Equation 3.47, the second-order rate constant can only be determined if one 
knows the instantaneous concentrations of the reactants, i.e. [𝐴]𝑡 and [𝐵]𝑡. However, 
this is very complicated and inconvenient. 8-10 As a result, second order rate 
constants are usually studied under adjusted experimental conditions which 
simplify the kinetics to first-order. This is achieved by providing one of the reagents 
in large excess such that its concentration remains constant during the reaction. 
These experimental conditions are known as pseudo first-order conditions. For 
instance if [𝐵]0 ≫ [𝐴]0 then the rate law in Equation 3.42 can be expressed as;  
                           − 
𝑑[𝐴]
𝑑𝑡
=  𝑘2 [𝐴]𝑡[𝐵]𝑡 = (𝑘2[𝐵]0)[𝐴]𝑡 =  𝑘𝑜𝑏𝑠[𝐴]𝑡                                   (3.48) 
where, 
                              𝑘𝑜𝑏𝑠 = 𝑘2[𝐵]0                                                                                                    (3.49) 
A plot of  𝑘𝑜𝑏𝑠 vs. [𝐵]0 will give a straight line passing through the origin, with a 
slope of 𝑘2. For square planar complexes, the value of 𝑘2 measures a direct attach of 
the incoming nucleophile to the metal centre.  
3.4 Measurements of activation parameters 
Apart from the rate law, the magnitude of activation parameters also helps in the 
elucidation of the mechanism of action in which inorganic substitution reactions 
proceed. The enthalpy, entropy and volume of activation can be determined by 
measuring the second-order rate constant as a function of temperature and pressure, 
respectively.11 The mechanism can be assigned based on the magnitudes and signs of 
the values of these parameters. These parameters are formulated on the transition 
theory.3,6 This theory works on the assumption that a reaction between the metal 
complex (A) and the incoming nucleophile (B) passes through the transition state 
where it forms an activated complex (AB≠) before it converts to product (C).12-13 This 
reaction pathway can be represented as;  
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                                                                 (3.50) 







                                                                                 (3.51) 
where kb = Boltzmann’s constant (1.38 x 10-23 J/K), h = Plank’s constant (6.626 x 10-34 
J/s), T = Temperature in Kelvin and K≠ = Equilibrium constant.12 
It is known that the equilibrium constant is related to the experimental second-order 
rate constant according to Equation 3.52. 
                              𝑘2(exp) =  
𝑘𝑏𝑇
ℎ
𝐾≠                                                                                            (3.52) 
The Gibb’s free energy, ∆G≠, is also related to the equilibrium constant according to 
Equation 3.53. 
                             ∆𝐺≠ =  −𝑅𝑇 In 𝐾≠ =  ∆𝐻≠ − 𝑇∆𝑆 ≠                                                         (3.53) 
Substituting Equation 3.53 into Equation 3.52 yields the following expression; 












)                                                    (3.54) 
Taking the natural logarithm on both sides of Equation 3.54 yields; 
                             In (
𝑘2(𝑒𝑥𝑝)
𝑇












)                                        (3.58) 
Therefore a plot of In (
𝑘2(𝑒𝑥𝑝)
𝑇
) against  
1
𝑇
 , known as the Ering plot,5,13,14 is a straight 
line with a slope of  
− ∆𝐻≠
𝑅






 from which the enthalpy of 
activation (∆𝐻≠) and the entropy of activation (∆𝑆≠) can be determined, respectively.    
In an associatively-activated ligand substitution reaction mechanism, the magnitude 
of the ∆𝐻≠ values are small while the values of  ∆𝑆≠ are large and negative 
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compared to a dissociatively-activated mechanism of action whose ∆𝐻≠ and ∆𝑆≠  
values are usually large and positive.14,15   
3.5 Measurement of the activation volume 
The values of entropy of activation are not totally reliable especially when they are 
too small because of the errors associated with the determination of these values 
from the y-intercept by extrapolating to infinite temperatures.15,16 The most powerful 
and reliable parameter that can be used to supplement the entropy of activation data 
is the volume of activation, ∆𝑉≠.3,6,15 This can be determined from a series of 
experiments in which the second-order rate constant, 𝑘2, is recorded as a function of 
pressure in an isothermal system. Therefore, these measurements are of great 
interest in ligand substitution reactions since they allow for precise assignment of 
the underlying mechanism.15,17 The principle on which the volume of activation is 
based on is outlined from the thermodynamic equation below;  












Δ                                                                                       (3.59) 
Substituting the expression of Gibb’s free energy (Equation 3.53) in Equation 3.59 
followed by rearranging the equation simplifies it to;  
                                       (
𝑑 In 𝑘2
𝑑𝑝
) =  − 
∆𝑉
𝑅𝑇
                                                                                 (3.60) 
where ∆𝑉 = the change in partial molar volume between products and reactants. 
In the transition state, Equation 3.60 can be used to write the expression for the 
volume of activation, ∆𝑉≠. 
                                     (
𝑑 In 𝑘2
𝑑𝑝
) =  − 
∆𝑉≠
𝑅𝑇
                                                                                 (3.61) 
Integrating this equation from P = 0  to P = P to gives; 









     
(3.62)                                                       
where 02)(k = second-order rate constant at zero pressure 
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A plot of In 𝑘2 against P is linear and the activation volume can be calculated from 
the slope of the graph. Positive values of ∆𝑉≠ signify a dissociative mechanism 
whereas negative ∆𝑉≠ values indicate an associative mechanism. Therefore, the 
volume of activation changes with the mechanism in the same way as the entropy of 
activation.  
3.6 Techniques for studying chemical kinetics 
Kinetic investigations are normally accomplished by monitoring the dependence of 
some physical variables (e.g. absorbance) which are proportional to the 
concentration of the reactants or products as a function of time. The experimental 
technique selected for kinetic measurements depends on how fast or slow the 
reaction is. For example, fast reactions that complete within time range from 10-14 s 
to 60 s require a specialised instrumentation for rapid mixing of the reactants and 
rapid data collection.18 Under such conditions, the instrument used to collect the 
kinetic data must be programmed to continuously record the concentration profiles 
of a reaction over time. For slow reactions, the reaction kinetics can be studied using 
conventional techniques.16,19  
Various experimental techniques have been developed to study reaction kinetics. 
These include flow methods (e.g. stopped-flow analysis), UV/visible 
spectrophotometry, pulse methods and nuclear magnetic resonance (NMR) 
spectroscopy.3,13 Despite the number of techniques available, only UV/visible and 
stopped-flow spectrophotometric methods will be briefly reviewed in this thesis.  
3.6.1 UV/visible spectrophotometric technique     
UV/visible spectrophotometer is used to monitor reactions which take longer than 
16 minutes to complete.20 It is a sensitive technique which can detect sample 
concentrations within the optimum range of 10-4 to 10-6 mol/dm3.20 The instrument 
consists of key components (Figure 3.2) including two light sources, one in the 
visible region (800-400 nm; Tungsten lamp) and another one in the ultraviolet region 
(400-200 nm; deuterium lamp), monochromator, detector, data processor and 
internal or external temperature control unit.19,21  
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Figure 3.2: Schematic representation of a UV/Visible spectrophotometer.21  
Photomultiplier tube is the detector commonly used in the UV/visible 
spectrophotometer which measures transmitted radiation as photons. This detector 
comprises of a photoemitive cathode that emits electrons when struck by photons 
from the UV/visible radiation. A cascade of electrons produced is amplified at the 
dynodes before they are collected at the anode, resulting in a current that is 
amplified and measured. Transparent tandem cuvettes made up of quartz are used 
for initiating the reaction. These cuvettes have two separate compartments that allow 
for reactants to be pre-equilibrated at a required temperature before manually 
mixing them to start the reaction.  
The light passing through the sample (transmittance) can be represented as; 
I
I
T 0                                                                                           (3.63)         
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where I0 is the intensity of the incident light obtained from the solvent reference cell 
and I is the transmitted light from the power source passing through the sample cell.  
This is related to the absorbance according to the following equation; 
TA  log                                                                                    (3.64) 
For dilute solutions, absorbance is also related to the concentration according to the 
Beer’s Law (Equation 3.65).19  
εclA                                                                                           (3.65) 
where A 3 mol-1 cm-1), c is the 
concentration (mol/dm3) and l is the path length (cm).  
For a first-order reaction, 
X Y
k1
                                                        (3.66) 
the absorbance at any time t can be written as;  
                                    [Y][X] YX εεAt   (3.67) 
X and Y= molar absorptivity of X and Y, respectively.  
Once the reaction has gone to completion, the absorbance can be represented as;  
                                     0Y0X [Y][X] εεA    (3.68) 
where A∞ = the absorbance at the end of the reaction and [X}0 & [X]0 = initial 
concentration of X and Y, respectively.  
The integrated rate law of the absorbance expressions (Equations 3.67 and 3.68), 
shown in Equation 3.69 can be used for kinetic analysis.  




















                                                     (3.69) 
From the above equation, a least-squares fit of the absorbance versus time at a 
specific wavelength can be used to determine the observed rate constant (kobs). By 
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monitoring the reaction at different concentrations, second-order rate constants can 
be determined. The reactions can also be performed at different temperatures and 
constant concentration to determine the activation parameters.  
3.6.2 Stopped-flow technique  
 Some chemical reactions occur too fast to be monitored by conventional UV/visible 
spectrophotometer. Such reactions require shorter sampling and mixing times. 
Stopped-flow technique is a commonly used tool for investigating kinetic processes 
that go to completion in the time range of milliseconds to hundreds of seconds.22 
Schematic diagram of the stopped-flow analyser is shown in Figure 3.3. In the 
stopped-flow analyser, the two reactants are mixed rapidly from the syringes by a 
compressed gas-driven piston (800 kPa) into a mixing jet or a reaction chamber 
(Figure 3.3). The mixing takes approximately 10-3 s then the resultant solution is 
driven into the cuvettes. The solution mixture is then allowed to rest at a fixed time 
interval. The reactive species is monitored and detected spectrophotometrically 
during the rest period. The reaction is monitored at a pre-determined constant 
temperature from the injection point to the reaction stage at the mixing chamber. 
Once the reaction is initiated, transmitted light is converted to an electric current in a 
photomultiplier unit then a signal is sent to a computer at an appropriate time 
interval. The data acquisition system promptly records absorbance–time resolved 
kinetic trace at a specific wavelength.        
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Chapter 4 
The role of substituents in a bidentate N,N-chelate on the 
substitution of aqua ligands from bifunctional Pt(II) 
complexes 
4.0 Abstract 
The rate of substitution of aqua ligands from three bifunctional Platinum(II) 
complexes, viz., [Pt{2-(pyrazol-1-ylmethyl)pyridine}(H2O)2](ClO4)2, [Pt(H2Py)], [Pt{2-
(3,5-dimethylpyrazol-1-ylmethyl)pyridine}(H2O)2](ClO4)2, [Pt(dCH3Py)], and [Pt{2-
[(3,5-bis(trifluoromethyl)pyrazoly-1-ylmethyl]pyridine}(H2O)2](ClO4)2, [Pt(dCF3Py)], 
by three neutral sulfur donor nucleophiles, viz., thiourea (TU), N,N-
dimethylthiourea (DMTU), and N,N,N’,N’-tetramethylthiourea (TMTU), were 
studied in aqueous perchloric acid medium of constant ionic strength. The 
substitution reactions were investigated under pseudo-first order conditions as a 
function of nucleophile concentration and temperature using UV/visible and 
stopped-flow spectrophotometries. The observed pseudo-first order rate constants, 
𝑘𝑜𝑏𝑠 (1 2⁄ ), for the step-wise substitution of the first and second aqua ligands obeyed 
the rate laws: 𝑘𝑜𝑏𝑠 (1 2⁄ )= 𝑘2 (1st 2nd⁄ )[Nu]. The first substitution reaction takes place 
trans to the pyrazole ligand, while the second entering nucleophile is stabilised on 
the reaction site trans to the pyridine ligand. The order of reactivity: Pt(dCF3Py) > 
Pt(H2Pyrd) > Pt(dCH3Py) was found for the first aqua substitution, while that of a 
second aqua was Pt(H2Py) ≈ Pt(dCF3Py) > Pt(dCH3Py). Spectrophotometric acid-
base titrations were performed to determine the pKa values of the coordinated aqua 
ligands. Lower pKa values were recorded for the aqua ligands trans to the pyridine 
ring, when compared to pKa values which were observed for the aqua ligand trans to 
the pyrazole ring. Density functional theoretical (DFT) calculations were performed 
to support the interpretation and discussion of the experimentally obtained kinetic 
and thermodynamic results.   
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4.1 Introduction 
The antitumor activity of cisplatin initiated extensive investigations on platinum 
coordination compounds.1 Cisplatin is still one of the most used anticancer drugs on 
the market.2 However, it has a narrow spectrum of activity and its clinical use is 
accompanied by severe side effects, including ototoxicity, neurotoxicity, 
nephrotoxicity, myelosuppression, nausea and vomiting.3 To overcome these 
limitations, considerable efforts have been made on designing new drugs with a 
potential to display improved therapeutic properties, through understanding their 
ligand exchange reactions which are thought to be responsible for cytotoxicity.3  
Early kinetic studies on the mechanism of action of cisplatin and its analogues, 
established the empirical relationships between the structures of the platinum 
complexes and their activity which Cleare and Hoeschele termed the structure-
activity relationships (SARs).4,5 A cis-geometry on the complex of the form cis-[Pt(N-
N)X2], where N = nitrogen donor ligands and X = labile group, was postulated as the 
basic requirement for the anticancer activity.  This cis-geometry is still of interest in 
the search for effective antitumour drugs. 
The conformational instability of the helical structure of DNA, caused by the binding 
of Pt(II) drugs is now known as one of the mechanisms responsible for cytotoxicity.6 
However, there are many other competing biomolecules that can react with the Pt(II) 
complexes such as peptides, proteins and enzymes.7 In particular, sulfur-containing 
biomolecules have a high affinity for Pt(II) drugs. Their reactions are associated with 
nephrotoxicity and neurotoxicity.7,8 It remains unclear how Pt(II) drugs reach their 
target (genomic DNA), despite their stronger affinity for binding to S-containing 
nucleophiles known to be ubiquitous in the blood serum and cytoplasm.8,9 A 
plausible hypothesis is that S-containing nucleophiles initially bind to the Pt(II) 
metal centre to form stable intermediates which subsequently convert to 
thermodynamically more stable Pt-DNA adducts in the nucleus.3,6 These Pt-Sulfur 
adducts  have been regarded as  Pt(II) drug reservoirs.  
Understanding the mechanistic pathways and the reactivity of Pt(II) complexes both 
in vitro and in vivo is vital in the rational design of new compounds with improved 
potency.6-9 Tailoring the steric and electronic properties of the non-leaving ligands 
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around Pt(II) ions can  be a useful tool for optimising cytotoxicity and circumvention 
of drug resistance.10  
Recent studies have shown that π-acceptors increase the electrophilicity of the Pt(II) 
centre due to π-back-bonding, resulting in an increase in the rate of nucleophilic 
substitution.11 van Eldik and co-workers12 systematically studied the effect of 
different N-donor non-leaving ligands on the reactivity of diaqua P(II) complexes of 
the type cis-[Pt(N-N)(H2O)2]2+, where N-N = ethylenediamine (en), 
diaminocyclohexane (dach), aminomethylpyridine (amp) and bipyridine (bpy).  
These complexes have one (amp) or two (bpy) π-accepting pyridine rings 
coordinated to the Pt(II) centre. Reactivity of the complexes increased in a 
proportional manner with an increase in π-accepting rings.  
In a related study of Pt(II) complexes with N-N/N-S bidentate ligands viz. cis-
[Pt(NH3)2Cl2], cis-[Pt(en)Cl2], cis-[Pt(dach)Cl2] and cis-[Pt(SMC)Cl2]− (where SCM = 
S-methyl-L-cysteine), the lability of the chloride was found to depend on both steric 
and electronic effects of the non-leaving group.13 The rate of substitution followed 
the order: [Pt(dach)Cl2] < [Pt(en)Cl2] < cis-[Pt(NH3)2Cl2] < [Pt(SMC)Cl2]−. High 
reactivity of [Pt(SMC)Cl2]− was attributed to the strong trans-labilization effect of the 
coordinated sulphur donor, as evidenced by the elongation of the Pt-Cl bond in a 
trans position. [Pt(dach)Cl2] was the least reactive complex because of the steric 
congestion due to the diaminocyclohaxane group which also imparts some positive 
inductive effect to the Pt(II) centre, making it less electrophilic.13  
To further our understanding on the role of cis and trans σ/π-effects as well as the 
steric influence on the thermodynamic and kinetic properties of Pt(II) complexes, 
three Pt(II) complexes with flexible (pyrazolylmethyl)pyridine ligands (Figure 4.1) 
were synthesised and their substitution kinetics were studied. The 
(pyrazolylmethyl)pyridine ligand was altered by incorporating  either methyl or 
trifluoromethyl groups in 3,5-positions of the pyrazole ring. Sulfur-containing 
nucleophiles, viz. thiourea (TU), N,N-dimethylthiourea (DMTU), and N,N,N’,N’-
tetramethylthiourea (TMTU) were used to substitute the two aqua labile ligands.  
Thiourea nucleophiles were chosen because of their neutral character, good 
solubility, high nucleophilicity, and biological relevence.3,14 Thiourea is used as a 
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protective agent to minimise nephrotoxicity, following cisplatin treatment.3 In 
addition, thioureas combine ligand properties of thiolates (σ-donors) and thioethers 
(σ-donors and π-acceptors) which are present in the biological systems.15                                                                          
The substitution kinetics of the diaqua complexes was undertaken, since they are 
considered to be reactive species in the crucial step of the binding of cisplatin to 
DNA.11 The density functional theoretical (DFT) calculations were used to support 







Figure 4.1: Chemical structures of the bifunctional Pt(II) complexes. The perchlorate 
(ClO4




All synthetic manipulations of the ligands were carried out in air, whereas the 
coordination of the ligands to the platinum metal was performed under inert 
atmosphere of nitrogen using standard Schlenk techniques. The ligand precursors, 2-
(chloromethyl)pyridine hydrochloride (98%), pyrazole (98%), 3,5-dimethylpyrazole 
(99%), 3,5-bis(trifluoromethyl)pyrazole (99%) as well as the metal salts, potassium 
tetracloroplatinate (K2PtCl4, 99+%) and sodium perchlorate monohydrate 
(NaClO4.H2O, 98%) were all purchased from Aldrich and used without further 
purification. Silver perchlorate (AgClO4, 99+%, Aldrich) was stored under nitrogen 
and used as received. Perchloric acid (HClO4, 70% solution) and hydrochloric acid 
(HCl, 32% solution) were obtained from Saarchem and used as supplied. The 
nucleophiles thiourea (TU, 99%), N,N-dimethylthiourea (DMTU, 99%) and 
N,N,N’,N’-tetramethylthiourea (TMTU, 98%) were also obtained from Aldrich and 
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used without further purification. Ultrapure water (MODULAB purification system) 
was used for all aqueous reactions. All other chemicals and solvents were of reagent 
grade and used as received.  
 
4.2.2 Synthesis of the ligands 
Three ligands, namely 2-(pyrazol-1-ylmethyl)pyridine (H2Py), 2-(3,5-dimethyl-
pyrazol-1-ylmethyl)pyridine (dCH3Py) and 2-[(3,5-bis(trifluoromethyl)pyrazol-1-
ylmethyl]pyridine (dCF3Py) were prepared via a phase transfer catalysed N-
alkylation reaction of either pyrazole, 3,5-dimethylpyrazole or 3,5-
bis(trifluoromethyl)pyrazole with 2-(chloromethyl)pyridine hydrochloride in a 
biphasic medium (Scheme 4.1) following a method described by Steel et al.16 Copious 
amount of water was used to completely remove tetrabutylamonium chloride 
(TBAC) from the organic phase. All ligands were obtained in moderate to high 
yields (63-90%) and collected as either yellow or brown oils of sufficient purity for 
subsequent use in platinum coordination. The purity of the ligands was confirmed 





R = H     ; (H
2
Py)
R = CH3 ; (dCH3Py)
R = CF3  ; (dCF3Py)  
Scheme 4.1: Synthesis of the (pyrazolylmethyl)pyridine ligands.   
 
2-(pyrazol-1-ylmethyl)pyridine (H2Py) 
A mixture of 2-(chlroromethyl)pyridine hydrochloride (2.72 g; 16.6 mmol) and 
pyrazole (1.13 g; 16.6 mmol) was dissolved in toluene (50 mL), to which 25 mL of 
40% aqueous NaOH and 10 drops of 40% aqueous tetrabutylammonium chloride 
(TBAC) was added. The mixture was refluxed for 24 h after which the organic phase 
was extracted with dichloromethane (CH2Cl2) and evaporated under reduced 
pressure to yield a brown-yellow oil. The crude product was re-dissolved in CH2Cl2, 
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washed with water (3 x 50 mL), and then further purified by column 
chromatography, using a short-column of aluminium oxide and CH2Cl2 as an eluent. 
The organic extracts were dried over anhydrous MgSO4 and evaporated under vacuo 
to afford an analytically pure bright yellow oil of H2Py.  
Yield = 2.379 g (90 %). 1H NMR (400 MHz: CDCl3): H (ppm); 5.37 (s, 2H, -CH2-), 6.22-
6.23 (t, 1H, pz), 6.87-6.89 (d, 1H, py), 7.07-7.09 (t, 1H, py), 7.44-7.45 (t, 1H, py), 7.48-
7.53 (m, 2H, pz), 8.46-8.47 (d, 1H, py). 13C NMR (100 MHz: CDCl3 C (ppm); 57.40, 
106.13, 121.59, 122.65, 129.94, 136.99, 139.84, 149.31, 156.66. TOF MS-ESI+ m/z: 
160.0873, 100% (M+1). Anal. calculated for C9H9N3:  C, 67.90; H, 5.70, N, 26.40%. 
Found: C, 67.26; H, 5.35; N, 26.54%. 
 
Ligands dCH3Py and dCF3Py were prepared following the same procedure for 
H2Py, with 3,5-dimethylpyrazole and 3,5-bis(trifluoromethyl)pyrazole used  instead 
of unsubstituted pyrazole, respectively. All ligands were stored under nitrogen until 
their subsequent platination.        
2-(3,5-dimethylpyrazolyl-1-ylmethyl)pyridine (dCH3Py) 
Yield = 1.917 g (77 %, bright-yellow oil). 1H NMR (400 MHz: CDCl3 H (ppm); 2.10 
(s, 3H, CH3, pz), 2.19 (s, 3H, CH3, pz), 5.28 (s, 2H, -CH2-), 5.82 (s, 1H, pz), 6.72-6.74 (d, 
1H, py), 7.04-7.07 (t, 1H, py), 7.47- 7.51 (t, 1H, py), 8.45-8.46 (d, 1H, py). 13C NMR 
(100 MHz: CDCl3 C (ppm); 10.97, 13.49, 54.32, 105.65, 120.89, 122.29, 128.25, 136.95, 
139.59, 149.17, 157.39. TOF MS-ESI+ m/z: 188.1185, 100% (M+1). Anal. calculated for 
C11H13N3:  C, 70.56; H, 7.00, N, 24.44%. Found: C, 70.09; H, 6.81; N, 22.69%. 
 
2-[(3,5-bis(trifluoromethyl)pyrazoly-1-ylmethyl]pyridine (dCF3Py) 
Yield= 1.483 (63%, light brown oil). 1H NMR (400 MHz: CDCl3 H (ppm); 5.68 (s, 
2H, -CH2-), 6.95-6.97 (d, 1H, py), 7.00 (s, 1H, pz), 7.26-7.30 (t, 1H, py), 7.68- 7.73 (t, 
1H, py), 8.61-8.62 (d, H, py). 13C NMR (100 MHz: CDCl3): C (ppm); 57.08, 106.57, 
117.73, 120.41, 120.97, 123.13, 133.91, 137.07, 142.64, 149.64, 154.35. TOF MS-ESI+ m/z: 
296.057, 100% (M+1). Anal. calculated for C11H7N3F6:  C, 44.76; H, 2.39, N, 14.24%. 
Found: C, 44.42; H, 2.46; N, 14.41%. 
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4.2.3 Synthesis of Pt(II) complexes 
The complexes, viz., [Pt{2-(pyrazol-1-ylmethyl)pyridine}Cl2], [Pt(H2Py)Cl2], [Pt{2-
(3,5-dimethylpyrazol-1-ylmethyl)pyridine}Cl2], [Pt(dCH3Py)Cl2], and [Pt{2-[(3,5-
bis(trifluoromethyl)pyrazoly-1-ylmethyl]pyridine}Cl2], [Pt(dCF3Py)Cl2], were 
synthesised following a common method adopted from Rauterkus et al.17 with minor 
modifications. K2PtCl4 (0.20 g; 0.48 mmol) was stirred for about 10 min in ultrapure 
water (35 mL).  To this solution the ligand (0.48 mmol) dissolved in a small amount 
of CH2Cl2 was added in a drop-wise manner. The reaction mixture was stirred under 
reflux for 24 h (in the dark) and then cooled to room temperature. The resulting 
yellow precipitate was collected by filtration and sequentially washed with small 
amounts of water, methanol and diethyl ether. It was then thoroughly dried under 
vacuum to get a fine yellow powder of the neutral complex. For the formation of the 
complex, [Pt(dCF3Py)Cl2], 0.01 M HCl solution was used instead of ultrapure water. 
The purity was confirmed by 1H NMR, 13C NMR, 195Pt NMR, elemental analysis, 
TOF MS-ESI+ and infrared (IR) spectroscopy.   
[Pt(H2Py)Cl2]. Yield: 154 mg (75 %). 1H NMR (400 MHz: DMSO-d6): H (ppm); 5.81 (s, 
2H, -CH2-), 6.56-6.57 (t, 1H, pz), 7.59-7.63 (t, 1H, py), 7.75-7.78 (d, 1H, py), 7.88- 7.89 
(d, 1H, py), 8.17-8.24 (dd, 2H, pz), 9.14-9.16 (d, 1H, py). 13C NMR (100 MHz: DMSO-
d6): C (ppm); 57.72, 107.67, 126.55, 126.76, 134.36, 141.03, 141.39, 151.96, 153.84. 195Pt 
NMR (107 MHz: DMSO-d6 Pt (ppm); -2189.72 . TOF MS-ESI+ m/z: 390.028 (M-Cl)+. 
IR (KBr) cm-1: 451, 617, 702, 759, 1078, 1155, 1273, 1421, 1611, 2852, 2922. Anal. 
calculated for C9H9N3PtCl2:  C, 25.42; H, 2.13, N, 9.88%. Found: C, 25.56; H, 2.60; N, 
9.97%. 
[Pt(dCH3Py)Cl2]. Yield: 186 mg (86%). 1H NMR (400 MHz: DMSO-d6): H (ppm); 2.42 
(s, 3H, CH3, pz), 2.44 (s, 3H, CH3, pz), 5.61-5.65 (d, 1H, -CH2-, AB-spin system), 5.81-
5.84 (d, 1H, -CH2-, AB-spin system), 6.14 (s, 1H, pz), 7.55-7.58 (t, 1H, py), 7.92-7.94 (d, 
1H, py), 8.11-8.22 (d, 1H, py), 8.94-9.14 (d, 1H, py). 13C NMR (100 MHz: DMSO-d6): 
C (ppm); 11.63, 14.34 , 53.06 , 108.14, 126.15, 126.63, 140.91, 142.90, 151.41, 152.97, 
153.93. 195Pt NMR (107 MHz: DMSO-d6): Pt (ppm); -2158.67. TOF MS-ESI+ m/z: 
418.060 (M-Cl)+. IR (KBr) cm-1: 454, 601, 675, 780, 800, 1154, 1225, 1278, 1418, 1471, 
- 80 - 
 
1552, 1605, 2163, 2853, 2919. Anal. calculated for C11H13N3PtCl2:  C, 29.14; H, 2.89, N, 
9.27%. Found: C, 28.99; H, 3.28; N, 9.20%.   
[Pt(dCF3Py)Cl2]. Yield:  170 mg (63%). 1H NMR (400 MHz: DMSO-d6): H (ppm); 5.89-
5.93 (d, 1H, -CH2-, AB-spin system), 6.39 (s, 1H, pz), 6.49-6.53 (d, 1H, -CH2-, AB-spin 
system), 7.61-7.65 (d, 1H, py), 7.93- 7.98 (t, 1H, py), 8.15-8.19 (t, 1H, py), 8.91-8.92 (d, 
1H, py). 13C NMR (100 MHz: DMSO-d6 C (ppm); 57.04, 107.93, 122.08, 123.76, 
124.03, 137.73, 141.51, 149.86, 154.61, 154.92, 15.92. 195Pt NMR (107 MHz: DMSO-d6): 
Pt (ppm); -2888.75. TOF MS-ESI+ m/z: 525.979 (M-Cl)+. IR (KBr) cm-1: 469, 778, 829, 
976, 1045, 1095, 1129, 1227, 1275, 1384, 1599, 1643, 2741, 2922. Anal. calculated for 
C11H7N3PtCl2F6:  C, 23.54; H, 1.26, N, 7.49%. Found: C, 23.70; H, 1.30; N, 7.54%.       
 
4.2.4 Preparation of diaqua Pt(II) complexes 
The solutions of diaqua Pt(II) complexes Pt(H2Py), Pt(dCH3Py) and Pt(dCF3Py) 
(Figure 4.1), were prepared as described in the literature.18 Accurately weighed 
dichloro Pt(II) complex and AgClO4 (1.98 molar ratio) were suspended in 0.01 M 
HClO4 and the mixture was vigorously stirred at 50 °C for 24 h in the dark. The 
white precipitate of silver chloride (AgCl) was filtered off through 0.45 μm nylon 
membrane using a Millipore filtration setup. The clear and colourless filtrate was 
diluted with 0.01 M HClO4 in a volumetric flask to make the required concentration 
of the complex in solution. An acidic medium (pH = 2) was necessary to ensure that 
only diaqua complexes and not the mixture of aqua/hydroxo complexes, were 
present in solution once the metathesis reaction was complete. The adjustment of I = 
0.10 M with NaClO4 was done to ensure a constant ionic strength throughout the 
kinetic measurements.  
 
4.2.5 Instrumentation and physical measurements    
NMR spectra of the ligands and complexes were recorded on the Bruker Avance 
DRX 400 or DRX 500. Low resolution electrospray ionization (ESI+) mass spectra of 
the ligands and the complexes were recorded on a time-of-flight (TOF) micromass 
spectrometer. Infrared (IR) spectra were acquired using KBr discs on a Perkin Elmer 
Spectrum One FTIR spectrometer. Elementary composition of all synthesised 
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compounds was determined on FLASH 2000 CHN analyser. Kinetic measurements 
of fast reactions were monitored using an Applied Photophysics (v4.33) SX.18 MV 
stopped-flow spectrophotometer coupled to an online data acquisition system. The 
temperature of the instrument was controlled to within ± 0.1 °C for all 
measurements. Spectrophotometric pH titrations, preliminary wavelength searching 
experiments as well as kinetic measurements for the slow reactions were recorded 
on a Cary 100 Bio UV-visible spectrophotometer equipped with a Varian Peltier 
temperature thermostat with an accuracy of ± 0.05 °C. The pH measurements were 
determined on a Jenway 4330 pH meter equipped with a 4.5 μm glass electrode. The 
microelectrode was calibrated at 25 °C using the standard buffer solutions (Merck) at 
pH 4.0, 7.0 and 10.0. pKa titration curves and time-dependent kinetic traces were 
graphically analysed using Origin 7.5® software package.19  
 
4.2.6 Measurements of pKa values of the diaqua Pt(II) complexes 
Spectrophotometric pH titrations of diaqua Pt(II) complexes were performed in the 
pH range of 2-10, using NaOH as a base. To minimise dilution effects due to the 
addition of the titrant, and hence the shifting of the baseline, a large volume (300 
mL) of the metal complex solution was used for titration and small amounts of 
crushed NaOH pellets were used within the pH range of 2-3. Dilute NaOH and 
HClO4 solutions of decreasing concentrations were used in the manner that ensured 
as many evenly distributed points were obtained on the rising or falling parts of the 
titration curve. Upon the addition of HClO4 as a titrant, the reversibility of the 
titration reaction was observed with the baseline remaining intact. Small vials were 
used for sampling out 2 mL aliquots of the complex solution for pH measurements. 
These aliquots were then discarded after each measurement to avoid the in situ 
contamination of the complex solution by chloride ions which may be released from 
the electrode. Following each titrant addition, the solution was allowed to stir before 
its pH and respective absorbance spectrum were acquired. Sample aliquots from 
each absorbance measurements were returned to the stock solution of the complex 
for re-use.   
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4.2.7 Kinetic measurements 
All substitution reactions were performed under pseudo first-order conditions, as a 
function of nucleophile concentration and temperature. The nucleophile 
concentration was provided in at least 20-fold excess over that of a bifunctional Pt(II) 
complex. This afforded a 10-fold excess of the nucleophile concentration for each of 
the two coordinated leaving groups, which is sufficient to force the reactions to go to 
completion. A pH of 2.0 was maintained throughout the kinetic runs to guarantee 
the presence of only diaqua complexes (based on the pKa results; Table 4.1). Slow 
reactions were initiated by manually mixing equal volumes of the complex and 
nucleophile solutions manually in a Suprasil tandem cuvette. For fast reactions, 
equal amounts of pre-equilibrated complex and nucleophile solutions were mixed 
through a pressure-driven cross-plunging technique in the chamber of the stopped-
flow analyser.  Suitable wavelengths at which kinetic measurements were performed 
were established spectrophotometrically by monitoring spectral changes 
(absorbance vs. wavelength) due to mixing of the Pt(II) metal complex and 
nucleophile solutions. These are summarised in Table SI 4.1 (supporting 
information). 
 
4.2.8 Computational calculations 
In an effort to gain insight into the experimental data as well as to understand the 
electronic differences of the bifunctional Pt(II) complexes, computational calculations 
were performed. The ground state electronic structures of Pt(H2Py), Pt(dCH3Py) and 
Pt(dCF3Py) were optimized at the Density Functional Theoretical (DFT) level, to 
identify energy-minimized structures based on B3LYP/LanL2DZ (Los Alamos 
National Laboratory 2 Double ζ) level of theory.20 B3LYP refers to Becke’s three 
parameter functional hybrid exchange with functional correlation gradient of Lee, 
Yang and Parr basis set.21,22 This method is suitable for gaseous simulations of 
compounds containing heavy atoms such as platinum. The aqua complexes were 
each modelled at +2 with respect to their total charge. A singlet state was assumed 
due to low electronic spin of Pt(II) complexes. Gaussian09 suite of programs was 
used for all computational analysis.23    
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4.3 Results  
In order to investigate the electronic and steric effects of the non-leaving ligands, 
three bifunctional Pt(II) complexes with (pyrazolylmethyl)pyridine ligands  (Figure 
4.1) were synthesised, characterised and their ligand substitution reactions studied 
kinetically and thermodynamically. The ligands were altered by introducing 
substituents on the 3,5-positions of the pyrazole ring. 
 
4.3.1 Acid-base equilibrium of diaqua Pt(II) complexes  
Representative spectral changes in absorbance recorded as a function of wavelength 
during the pH titration of Pt(dCH3Py) with NaOH are shown in Figure 4.2. The pKa 
value of each coordinated aqua ligand was determined by plotting the absorbance as 
a function of pH at a suitable wavelength. A typical example is presented as an inset 
in Figure 4.2. The resulting pKa values of the coordinated aqua ligands were 
obtained by fitting the data to two concerted sigmoidal function (Boltzman) using 
origin 7.5® software.19  
 
Figure 4.2: UV/visible spectra for the titration of 0.06 mM Pt(dCH3Py) with NaOH 
in the pH range 2-10 at T = 298.15 K. Insert:  Boltzmann fit of the pH data at 305 nm. 
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All diaqua Pt(II) complexes exhibited three different absorbance maxima, which 
shifted towards higher wavelengths with increasing pH (also see Figure SI 4.3). This 
suggests the presence of three different species in solution as a function of pH viz. 
diaqua, aqua-hydroxo and dihydroxo complexes. This is also supported by the 
presence of three isosbestic points. In addition, the absorbance versus pH plots for all 
diaqua complexes exhibited two quasi-inflection points, which is a clear indication of 
two concerted deprotonation steps with equilibrium constants, Ka1 and Ka2 as shown 










 Scheme 4.2: Proposed stepwise deprotonation of the diaqua Pt(II) complexes.  
 
Table 4.1 summarises the pKa values for diaqua Pt(II) complexes. Included for 
comparison purposes are the pKa values of [Pt(aminimethylpyridine)(H2O)2]2+ 
Pt(amp) and [Pt(N,N’-bipyridine(H2O)2]2+, Pt(bpy).12  
 
Table 4.1.   Summary of pKa data for the deprotonation of Pt-bound aqua ligands in 
the bifunctional Pt(II) complexes 
 
van Eldik and co-workers,12,24,25 investigated a set of similar bifunctional Pt(II) 
complexes with bidentate nitrogen-donor ligands. A distinction between the first 
and second deprotonation site was made. They proposed the first step to occur at an 
aqua trans to the pyridine ring. Because of the similarity of their complexes to those 
investigated in this work, we also postulate that the first deprotonation step occurs 
 Pt(H2Py) Pt(dCH3Py) Pt(dCF3Py) Pt(amp) Pt(bpy) 
pKa1 4.85 ± 0.06 5.29 ± 0.10 4.76 ± 0.05 5.82a 4.80a 
pKa2 6.30 ± 0.02 6.32 ± 0.14 6.27 ± 0.02 6.83a 6.32a 
a pKa value of related bifunctional  Pt(II) complexes extracted from ref.12 
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to the aqua ligand trans to the pyridine ring, followed by the one trans to pyrazole 
ring as indicated in Scheme 4.1. The electron density on the Pt(II) centre and the 
coordinated hydroxo ligands are stabilised by the electron-withdrawing ability of 
the π-accepting pyridine ring, which leads to lower pKa values.24,25 The pyrazole ring 
has a stronger σ-donor strength than pyridine, making the bond between aqua 
ligand positioned trans to this group weaker due to its strong trans-influence in the 
ground state. 24,25 This is evidenced by a longer Pt−OH2 (1) bond trans to the pyrazole 
ring compared to the Pt−OH2 (2) bond trans to the pyridine ring (Table 4.2). 
Consequently, a higher pKa value is obtained for the aqua ligand trans to the 
pyrazole ring, compared to the one trans to pyridine (Table 4.1).  
Previous studies have shown that the pKa values of aqua Pt(II) complexes decrease 
as the π-accepting capacity of the core ligand increases due to an increased acidity of 
the coordinated aqua ligand.11,25,26 However, the enhancement of the σ-donor 
strength of the ligand leads to a higher pKa value due to the increased basicity of the 
coordinated aqua ligand.24,26,27 Similarly, the introduction of electron-donating 
methyl groups to the pyrazole ring as in Pt(dCH3Py) increase the σ-donor strength of 
the coordinated pyrazole resulting in a moderate increase in the pKa(1/2) values for 
this complex compared to Pt(H2Py). Alternatively, the introduction of an electron-
withdrawing trifluoromethyl groups to the pyrazole ring as in Pt(dCF3Py) results 
into a decrease in the pKa(1/2) values due to an increased π-acceptibility and decreased 
σ-donor capacity of the pyrazole ring. It is also noted that the formation of dihydroxo 
species from the aqua/hydroxo species occurs at a higher pH than the first 
deprotonation step. This has been reported before in related bufunctional Pt(II) 
complexes,12,25 and is attributed to a decrease in the overall charge from +2 to +1 on 
forming the hydroxo species. Since the pKa values depend on the electrophilicity of 
the metal centre,11,26,27 the introduction of different substituents on the pyrazole 
ligand has a significant influence on the lability of the coordinated aqua ligands in 
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4.3.2 DFT-calculated optimised structures 
The geometry-optimised structures for the bifunctional Pt(II) complexes and the 
calculated data are shown in Figure 4.3 and Table 4.2, respectively. The 
(pyrazolymethyl)pyridine ligand coordinates to the metal centre via its two nitrogen 
donors, forming a six-membered chelate ring which can exist in either chair or boat 
conformation due to the flexibility of the methylene (−CH2−) linker between 
pyrazole and pyridine rings. The two aqua ligands complete the coordination 
spheres resulting in the slightly distorted square planar geometry around the metal 
centre.  
This is shown by the magnitude of bond angles, a and d (~90 °) as well as nearly 
linear arrangement of the atoms: Npz−Pt−OH2 (1) and Npy−Pt−OH2 (2) (see Table 4.2). 
The mapping of the frontier orbitals indicate that the HOMOs are concentrated 
directly above and below the Pt(II) ion for Pt(H2Py) and Pt(dCF3Py), with no 
significant contribution from the ligand and the leaving groups. The HOMO for 
Pt(dCH3Py), is delocalised on 3,5-dimethylpyrzole, metal centre as well as on the 
aqua ligand in the trans axis. The 3,5-methyl groups donate electrons into the 
pyrazole ring coordinated to the metal centre, thereby labilising the aqua ligands in 
the ground state.  
In Pt(H2Py) and Pt(dCH3Py), the LUMOs are delocalised on the metal centre and the 
pyridine ring with no significant contribution from the pyrazole ring.  Thus, the 
electron density on the metal can be back-donated into low-energy π*-orbitals of the 
pyridine ring. The location of the LUMOs in Pt(H2Py) and Pt(dCH3Py) also indicates 
that the extent of π-backbonding between the metal centre and the pyrazole is very 
weak, which is consistent with pyridine being a better π-acceptor than pyrazole. 
However, for Pt(dCF3Py) the LUMOs are mainly localised on 3,5-
bis(trifluoromethyl)pyrazole, with moderate contributions from the metal centre and 
pyridine nitrogen.  The 3,5-trifluoromethyl (−CF3) substituents withdraw electron 
density from pyrazole ring. This activates its π-acceptor strength and enhances back-
donation of the electron density from the metal centre. This is another confirmation 
that the σ-donor or π-acceptor strength of pyrazole can be controlled by introducing 
substituents in its 3,5-positions.  
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Property  Pt(H2Py) Pt(dCH3Py) Pt(dCF3Py) 
MO Energy (eV)    
LUMO -2.46 -2.43 -3.06 
HOMO -7.33 -7.19 -7.61 
∆EL-H  4.87  4.76  4.55 
NBO charges    
Pt  0.950  0.913  0.991 
Bond lengths (Ǻ)     
d Pt−Npy 2.020 2.016 2.018 
d Pt−Npz 1.990 2.000 2.010 
d Pt−OH2 (1) 2.103 2.103 2.094 
d Pt−OH2 (2) 2.100 2.101 2.078 
Bond angles (°)    
< 1Npz−Pt−OH2 (1) 179.0 178.5 177.8 
< 1Npy−Pt−OH2 (2) 179.6 179.2 179.9 
< a 90.3 92.1 91.1 
< b 89.3 88.3 88.8 
< c 90.2 90.5 90.2 
< d 90.2 89.1 89.9 
1 Npy is the coordinated N-donor atom in the pyridine ring (py) and Npz is the 
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Figure 4.4: The effect of substituents on the pyrazole ring in the energies of HOMO 
and LUMO orbitals and the resultant LUMO-HOMO energy gap.  
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Because of the location of the HOMO and LUMO, electron donation into the metal 
centre has an expected effect of raising the energy level of the HOMO and destabilise 
the LUMO as shown in Figure 4.4 for Pt(dCH3Py). The opposite is observed for 
Pt(dCF3Py) which bears an electron-withdrawing group on the coordinated pyrazole 
ring. What is more intriguing is that the electron-withdrawal effect of the −CF3 
groups convert the pyrazole ring into a stronger  π-acceptor, possibly better than the 
pyridine ring, by stabilising its LUMO frontier orbitals. This lowers the HOMO-
LUMO energy gap, leading to a more reactive Pt(II) metal centre.   
 
4.3.3 Ligand substitution kinetics of the diaqua Pt(II) complexes  
The substitution reactions of all diaqua Pt(II) complexes with thiourea nucleophiles 
(TU, DMTU and TMTU) occurred in two consecutive steps as shown in Scheme 4.3.  
+  H2O










Scheme 4.3: The proposed stepwise substitution of aqua ligands from bifunctional 
Pt(II) complexes by thiourea nucleophiles.        
 
The two steps are characterised by the second-order rate constants, 𝑘2(1𝑠𝑡) 
and 𝑘2(2𝑛𝑑). Each step represents the substitution of one of the coordinated aqua 
leaving groups. Two different substitution steps were expected due to different 
trans-labilization effect of the pyridine and pyrazole rings. The substitution of the 
first aqua ligand was monitored by the stopped-flow technique while the slower and 
second substitution step was followed by UV/visible spectrophotometry. A 
representative time-dependent kinetic trace for the first substitution step in the two-
step reaction between Pt(dCF3Py) and  40-fold TU is shown in Figure 4.5. 
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Figure 4.5: A typical kinetic trace for the first substitution step in a two-step reaction 
between Pt(dCF3Py) (0.133 mM) and TU (5.32mM) recorded at 310 nm, T = 298 K, 
pH = 2.0, I = 0.1 M (HClO4/NaClO4) on the stopped-flow spectrophotometer. 
 
The kinetic traces of the ligand substitution reactions for the diaqua Pt(II) complexes 
gave excellent fits to a single exponential function used to generate the pseudo first-
order rate constants, 𝑘𝑜𝑏𝑠 (1) and 𝑘𝑜𝑏𝑠 (2) at specific nucleophile concentration and 
temperature, for the first and second substitution steps, respectively. The values of 
𝑘𝑜𝑏𝑠 (1/2)  considered in subsequent analysis are averages of 8-10 independent kinetic 
runs from the stopped-flow analyser and duplicate runs from UV/visible 
spectrophotometer, respectively.  
The observed pseudo-first order rate constants, 𝑘𝑜𝑏𝑠 (1/2), were found to vary linearly 
with the concentration of the nucleophile, according to the rate laws described by 
equations (4.1).28   
𝑘𝑜𝑏𝑠 (1/2)  =  𝑘2 (1st/2nd) [Nu]  +  𝑘−1 (1st/2nd)  ≈  𝑘2 (1st/2nd) [Nu]          (4.1) 
 
Representative plots displaying a linear dependence of 𝑘𝑜𝑏𝑠 (1/2) on the concentration 
of the entering nucleophiles are shown in Figure 4.6 (also see Figures SI 4.4).  
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Figure 4.6: Pseudo-first-order rate constants, kobs1 and kobs2, plotted as a function of 
thiourea nucleophile concentration for the substitution of the first (a) and second (b) 
aqua ligand from Pt(dCF3Py) at pH = 2.0, T = 298 K and I = 0.1 M (HClO4/NaClO4). 
 
All linear regression plots pass through the origin, suggesting the insignificance or 
absence of the solvolytic or reverse reaction pathways.29 The second-order rate 
constants, 𝑘2 (1st/2nd ) were calculated from the slopes of 𝑘𝑜𝑏𝑠 (1/2) vs. nucleophile 
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Table 4.3.   Summary of the second-order rate constants for the stepwise substitution 































Complex Nu  𝒌𝟐 (𝟏𝐬𝐭) / 
𝐌−𝟏 𝐬−𝟏 
 𝒌𝟐 (𝟐𝐧𝐝) / 
𝟏𝟎−𝟏 𝐌−𝟏 𝐬−𝟏 
 
Pt(H2Py) 




30.2 ± 0.4 
 




29.2 ± 0.4 
 




19.7 ± 0.2 
 







20.7  ± 0.2 
 




15.4  ± 0.2 
 




  2.1  ± 0.1 
 







147 ± 1 
 




 88.0 ± 2 
 




18.8 ± 0.1 
 
0.26 ± 0.03 
- 93 - 
 
4.3.4 Activation parameters 
The temperature dependence of the second-order rate constants, 𝑘2 (1st/2nd), was 
investigated over the temperature range of 15 - 45 °C at the increments of 5 °C. 
Typical Eyring plots30 are shown for the reactions of Pt(dCH3Py) and thiourea 
nucleophiles in Figure 4.7 {also see Figure SI 4.5 for the reactions of Pt(H2Py) and 
Pt(dCF3Py) with thiourea nucleophiles}. The calculated values for the change in 
activation enthalpy (∆𝐻1/2
≠ ) and activation entropy (∆𝑆1/2
≠ ) are summarised in Table 
4.4.   
 
Figure 4.7: Plots of ln (𝑘2 /𝑇) versus (1/𝑇) for the substitution of the first (a) and 
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Table 4.4.   Summary of the activation parameters for the stepwise substitution of 
aqua ligands from the diaqua Pt(II) complexes. 
 
 
4.4 NMR studies 
Due the asymmetrical nature of bidentate ligands of the Pt(II) complexes, the aqua 
ligands are susceptible to substitution at a different rate. Their reactions with the 
nucleophiles therefore proceed via a stepwise mechanism as shown in Scheme 4.3. 
To test this assumption, we followed the substitution reaction of [Pt(H2PyCl2)] and 
thiourea (TU) for 19 h using 1H NMR spectroscopy. The complex, [Pt(H2Py)Cl2], 
dissolved in DMSO-d6 was reacted with two mole equivalents of TU at 303 K. An 
array of the 1H NMR spectra recorded during the substitution process is shown in 
Figure 4.8. The numbering scheme employed for the protons in [Pt(H2Py)Cl2] is 
presented in Scheme 4.4. Pyridyl and pyrazolyl protons labelled Ha and Hb, 
respectively, were used to monitor the progress of the reaction since they are closest 
to the N-donor atoms coordinated to the Pt(II) centre at which the substitution 



















Pt(H2Py) TU 39 ± 1 17 ± 1 - 85 ± 2 - 210 ± 3 
 DMTU 38 ± 2 31 ± 1 - 89 ± 8 - 163 ± 1 
 TMTU 40 ± 2 46 ± 2 - 86 ± 6 - 112 ± 8 
Pt(dCH3Py) TU 45 ± 1 47 ± 1 - 69 ± 4 - 107 ± 4 
 DMTU 50 ± 2 56 ± 5 - 55 ± 6 -   82  ± 2 
 TMTU 49 ± 1 37 ± 2 -75 ± 4 - 159 ± 8 
Pt(dCF3Py) TU 41 ± 2 46 ± 2 - 67 ± 3 - 101 ± 7 
 DMTU 45 ± 2 48 ± 2 - 58 ± 6 - 101 ± 7 
 TMTU 36 ± 2 58 ± 3 - 101 ± 7 - 121 ± 1 
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Scheme 4.4: Numbering scheme employed for the protons in [Pt(H2Py)Cl2]. 
 
Figure 4.8: 1H NMR spectral arrays acquired during the reaction of [Pt(H2Py)Cl2] and 2 equiv. of TU in DMSO-d6 at 303 K.  
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These protons resonate at δ(Ha) = 9.14 ppm and δ(Hb) = 8.26 ppm, respectively, in an 
unreacted [Pt(H2Py)Cl2] complex (Figure 4.8; t = 0 min). The δ(Ha’) = 8.35 ppm and 
δ(Hb’) = 7.70 ppm resonances are shifted upfield (t = 8 min), due to the replacement 
of a more electronegative chloride ligand by sulphur donor, indicating the formation 
of the TU-coordinated intermediate i.e. [Pt(H2Py)(TU)Cl]+. During the reaction, Ha’ 
and Hb’ resonance of the intermediate product formed on the onset (t = 8 min) 
further grew, while the corresponding resonances of the unreacted [Pt(H2Py)Cl2] 
complex (Ha and Hb) decreased accordingly. The Ha and Hb resonances disappeared 
after 45 min, indicating that the first and fast substitution reaction has gone to 
completion. Subsequent snaps of the 1H NMR spectra (7-19 h), do not indicate that 
these resonances (Ha’ and Hb’) vanish within the timeframe of the reaction.  
195Pt NMR spectroscopy is an effective method to determine the coordination details 
of complexes, since the chemical shift of 195Pt resonance is influenced by the type of 
donor atoms coordinated to the platinum centre. In this respect, the reaction between 
[Pt(H2Py)Cl2] and two equivalents of TU was also monitored by 195Pt NMR 
spectroscopy for a much  longer time, to confirm the proposed stepwise mechanism 
(Scheme 4.3). An evolution of the 195Pt NMR spectra during the substitution reaction 
is presented in Figure 4.9. The peak at δ(195Pt) = -2189 ppm (shown as an inset of 
Figure 4.9) corresponds to resonance due to the unreacted [Pt(H2Py)Cl2] complex. 
During the substitution process, new peaks at δ(195Pt) = -2930 ppm and δ(195Pt) = -
3535 ppm are observed, suggesting the formation of two new species in solution. It is 
well-known from literature31 that the 195Pt NMR chemical shift within the range of -
2750 to -3150 ppm corresponds to the [PtN2SCl] coordination sphere, whereas the 
one for [PtN2S2] resonate within the range of -3150 to -3550 ppm. Therefore, the two 
peaks observed at δ(195Pt) = -2930 ppm and δ(195Pt) = -3535 ppm correspond to 
[Pt(H2Py)(TU)Cl]+ and [Pt(H2Py)(TU)2]+ species, respectively. The resonance peaks 
of the intermediate decrease while those of the final product increase.   




Figure 4.9: 195Pt NMR spectra acquired during the reaction of [Pt(H2Py)Cl2] and 2 equiv. of TU in DMSO-d6 at 303 K. Insert: 195Pt 
NMR spectrum of [Pt(H2Py)Cl2] before the reaction.  
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In addition, there was no evidence observed for the de-coordination of the 
(pyrazolylmethyl)pyridine (H2Py) as would be evidenced by a δ(195Pt) peak  within -
3800 to -4000 ppm for [PtS4] coordination sphere.31,32 Thus, despite the strong 
nucleophilicity of thiourea, the non-leaving ligand, H2Py remains coordinated to the 
metal centre. This does not exclude the possibility of de-coordination or 
decomposition of a non-leaving group at longer reaction times. This observation 
suggests that the increase in the steric hindrance and reduced electrophilicity 
imparted by the coordination of two thourea nucleophiles at the metal centre, 
retards de-coordination or decomposition of H2Py from the metal centre. Therefore, 
it can be concluded that the final product is a bifunctional Pt(II) complex with two 
thiourea nucleophiles coordinated to the metal centre and that the substitution 
mechanism is a sequential process as represented in Scheme 4.3.     
 
4.5 Discussion 
By introducing the inductive electron-donating or electron-withdrawing substituents 
at the 3,5-positions of the pyrazole ring, it is possible to quantify their electronic and 
steric influence on the reactivity of bifunctional Pt(II) complexes. For all complexes, 
the substitution of the aqua ligands by thiourea nucleophiles involves two reaction 
steps differing by a factor of at least two orders of magnitude. The large difference in 
the rate constants between the first and the second substitution step is ascribed to an 
increased steric hindrance around the metal centre arising from the incorporation of 
the first thiourea nucleophile as well as a decreased eletrophilicity of the Pt(II) metal 
centre due to σ-donor capacity of the coordinated thiourea nucleophile. These two 
factors retards the aerial approach of the nucleophile at the transition state, thereby 
decreasing the rate of substitution.  
For structurally similar types of complexes with different N-donors,12-13,24-25 the two 
steps were ascribed to stepwise substitution of each of the aqua ligand coordinated 
to the Pt(II) centre. In order to address the question of which aqua ligand is 
substituted first, as well as to clarify the trends in the lability of each of the 
coordinated aqua ligands, a key structural differences in the donor properties of the 
(pyrazolylmethyl)pyridine core ligand should be highlighted. The coordinated 
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ligands consist of two different types of donors, i.e. a pyridine ring with a strong π-
accepting ability and a pyrazole ring with a strong σ-donor capacity. These electronic 
properties may compete with each other during substitution.  
Theoretically, the first substitution step should take place trans to pyrazole ring, 
whereas the second substitution step should take place trans to pyridine ring, with 
both steps dependent on the electronic nature of the 3,5-substituents of the pyrazole 
ring. Consistent with this view is that the length of the Pt−OH2(1) bond trans to 
pyrazole which is  marginally longer than the one trans to pyridine (Pt−OH2(2)), 
Table 4.2) for all complexes. This aqua ligand is substituted first. The sensitivity of 
the Pt(II) centre towards the 3,5-substituents on the pyrazole ring is shown by the 
difference in NBO charges and the HOMO-LUMO energy gaps of the complexes 
(Table 4.2 and Figure 4.4). The experimentally obtained thermodynamic and kinetic 
data, i.e. the trends in the pKa values and the second-order rate constants 
respectively, are also in good agreement with the DFT-calculated parameters.  
 
4.5.1 First substitution step 
In comparing the rate of substitution of the first aqua ligand, 𝑘2(1st), data in Table 4.3 
shows that the reactivity of the  bifunctional Pt(II) complexes follow the trend 
Pt(dCF3Py) > Pt(H2Py) > Pt(dCH3Py). If the reactivity of Pt(dCH3Py) with TU is 
taken as a reference, the ratio of reactivity is 7.1: 1.5: 1.0, respectively for Pt(dCF3Py): 
Pt(H2Py): Pt(dCH3Py). The difference in the reactivity can be accounted for, in terms 
of the nature of the 3,5-substituents on the pyrazole ring.  If we assume that the first 
substitution site occurs to the aqua ligand trans to the pyrazole ring, the results of 
Table 4.3 corroborates that the two methyl (−CH3) substituents at the 3,5-positions 
enhance the trans σ-effect of the pyrazole ring more in the transition state than in the 
ground state. The electron-donating −CH3 groups in Pt(dCH3Py) inductively donate 
electron density to the pyrazole ring coordinated to the metal centre. This causes the 
accumulation of the electron density at the metal centre, and decelerates the 
substitution process by making the Pt(II) centre less electrophilic or more 
electronegative.33,34 Not only does the σ-inductive effect repel the approach of the 
nucleophile towards the metal centre, but it also suppresses the stabilization of the 
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18-electron-rich 5-coordinate transition state, thereby retarding the rate of aqua 
ligand substitution by the thiourea nucleophiles. The trifluoromethyl (−CF3) groups 
at the 3,5-positions of the coordinated pyrazole ring withdraw electron density from 
the ring, switching it from a net σ-donor to a π-acceptor. This makes the Pt(II) atom 
more electrophilic or electropositive and thus accelerates the rate of ligand 
substitution by increasing the affinity of the metal centre for an entering nucleophile. 
The reduced accumulation of electron density on the Pt(II) centre also facilitates 
facile substitution of the aqua ligands by stabilising the 18-electron-rich 5-coordinate 
transition state. The increased electrophilicity and reactivity of Pt(dCF3Py) is 
supported by relatively lower pKa values,  a small HOMO-LUMO energy gap as well 
as a large and positive NBO charge value of the platinum centre. Therefore, it can be 
concluded that the lability of the aqua ligand in the first substitution step is 
dependent on the σ-donor and π-acceptor strength of the substituents on the 
pyrazole ring.  
The reactivity of the complexes decreases with an increase in the σ-donor capacity of 
the pyrazole ring or alternatively increases with an increase in its π-acceptor 
strength. Experimental data obtained in this study supports the conclusions drawn 
by Jaganyi and co-workers35,36 for monofunctional Pt(II) complexes with electron 
donating- or electron-withdrawing groups in the ancillary positions of the 
polypyridyl tridentate (NNN/NNC) ligand framework. A moderate decrease in the 
reactivity of the metal centre was noted upon the addition of the electron-donating 
tert-butyl33,34a or methyl groups,34 while the placement of electron-withdrawing 
trifluoromethyl groups34 led to an increased reactivity of the metal centre.      
 
4.5.2 Second substitution step 
Data in Table 3 shows that the rate of substitution of the second aqua ligand, 𝑘2 (2nd), 
follows the order: Pt(H2Py) ≈ Pt(dCF3Py) > Pt(dCH3Py). Taking the second 
substitution step with TU as a reference, the reactivity of the Pt(II) complexes 
decrease in the order: {(2.65 ± 0.01) ≈ (2.52 ± 0.05) > (0.82 ± 0.01)} × 10−1 M−1 s−1 for 
Pt(H2Py), Pt(dCF3Py) and Pt(dCH3Py), respectively. However, Pt(dCF3Py) was 
expected to be much faster than Pt(H2Py) due the electron-withdrawing −CF3 
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substituents as reflected by the increased positive charge of the metal centre (NBO 
charge) and the corresponding decrease in the separation of the frontier orbitals 
(∆EL-H; Table 4.2). This suggests that there is a combination of electronic and steric 
influence imparted by the substituents, on the lability of the aqua ligand cis to the 
3,5-substituted pyrazole ring. These two properties are working anti to each other, 
and the net effect is that rate constants for Pt(H2Py) is approximately equal to that of 
Pt(dCF3Py) as a result of a more dominant steric effect in the latter complex.  
The replacement of a hydrogen (H) atom by either a −CH3 or −CF3 group at the 3-
position of the pyrazole ring causes a steric hindrance to the approach of the second 
nucleophile which overrides the cis σ- or π-electronic effect, thereby slowing down 
the rate of the reaction. This is contrary to the substitution of the first aqua ligand 
(i.e. trans to the 3,5-disubsituted pyrazole) where the substituent on the 3-position 
has limited  steric influence on the rate of reaction. The effect of steric crowding in 
the cis position on the rate of substitution has been well documented for Pt(II)/Pd(II) 
complexes.37,38 It is known that increasing the steric bulk of the cis ligand decelerates 
the rate of an associative substitution reaction, due to an increase in steric hindrance 
in the 5-coordinate transition state.35-39 This steric cis-effect reduces the reactivity 
more than the corresponding steric trans-effect.35-37 
The data also shows that the substitution rate constant of the second aqua 
ligand 𝑘2 (2nd), decrease in the order: Pt(dCF3Py) > Pt(dCH3Py), with the former 
complex reacting three times faster than the latter when TU is used as a reference. 
This is despite the −CF3 group being more bulk than the −CH3 group. However, 
both Pt(dCF3Py) and Pt(dCH3Py) complexes have a relatively larger steric bulk 
substituents on their core ligands compared to Pt(H2Py). Therefore, between these 
two complexes, the rate of substitution of the second and cis aqua ligand can be 
ascribed entirely to the difference in the electronic effects of the 3,5-substituents of 
the pyrazole ring. The electron-withdrawing –CF3 substituents in Pt(dCF3Py) 
withdraw the electrons from the pyrazole ring via π-back bonding, thereby 
increasing the electrophilicity of the metal centre (vide supra). This increases the rate 
of substitution. The electron-donating –CH3 substituents in Pt(dCH3Py), increase the 
σ-donor strength of the pyrazole ring through positive inductive effects, thereby 
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decreasing the lability of the second aqua ligand. Thus, for these complexes, the cis 
π-effect is greater than the cis σ-effect.       
    
4.5.3 Activation parameters and reactivity of the nucleophiles  
The activation parameters in Table 4.4 support an associative mechanism, with 
relatively low enthalpies of activation (∆𝐻1/2
≠ ), signifying how it is energetically 
favourable to form a biomolecular transition state. In addition, the entropies of 
activation (∆𝑆1/2
≠ ) are large and negative, indicating a highly ordered and more 
compact transition state compared to the micro-states of the reactants or products.  
All this confirms that the nucleophilic substitution reactions proceed via an 
associative mechanism.11,34,36  
The substitution of the aqua ligands depends on the steric hindrance of the entering 
nucleophiles, with the less sterically hindered thiourea (TU) nucleophile having the 
highest rate of substitution, while the most sterically hindered nucleophile, 
N,N,N’,N’-tetramethylthiourea (TMTU) is reacting significantly slower (Table 4.3). 
Not only does the more bulk nucleophile find it increasingly difficult to approach 
the Pt(II) centre,33but also upon coordination supresses the stabilization of the 5-
coordinate transition state,37 thereby decreasing the substitution rate.  
 
4.6 Conclusion 
The introduction of the substituents in the 3,5-positions of the pyrazole ring in the 
N,N-bidentate chelate influences its σ-donicity and π-acceptibility. Consequently, this 
controls the electrophilicity of the Pt(II) centre, which in turn affects the lability of 
the two coordinated aqua leaving groups. The first substitution step takes place trans 
to the pyrazole ring. The σ-donation effect of the coordinated pyrazole ring causes 
the second entering nucleophile to be stabilised on the reaction site trans to the 
pyridine ring. The inductive electron-donating −CH3 substituents decrease the rate 
of substitution whereas the inductive electron-withdrawing −CF3 substituents 
increase the rate of substitution. This is supported by the order of reactivity of 
Pt(dCF3Py) > Pt(H2Py) > Pt(dCH3Py) for the substitution of the aqua ligand trans to 
the pyrazole ring. On the other hand, the lability of the aqua ligand cis to the 
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pyrazole ring followed the order: Pt(H2Py) ≈ Pt(dCF3Py) > Pt(dCH3Py). This 
indicates that 3-substituent on the pyrazole ring causes a steric retardation on the 
lability of the aqua ligand in a cis position. Therefore, the steric of the 3-pyrazole 
substituent is stronger than the expected electronic cis σ/π-effect. The comparison of 
the complexes with 3,5-disubstituted pyrazole ring on the lability of the cis aqua 
ligand, indicates that the cis π-effect is stronger than the cis σ-effect. The DFT and pKa 
data both support the experimentally obtained kinetic data. The mode of action 
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4.8 Supporting information 
 
Table SI 4.1a . Summary of wavelengths (nm) used for monitoring the first 
substitution reactions between a series of bifunctional Pt(II) complexes and thiourea 
nucleophiles. 
 
Complex Nucleophile Wavelength (nm) 
Pt(H2Py) TU 289 
DMTU 280 
TMTU 335 
Pt(dCH3Py) TU 300 
DMTU 300 
TMTU 330 




Table SI 4.1b. Summary of wavelengths (nm) used for monitoring the second 
substitution reactions between a series of bifunctional Pt(II) complexes and thiourea 
nucleophiles. 
 
Complex Nucleophile Wavelength (nm) 
Pt(H2Py) TU 278 
DMTU 275 
TMTU 320 
Pt(dCH3Py) TU 292 
DMTU 315 
TMTU 280 







Figure SI 4.1a: 1H NMR spectrum of 2-(pyrazol-1-ylmethyl)pyridine (H2Py) in CDCl3.  
 






Figure SI 4.1c: Low resolution ESI+ mass spectrum of 2-(pyrazol-1-ylmethyl)pyridine 
(H2Py).  
 
Figure SI 4.2a: 1H NMR spectrum of [Pt{2-(3,5-dimethylpyrazol-1-




Figure SI 4.2b: 13C NMR spectrum of [Pt{2-(3,5-dimethylpyrazol-1-
ylmethyl)pyridine}Cl2], [Pt(dCH3Py)] in DMSO-d6.  
 
 
Figure SI 4.2c: 195Pt NMR spectrum of [Pt{2-(3,5-dimethylpyrazol-1-







Figure SI 4.3: UV/Visible spectra for the titration of 0.054 mM Pt(dCF3Py) with 
NaOH in the pH range 2-10 at T = 298.15 K. Inset: Absorbance versus pH plot at 295 
nm for Pt(dCF3Py) complex. 
 
Table SI 4.2a. Average observed rate constants, kobs1, for the displacement of the first 
aqua ligand in Pt(H2Py) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 M 
(HClO4/NaClO4). 
 
[TU]/ M kobs1/ S-1 [DMTU]/ M kobs1/ S-1 [TMTU]/ M kobs1/ S-1 
0.001764 0.0532998 0.001764 0.060781 0.001764 0.03839121 
0.003528 0.0968539 0.003528 0.101665 0.003528 0.07085705 
0.005292 0.1602171 0.005292 0.156104 0.005292 0.10713093 
0.007056 0.2161881 0.007056 0.207837 0.007056 0.13684907 
0.008820 0.2685696 0.008820 0.254593 0.008820 0.17279378 
 
Table SI 4.2b. Average observed rate constants, kobs1, for the displacement of the first 
aqua ligand in Pt(dCH3Py) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 M 
(HClO4/NaClO4). 
 
[TU]/ M kobs1/ S-1 [DMTU]/ M kobs1/ S-1 [TMTU]/ M kobs1/ S-1 
0.0016548 0.031694 0.0024822 0.034991 0.0049644 0.0086561 
0.0033096 0.064188 0.0049644 0.071305 0.0097880 0.0186228 
0.0049644 0.104314 0.0074466 0.112241 0.0148932 0.0301868 
0.0066192 0.139097 0.0099288 0.155755 0.0198576 0.0412438 




Table SI 4.2c. Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 
M (HClO4/NaClO4). 
 
[TU]/ M kobs1/ S-1 [DMTU]/ M kobs1/ S-1 [TMTU]/ M kobs1/ S-1 
0.0013365 0.209136 0.0013365 0.1062663 0.0013365 0.02589553 
0.0026730 0.379717 0.0026730 0.2088192 0.0026730 0.05136792 
0.0040095 0.584138 0.0040095 0.3379142 0.0040095 0.07594849 
0.0053460 0.805353 0.0053460 0.4778034 0.0053460 0.09938629 
0.0066825 0.975599 0.0066825 0.6032466 0.0066825 0.12552738 
 
Table SI 4.2d. Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(H2Py) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 
M (HClO4/NaClO4). 
[TU]/ M kobs2/ S-1 [DMTU]/ M kobs2/ S-1 [TMTU]/ M kobs2/ S-1 
0.00176 9.18814E-05 0.00176 5.98523E-05 0.00176 0.000133622 
0.00352 0.000438506 0.00352 0.000229481 0.00352 0.000253572 
0.00528 0.000932244 0.00528 0.000472197 0.00528 0.000364966 
0.00704 0.001428284 0.00704 0.000744978 0.00704 0.000515384 
0.00880 0.001930135 0.00880 0.001047522 0.00880 0.000669135 
 
Table SI 4.2e. Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCH3Py) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 
0.1 M (HClO4/NaClO4). 
[TU]/ M kobs2/ S-1 [DMTU]/ M kobs2/ S-1 [TMTU]/ M kobs2/ S-1 
0.0016548 0.000114145 0.0016548 0.000104634 0.0016548 1.05835E-05 
0.0033096 0.000265083 0.0033096 0.000175988 0.0033096 3.41050E-05 
0.0049644 0.000402572 0.0049644 0.000264663 0.0049644 6.47261E-05 
0.0066192 0.000541993 0.0066192 0.000345894 0.0066192 9.09161E-05 
0.0082740 0.000685695 0.0082740 0.000414915 0.0082740 0.000117287 
 
Table SI 4.2f. Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 
0.1 M (HClO4/NaClO4). 
[TU]/ M kobs2/ S-1 [DMTU]/ M kobs2/ S-1 [TMTU]/ M kobs2/ S-1 
0.0006833 0.000166531 0.0006833 8.56831E-05 0.0013665 3.1800E-05 
0.0013666 0.000332366 0.0013666 0.000192329 0.0027330 7.3600E-05 
0.0020499 0.000514252 0.0020499 0.000303338 0.0040995 1.0900E-04 
0.0027332 0.000658979 0.0027332 0.000418477 0.0054660 1.4000E-04 
0.0034165 0.000892367 0.0034165 0.000521954 0.0068325 1.7700E-04 
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Table SI 4.3a. Temperature dependence of the second-order rate constants, 
𝑘2 (1𝑠𝑡), M
−1 s−1 for the displacement of the first aqua ligand in Pt(H2Py) by thiourea 
nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4).   
 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -2.85341 0.003470415 -2.81901 0.003470415 -3.31794393 
0.003411223 -2.58079 0.003411223 -2.53794 0.003411223 -2.98925905 
0.003354016 -2.28726 0.003354016 -2.31327 0.003354016 -2.68974123 
0.003298697 -2.02887 0.003298697 -2.09197 0.003298697 -2.48454498 
0.003245173 -1.79451 0.003245173 -1.75174 0.003245173 -2.20686541 
 
Table SI 4.3b. Temperature dependence of the second-order rate constants, 
𝑘2 (1𝑠𝑡), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCH3Py) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -3.32996 0.003470415 -3.683904 0.003470415 -5.67997962 
0.003411223 -3.02483 0.003411223 -3.274142 0.003411223 -5.30077158 
0.003354016 -2.65248 0.003354016 -2.984706 0.003354016 -4.99109667 
0.003298697 -2.42749 0.003298697 -2.666791 0.003298697 -4.65832806 
0.003245173 -2.09758 0.003245173 -2.296801 0.003245173 -4.47252569 
 
Table SI 4.3c. Temperature dependence of the second-order rate constants, 
𝑘2 (1𝑠𝑡), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCF3Py) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -1.94020813 0.003470415 -1.82993478 0.003470415 -3.33277200 
0.003411223 -1.24929178 0.003411223 -1.52737825 0.003411223 -3.05254003 
0.003354016 -0.71612601 0.003354016 -1.26347124 0.003354016 -2.75620791 
0.003298697 -0.40161104 0.003298697 -0.93898081 0.003298697 -2.55663744 









Table SI 4.3d. Temperature dependence of the second-order rate constants, 
𝑘2 (2𝑛𝑑), M
−1 s−1 for the displacement of the first aqua ligand in Pt(H2Py) by thiourea 
nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -7.76273 0.003470415 -8.65780 0.003354016 -8.37174311 
0.003411223 -7.65076 0.003411223 -8.42840 0.003298697 -8.03141772 
0.003354016 -7.56529 0.003354016 -8.22820 0.003245173 -7.67855270 
0.003298697 -7.44832 0.003298697 -8.02290 0.003193358 -7.44099524 
0.003245173 -7.27691 0.003245173 -7.81510 0.003143171 -7.20103030 
 
Table SI 4.3e.  Temperature dependence of the second-order rate constants, 
𝑘2 (2𝑛𝑑), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCH3Py) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003354016 -8.20977099 0.003354016 -8.62918677 0.003354016 -10.0374808 
0.003298697 -7.92752219 0.003298697 -8.50688154 0.003298697 -9.76256976 
0.003245173 -7.59254944 0.003245173 -8.05662456 0.003245173 -9.51511435 
0.003193358 -7.27852335 0.003193358 -7.70298613 0.003193358 -9.33516011 
0.003143171 -7.03205966 0.003143171 -7.45585711 0.003143171 -9.19287380 
 
Table SI 4.3f. Temperature dependence of the second-order rate constants, 
𝑘2 (2𝑛𝑑), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCF3Py) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003354016 -7.08042913 0.003354016 -7.60829774 0.003354016 -9.32225342 
0.003298697 -6.82076324 0.003298697 -7.22648780 0.003298697 -8.89819742 
0.003245173 -6.45131890 0.003245173 -6.91286531 0.003245173 -8.57414989 
0.003193358 -6.16827619 0.003193358 -6.65181158 0.003193358 -8.28614497 





Figure SI 4.4: Concentration dependence plots of kobs1, s-1, for the displacement of the 
first aqua ligand of Pt(H2Py) (a) and Pt(dCH3Py) (b) by thiourea nucleophiles, pH = 
2.0, T = 298 K, and I = 0.1 M (HClO4/NaClO4). 
 
Figure SI 4.5: Eyring plots for the substitution of the first aqua ligand of Pt(H2Py) (a) 






Figure SI 4.6: 1H NMR spectrum of [Pt{2-[(3,5-bis(trifluoromethyl)pyrazoly-1-
ylmethyl]pyridine}Cl2], [Pt(dCF3Py)Cl2] in DMSO-d6. 
 
Figure SI 4.7: 13C NMR spectrum of [Pt{2-[(3,5-bis(trifluoromethyl)pyrazoly-1-





The influence of substituents and extended π-conjugation in 
bidentate N,N-chelate on the substitution kinetics of aqua ligands 
from platinun(II) complexes 
5.0 Abstract 
Substitution reactions of aqua ligands from four bifunctional Pt(II) complexes, 




[Pt(dCF3Py)], with three sulphur donor nucleophiles, viz., thiourea (TU), N,N-
dimethylthiourea (DMTU), N,N,N’,N’-tetramethylthiourea (TMTU), were studied. 
The reactions were followed under pseudo first-order conditions as a function of 
nucleophile concentration and temperature, using stopped-flow and UV/visible 
spectrophotometry. The second-order rate constants for the lability of the aqua 
ligands in the first substitution step increased in the order of Pt(dCH3Qn) <
 Pt(dCF3Qn) < Pt(H2Qn) < Pt(dCF3Py), while that of the second substitution step  
was Pt(dCH3Qn) <  Pt(dCF3Qn) < Pt(dCF3Py) <  Pt(H2Qn). The observed 
substitution steps were ascribed to a sequential substitution of the labile aqua 
ligands. The reactivity trend confirms that quinoline substructure in the 
(pyrazolylmethyl) quinoline ligands acts as an apparent donor of electron density 
towards the metal centre rather than being a π-acceptor. Measured pKa values from 
spectrophotometric acid-base titrations were respectively, Pt(H2Qn) (pKa1 = 4.56; 
pKa2 = 6.32), Pt(dCH3Qn) (pKa1 = 4.88; pKa2 = 6.31), Pt(dCF3Qn) (pKa1 = 4.07; pKa2 = 
6.35), and Pt(dCF3Py) (pKa1 = 4.76; pKa2 = 6.27). The activation parameters from the 
temperature dependence of the second-order rate constants support an associative 





Complexes of pyrazole-based ligands hold a great promise in medicine.1 In 
particular, platinum(II) complexes with pyrazole ligands have shown interesting 
biological activities including anticancer, antibacterial and anti-inflammatory 
properties.1 Pt(II) complexes  display a wide range of anticancer properties owing to 
their ability to bind covalently or through intercalation to the nuecleophilic sites of 
DNA.2,3 This alters the conformational structure of DNA, resulting onto apoptotic 
death of cancerous cells.2,4 In this respect, mechanistic studies of Pt(II) complexes 
with biologically relevant nucleophiles should be explored to provide a detailed 
insight into specific kinetic and thermodynamic properties that control the reactivity 
of such complexes.  
The rate of substitution in chelated square-planar Pt(II) complexes can be controlled 
by varying the electronic and steric factors of the coordinated non-leaving ligand. 
These factors can be either cooperative or antagonistic depending on the electronic 
properties as well as spatial orientation of the non-leaving ligand.5,6,7 A substructure 
within the ligand which donates electron density trans to the leaving group usually 
increase the rate of substitution via its trans-influence on the ground state properties 
of the complex. This is also true for π-acceptors, especially those with extended 
molecular orbital within the substructure which withdraw electron density at the 
metal centre thereby increasing the electrophilicity of the metal centre in the 
transition state. These two are termed the trans-effect.8-14  
However, when the donation of the electron density occurs cis to the leaving group, 
it retards the rate due to an increase in electron density at the metal centre which 
repels the incoming nucleophile in the trasition state. This is termed the cis-effect.8-14 
It is generally assumed to be much weaker than the trans-effect.11,13 This assumption 
has not been fully validated and the experimental results are somehow 
contradictory.10,11,12 For example, in a study by Romeo,15 the rate of substitution 
decreased when a  chelated π-acceptor ligand had a strong σ-donor moiety 
coordinated cis to the leaving group. The electron-donating effect dominated over 
the electron-withdrawing of the rest of the chelate ligand. In a related study, the rate 
of substitution was higher for a complex with a cis π-accepting moiety than that with 
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same moiety on the trans position.10 Therefore, if the ligand contains both σ-donor 
and π-acceptor properties, the observed overall cis-effect is dependent on whichever 
effect is stronger, since the latter accelerates while the former decelerates the 
reaction. Jaganyi et al. have studied in detail the effect on the rate of changing the π-
acceptability of tridentate popyridyl nitrogen-donor ligands by varying the number 
of pyridine rings or attaching electron-withdrawing or electron-donating 
substituents on the ligand framework.16,17,18 A somehow surprising result to what 
has been reported elsewhere in literature was that,21,22 when a quinoline or 
isoquinoline formed part of the tridentate ligand in the cis position to the leaving 
group, an anomalous decrease in the reactivity was observed.17,19,20 This  was 
ascribed to a weaker  back-bonding between the quinoline moiety and the metal 
centre which weaken the  π-acceptability of the whole ligand.  
Equally important about the structure of the non-leaving ligand are its steric effects 
on reactivity and cytotoxicity. The effects can be due to spatial size (steric demad) 
and/or due to spatial orientation (steric hindrance) relative to the leaving group. An 
advantageous consequent on antitumour activity of Pt(II) complexes due to steric 
hindrance by a non-leaving ligand is revealed on the relative cytotoxicity indices of 
two isomeric complexes cis-[Pt(NH3)2(2-methylpyridine)Cl]+ and cis-[Pt(NH3)2(4-
methylpyridine)Cl]+.8,9 The former complex was found to be more active due to its 
reduced rates of deactivation by sulphur nuclophiles caused by an aerial block to 
substitution by the ortho-methyl substituent.  
The steric influence on reactivity imposed onto an incoming nucleophile especially if 
it is cis-positioned (steric cis-effect) to the leaving group is usually strong and can 
dominate over its electronic contribution.11,13  It was demonstrated in Chapter 4 that 
an increase in the π-accepting capacity of an N,N-bidentate chelate  incoparating a 
3,5-bis(trifluoromethyl)pyrazole moiety  is counteracted by a steric retardation to the 
substitution rate of the aqua ligand in the cis position. The 3-positioned 
trifluoromethyl substituent of pyrazole shields the leaving group, thus slowing 
down the rate of substitution. 
To further our understanding on the influence on the rate of substituents of an N,N- 
bidentate core, four Pt(II) complexes bearing (pyrazolylmethyl)quinoline/pyridine 
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ligands (see Figure 5.1) were synthesized and their substitution kinetics were 
studied. The choice of complexes was based on impressive cytotoxic data reported 
for structurally similar Pt(II) complexes.23 Biologically relevant sulfur-containing 
nucleophiles viz., thiourea (TU), N,N-dimethylthiourea (DMTU) and N,N,N’,N’-
tetramethylthiourea (TMTU) were used as substituting nucleophiles. Density 
functional theoretical (DFT) calculations were used to aid the interpretation of the 









Figure 5.1: Chemical structures of the bifunctional Pt(II) complexes. Perchlorate 
counter ions (ClO4-) are omitted for clarity. 
5.2 Experimental 
5.2.1 Chemicals and reagents 
All synthetic manipulations of the ligands were carried out in air, whereas the 
coordination of the ligands to the platinum metal was performed under inert 
atmosphere of nitrogen using standard Schlenk techniques. The ligand precursor 2-
(chloromethyl)quinoline hydrochloride (97%) was purchased from Aldrich and used 
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without further purification. All other chemical were purchased from suppliers as 
already described in Chapter 4, section 4.2.1. 
5.2.2 Preparation of the ligands 
Three (pyrazolylmethyl)quinoline ligands and one (pyrazolylmethyl)pyridine 
ligand, namely, 2-(pyrazol-1-ylmethyl)quinoline (H2Qn), 2-(3,5-dimethylpyrazol-1-
ylmethyl)quinoline (dCH3), 2-[(3,5-bis(trifluoromethyl)pyrazol-1-ylmethyl]quinoline 
(dCF3Qn), and 2-[(3,5-bis(trifluoromethyl)pyrazol-1-ylmethyl]pyridine (dCF3Py)  
were prepared using the same procedure described for the ligand used in Chapter 4, 
section 4.2.2. However, 2-(chloromethyl)quinoline was used instead of 2-
(chloromethyl)pyridine for synthesizing the quinolone bearing ligands. All ligands 
were obtained in moderate yields (59-61%) and collected as brown oils of sufficient 
purity for subsequent use in platinum coordination. The purity of the ligands was 
confirmed by 1H NMR, 13C NMR, TOF-MS-ESI+ and elemental analysis.   
2-(pyrazol-1-ylmethyl)quinoline (H2Qn) 
Yield = 0.7131 g (60%). 1H NMR (400 MHz: CDCl3 H (ppm); 5.66 (s, 2H, -CH2-), 
6.35-6.36 (t, 1H, pz), 7.11-7.13 (d, 1H, py), 7.54-7.58 (dd, 2H, pz), 7.62- 7.63 (t, 1H, ph), 
7.73-7.77 (t, 1H, ph), 7.80-7.82 (d, 2H, ph), 8.08-8.13 (dd, 2H, py, ph). 13C NMR (100 
MHz: CDCl3 C (ppm); 57.60, 79.63, 106.23 , 119.94, 127.02, 127.42, 128.33, 130.37, 
137.58, 139.95, 139.95, 147.37, 157.97. TOF MS-ESI+ m/z: 210.027, 100% (M+1). Anal. 
calculated for C13H11N3:  C, 74.62; H, 5.30, N, 20.08%. Found: C, 74.29; H, 5.36; N, 
19.67%. 
2-(3,5-dimethylpyrazolyl-1-ylmethyl)quinoline (dCH3Qn) 
Yield = 0.797 g (59%). 1H NMR (400 MHz: CDCl3): H (ppm); 2.19 (s, 3H, CH3), 2.30 (s, 
3H, CH3), 5.54 (s, 2H, -CH2-), 5.91 (s, 1H, pz), 6.96-6.98 (d, 1H, py), 7.52-7.56 (t, 1H, 
ph), 7.71-7.7.76 (t, 1H, ph), 7.79- 7.81 (d, 1H, ph), 8.06-8.10 (dd, 2H, ph, py). 13C NMR 
(100 MHz: CDCl3 C (ppm); 11.14, 13.56, 55.39, 105.94, 118.85, 126.46, 127.35, 127.63, 
129.01, 129.78, 137.30, 139.92, 147.55, 148.14, 157.76. TOF MS-ESI+ m/z: 238.134, 100% 
(M+1)+. Anal. calculated for C15H15N3:  C, 75.92; H, 6.37, N, 17.71%. Found: C, 75.05; 




Yield = 1.10 g (56%). 1H NMR (400 MHz: CDCl3): H (ppm); 5.84 (s, 2H, -CH2-), 7.01(s, 
1H, pz), 7.04-7.06 (d, 1H, py), 7.56-7.59 (t, 1H, ph), 7.73- 7.77 (t, 1H, ph), 7.82-7.89 (d, 
1H, ph), 8.05-8.03 (d, 1H, py), 8.15-8.17 (d, 1H, ph). 13C NMR (100 MHz: CDCl3 C 
(ppm); 57.78, 106.66, 118.18, 121.71, 126.98, 127.44, 127.60, 129.34, 130.08, 134.08, 
137.46, 142.32, 142.71, 147.64, 154.28. TOF MS-ESI+ m/z: 346.073, 100% (M+1)+. 
calculated for C15H9N3F6:  C, 52.18; H, 2.63, N, 12.17%. Found: C, 51.94; H, 2.53, N, 
11.96%. 
2-[(3,5-bis(trifluoromethyl)pyrazol-1-ylmethyl]pyridine (dCF3Py) 
Yield = 1.02 g (61%). 1H NMR (400 MHz: CDCl3): H (ppm); 5.68 (s, 2H, -CH2-), 6.95-
6.97 (d, 1H, py), 7.00 (s, 1H, pz), 7.26-7.30 (t, 1H, py), 7.68- 7.73 (t, 1H, py), 8.61-8.62 
(d, 1H, py). 13C NMR (100 MHz: CDCl3 C (ppm); 57.08, 106.57, 117.73, 120.41, 
120.97, 123.13, 133.91, 137.07, 142.64, 149.64, 154.35. TOF MS-ESI+ m/z: 296.057, 100% 
(M+1). Anal. calculated for C11H7N3F6:  C, 44.76; H, 2.39, N, 14.24%. Found: C, 44.42; 
H, 2.46; N, 14.41%. 
5.2.3 Synthesis of the platinum complexes 
The semi-flexible and versatile dichloro platinum(II) complexes, namely, [Pt{2-
(pyrazol-1-ylmethyl)quinoline}Cl2], [Pt(H2Qn)Cl2], [Pt{2-(3,5-dimethylpyrazol-1-
ylmethyl)quinoline}Cl2], [Pt(dCH3Qn)Cl2], [Pt{2-[(3,5-bis(trifluoromethyl)pyrazol-1-
ylmethyl]quinoline}Cl2], [Pt(dCF3Qn)Cl2], as well as [Pt{2-[(3,5-bis(trifluoromethyl)-
pyrazol-1-ylmethyl]pyridine}Cl2], [Pt(dCF3Qn)Cl2] were synthesised following the 
same procesure described for pyridine-bearing Pt(II) complexes in Chapter 4, section 
4.2.3. For the formation of the complexes, [Pt(dCF3Qn)Cl2] and [Pt(dCF3Py)Cl2], 0.01 
M HCl solution was used instead of ultrapure water to dissolve the platinum 
precursor, sodium tetrachloropalatinate (K2PtCl4). All dichloro Pt(II) complexes were 
isolated as a yellow powders and their purity was confirmed by 1H NMR, 13C NMR, 
195Pt NMR, elemental analysis, TOF MS-ESI+ and infrared (IR) spectroscopy.   
[Pt(H2Qn)Cl2]. Yield: 187 mg (82%). 1H NMR (400 MHz: DMSO-d6): H (ppm); 5.68 (s, 
2H, -CH2-), 6.37-6.38 (t, 1H, pz), 7.13-7.16 (d, 1H, py), 7.53-7.57 (d, 1H, ph), 7.61- 7.64 
(t, 1H, ph), 7.76-7.83 (t, 1H, ph), 7.96-8.04 (dd, 2H, pz), 8.06-8.13 (d, 1H, py), 8.34-8.38 
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(d, 1H, ph). 13C NMR (100 MHz: DMSO-d6 C (ppm); 57.57, 106.22 , 119.95, 127.05, 
127.42, 128.35, 129.01, 130.40, 131.52, 137.61, 139.95, 147.36, 158.01. 195Pt NMR (107 
MHz: DMSO-d6 Pt (ppm); -2963.56. TOF MS-ES+ m/z: 440.056 (M-Cl)+. IR (KBr) cm-
1: 566, 607, 762, 820, 904, 1075, 1278, 1420, 1511, 1589, 2852, 2923, 3124. Anal. 
calculated for C13H11N3PtCl2:  C, 32.86; H, 2.33, N, 8.84%. Found: C, 32.66; H, 2.81; N, 
8.60%.  
[Pt(dCH3Qn)Cl2]. Yield: 175 mg (73 %). 1H NMR (400 MHz: DMSO-d6): H (ppm); 2.41 
(s, 3H, CH3), 2.45 (s, 3H, CH3), 5.87-5.91 (d, 1H, AB-spin system, -CH2-), 6.12 (s, 1H, 
pz), 6.36-6.40 (d, 1H, AB-spin system, CH2), 7.73-7.76 (d, 1H, py), 7.96-7.99 (d, 1H, 
ph), 8.06-8.11 (t, 2H, ph), 8.75-8.77 (d, 1H, py), 9.36-9.39 (d, 1H, ph). 13C NMR (100 
MHz: DMSO-d6 C (ppm); 11.65, 13.91, 54.7, 105.7, 119.7, 126.9, 127.4, 129.0, 130.4, 
131.4, 141.9, 143.3, 147.5, 150.9, 156.7. 195Pt NMR (107 MHz: DMSO-d6 Pt (ppm); -
2991.37. TOF MS-ES+ m/z: 468.194 (M-Cl)+. IR (KBr) cm-1: 412, 512, 702, 758, 780, 795, 
818, 905, 1149, 1288, 1408, 1512, 1552, 1590, 2923, 2962, 3171. Anal. calculated for 
C15H15N3PtCl2:  C, 35.80; H, 3.00, N, 8.35%. Found: C, 35.65; H, 2.86; N, 8.83%.  
[Pt(dCF3Qn)Cl2]. Yield: 164 mg (56%). 1H NMR (400 MHz: DMSO-d6): H (ppm); 5.95 
(s, 2H, -CH2-), 7.34-7.36 (d, 1H, py), 7.60-7.64 (t, 1H, ph), 7.74 (s, 1H, pz), 7.76- 7.78 (t, 
1H, ph), 7.86-7.88 (d, 1H, ph), 7.98-8.00-8.03 (d, 1H, py), 8.41-8.43 (d, 1H, ph). 13C 
NMR (100 MHz: DMSO-d6 C (ppm); 57.64, 108.09, 119.63, 120.88, 122.34, 127.39, 
127.57, 128.43, 129.00, 130.65, 133.95, 138.02, 143.28, 147.22, 155.20. 195Pt NMR (107 
MHz: DMSO-d6 Pt (ppm); -2962.18. TOF MS-ES+ m/z: 575.440 (M-Cl)+. IR (KBr) cm-
1: 467, 500, 641, 703, 775, 840, 997, 1056, 1143, 1200, 1269, 1428, 1572, 1610, 2930, 3090, 
3115, 3149. Anal. calculated for C15H9N3PtCl2F6: C, 29.47; H, 1.46, N, 6.87%. Found: C, 
29.92, H, 1.19, N, 7.06%. 
[Pt(dCF3Py)Cl2]. Yield: 170 mg (63%). 1H NMR (400 MHz: DMSO-d6): H (ppm); 5.89-
5.93 (d, 1H, AB-spin system, -CH2-), 6.39 (s, 1H, pz), 6.49-6.53 (d, 1H, AB-spin 
system, -CH2-), 7.61-7.65 (d, 1H, py), 7.93- 7.98 (t, 1H, py), 8.15-8.19 (t, 1H, py), 8.91-
8.92 (d, 1H, py). 13C NMR (100 MHz: DMSO-d6 C (ppm); 57.04, 107.93, 122.08, 
123.76, 124.03, 137.73, 141.51, 149.86, 154.61, 154.92, 15.92. 195Pt NMR (107 MHz: 
DMSO-d6 Pt (ppm); -2888.75. TOF MS-ES+ m/z: 525.979 (M-Cl)+. IR (KBr) cm-1: 469, 
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778, 829, 976, 1045, 1095, 1129, 1227, 1275, 1384, 1599, 1643, 2741, 2922. Anal. 
calculated for C11H7N3PtCl2F6:  C, 23.54; H, 1.26, N, 7.49%. Found: C, 23.70; H, 1.30; 
N, 7.54%. 
5.2.4 Preparation of diaqua Pt(II) complex and nucleophile solutions 
The solutions of diaqua Pt(II) complexes Pt(H2Qn), Pt(dCH3Qn), Pt(dCF3Qn) and 
Pt(dCF3Py)  (Figure 5.1), were prepared following a literature procedure of Bugarčić 
et al.24 A detailed procedure was described in Chapter  4, section 4.2.4. Solutions of 
the nucleophiles TU, DMTU and TMTU were prepared by dissolving known 
amounts of the nucleophile in 0.01 M HClO4 solution of constant 0.10 M ionic 
strength. The adjustment of constant ionic strength was done to ensure a constant 
ionic strength throughout the kinetic measurements.  
5.2.5 Instrumentation and physical measurements    
Bruker Avance DRX 400 or DRX 500 NMR spectrometer was used to record the 
NMR spectra of the ligands and complexes. All chemical shifts (proton and carbon) 
are quoted relative to the signals of relevant solvents. All data were recorded at 25 
°C unless otherwise stated. The mass spectrometric data of the ligands and the 
complexes were acquired on the micromass spectrometer equipped with a positive 
electron-sprayer (ESI+) and a time of flight (TOF) analyser. The elementary 
compositions of all synthesised compounds were determined on a Thermo Scientific 
FLASH 2000 CHN Automatic Elemental Analyser. Infrared (IR) spectra were 
acquired using KBr discs on a Perkin Elmer Spectrum One FTIR spectrometer. 
Selected NMR and mass spectra of the synthesised compounds are represented as 
supplementary information in Figure SI 5.1. A Varian Cary 100 Bio UV-visible 
spectrophotometer, equipped with a thermostat which can accurately measure 
temperature within ± 0.05 °C was used for spectrophotometric titrations, preliminary 
wavelength searching experiments and kinetic measurements for slow reactions. 
Kinetic measurements of fast reactions were monitored using an Applied 
Photophysics (v4.33) SX.18 MV stopped-flow spectrophotometer coupled to an 
online data acquisition system. The temperature of the instrument was controlled to 
within ± 0.1 °C for all measurements. The pKa measurements were determined on a 
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Jenway 4330 pH meter equipped with a 4.5 μm glass electrode. The microelectrode 
was calibrated at 25 °C using the standard buffer solutions (Merck) at pH 4.0, 7.0 and 
10.0. pKa titration curve and time-dependent kinetic traces were graphically analysed 
using Origin 7.5® software package.25  
5.2.6 Kinetic measurements 
Prior to the kinetic measurements, preliminary experiments recording the spectral 
changes resulting from mixing the complex with the nucleophile were made to 
establish the appropriate wavelength at which the kinetics could be studied. A 
typical trial scan and suitable wavelengths chosen for studying the kinetic reactions 
are shown in Figure SI 5.2 and Table SI 5.1 (supporting information). All 
substitution kinetics reactions were performed under pseudo first-order conditions, 
as a function of nucleophile concentration and temperature, at constant temperature 
(298.1 K) and concentration respectively. The pseudo first-order conditions were 
achieved by providing the nucleophile concentration in at least 20-fold excess over 
that of a bifunctional Pt(II) complex. This afforded at least 10-fold excess of the 
nucleophile concentration for each of the two coordinated leaving group (after 
mixing), which is sufficient to force the reaction to go to completion. A pH of 2.0 was 
maintained throughout the kinetic runs to guarantee the presence of only diaqua 
complexes. Slow reactions were initiated by manually mixing equal volumes of the 
complex and the nucleophile solutions in a Suprasil tandem cuvette.  For fast 
reactions, equal amounts of pre-equilibrated complex and nucleophile solutions 
were mixed through a pressure-driven cross-plunging technique in the chamber of 
the stopped-flow analyser.   
5.2.7 Computational details 
In order to gain an in depth understanding of structural and electronic differences 
that exist between the bifunctional Pt(II) complexes studied, computational 
calculations were performed. The ground state electronic structures of Pt(H2Qn), 
Pt(dCH3Qn), Pt(dCF3Qn)  and Pt(dCF3Py) were optimized by Density Functional 
Theoretical (DFT) calculatuions using B3LYP/LanL2DZ level of theory.26 This 
method is suitable for calculations of systems containing heavy atoms as in this 
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study (Pt atom).27 The complexes were modelled as +2 gaseous ions. The singlet state 
was used due to the low electronic spin of Pt(II) complexes. Gassian09 suite of 
programs was used for all computational analysis modelling and Gaussview5.0 was 
used to generate the frontier molecular orbitals of the modelled complexes at the 
same level of theory.28     
5.3 Results  
5.3.1 Acidity of diaqua Pt(II) complexes 
Spectrophotometric titrations of bifunctional Pt(II) complexes with NaOH show that 
the deprotonation of the two coordinated aqua ligands occurred in two successive 
steps. Therefore, the deprotonation steps for pH dependence can be represented by 






Scheme 5.1: Proposed stepwise deprotonation for the pH dependence of 
mononuclear bifunctional Pt(II) system of complexes with different donors. 
Typical UV/visible spectra obtained during the pH titration of Pt(dCF3Qn) with 




Figure 5.2:   UV/Visible spectra for the titration of 0.05 mM Pt(dCF3Qn) with NaOH 
in the pH range 2-9 at T = 298.15 K. Inset: Absorbance vs. pH at 275 nm for 
Pt(dCF3Qn) complex. 
The change in absorbance as a function of pH was fitted to two separate sigmoidal 
functions (Boltzmann) using Origin 7.5® software,25 resulting in two pKa values 
which are summarised in Table 5.1.  
Table 5.1.   Summary of pKa values for the deprotonation of Pt-bound aqua ligands 
in bifunctional Pt(II) complexes studied. 
 
5.3.2 DFT-calculated optimised structures 
Substituents of different electronic nature at the 3,5-positions of the pyrazole ring 
and the extended π-conjugation of a quinoline ligand are the two important 
structural parameters affecting the substitution chemistry of the Pt(II) complexes 
studied. Computational calculations were performed to simulate the structural and 
 Pt(H2Qn) Pt(dCH3Qn) Pt(dCF3Qn) Pt(dCF3Py) 
pKa1 4.56 ± 0.02 4.88 ± 0.10 4.07 ± 0.08 4.76 ± 0.05 
pKa2 6.32 ± 0.05 6.31 ± 0.05 6.35 ± 0.07 6.27 ± 0.02 
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electronic properties of the bifunctional Pt(II) complexes in the ground state.  A 
summary of the geometry-optimised data is presented in Table 5.2 and Figure 5.3.  
Bond angles around each Pt(II) centre reflect a slightly distorted square-planar 
geometry (Table 5.2). Looking at the calculated NBO charges in Table 5.2, the 
effective charges on the Pt(II) centre increase in the order of Pt(dCH3Qn) (0.840) < 
Pt(H2Qn) (0.876) < Pt(dCF3Qn) (0.909) < Pt(dCF3Py) (0.991). Thus, the charges on the 
complexes are significantly affected not only by the electronic nature of the 
substituents in the 3,5-positions of the pyrazole ring but also by the replacement of 
the pyridine ring (a known strong  π-acceptor moieity) with a  quinoline  ring in the 
N,N-bidentate ligand. The electron-donating methyl groups of Pt(dCH3Qn)  
decrease the charge on the Pt(II) ion relative to that of Pt(H2Qn), while the electron-
withdrawing trifluoromethyl substituents of Pt(dCF3Qn) increase the charge on 
Pt(II) ion. Despite the quinoline having delocalised π-molecular orbitals when 
compared to pyridine, this substructure decreases the charge on the Pt(II) metal 




























Property  Pt(H2Qn) Pt(dCH3Qn) Pt(dCF3Qn) Pt(dCF3Py) 
MO Energy (eV)     
LUMO -2.93 -2.91 -3.22 -3.06 
HOMO -7.21 -7.16 -7.34 -7.61 
∆EL-H  4.28  4.25  4.12  4.55 
NBO charges     
Pt  0.876  0.840  0.909  0.991 
1Nqn/py -0.406 -0.407 -0.410 -0.400 
1Npz -0.288 -0.373 -0.320 -0.337 
Bond lengths (Ǻ)      
d Pt−Npy 2.034 2.032 2.033 2.018 
d Pt−Npz 1.991 1.996 2.004 2.010 
d Pt−OH2 (1) 2.099 2.100 2.077 2.094 
d Pt−OH2 (2) 2.102 2.112 2.108 2.078 
Bond angles (°)     
< Npz−Pt−OH2 (1) 176.3 176.9 177.3 177.8 
< Nqn/py−Pt−OH2 (2) 177.9 176.4 175.5 179.9 
< a 94.5 86.8 97.0 91.1 
< b 87.2 94.9 85.9 88.8 
< c 94.7 82.0 94.0 90.2 
< d 83.5 89.1 82.9 89.9 
1 Nqn/py is the coordinated N-donor atom in the quinoline or pyridine head and Npz is the 























            
 
              
   
                        










                






     
 
         
 

















5.3.3   Kinetics of the substitution reactions with thiourea nucleophiles 
Substitution of the labile aqua ligands from each of the bufunctional Pt(II) complexes 
(Figure 5.1) by thiourea nucleophiles i.e. TU, DMTU, and TMTU, occurred in two 
consecutive steps characterised by 𝑘2 (1st) and 𝑘2 (2nd) as shown in Scheme 5.2. Each 
step corresponds to the nucleophilic substitution of the coordinated aqua leaving 
groups, respectively.  
k2 (1st ) k2 (2nd )
Nu = TU, DMTU and TMTU





  +  H2O
 
Scheme 5.2:   The proposed stepwise substitution of diaqua ligand from bifunctional 
Pt(II) complexes by thiourea nucleophiles.        
The substitution of the first aqua ligand was monitored by the stopped-flow 
technique while the slower and second substitution step was followed by the 
UV/visible spectrophotometry. The reduced reactivity of the Pt(II) metal centre in 
the second substitution step is ascribed to an increased steric hindrance around the 
metal centre upon the coordination of the first thiourea nucleophile as well as a 
decreased eletrophilicity of the Pt(II) metal centre due to σ-donor capacity of the 
thioureas. These two factors retards the aerial approach of the nucleophile towards 
the Pt(II) centre, thereby decreasing the rate of substitution. An exemplary time-
dependent kinetic trace for the first substitution step for the reaction of Pt(dCH3Qn) 




Figure 5.4:   A typical kinetic trace for the first substitution step in a two-step 
reaction between Pt(dCH3Qn) (0.15 mM) and TU (6.0 mM) recorded at 290 nm, T = 
298 K, pH = 2.0, I = 0.1 M (HClO4/NaClO4) on the stopped-flow spectrophotometer. 
The UV/visible spectral changes in absorbance resulting from the reaction of 
Pt(H2Qn) and  20-fold TU in the second substitution are shown in Figure 5.5. The 
appearance of an isosbestic point (325 nm) in the UV-visible spectra clearly indicates 
the conversion of reactants to products i.e. the conversion of [Pt(H2Qn)(H2O)TU]2+ 
to [Pt(H2Qn)(TU)2]2+ or  indicates the presence of these two species in solution 
during the substitution reaction. 29 The time-dependent kinetic trace obtained for this 
reaction is shown as an insert in Figure 5.5.     
 





















Figure 5.5:   UV/visible spectra recorded during a two-step reaction of 0.22 mM 
Pt(H2Quin) and 4.4 mM TU recorded at pH = 2, T = 298 K and I = 0.1 M (HClO4/ 
NaClO4). Inset: Kinetic trace at 293 nm. 
 
In both substitution steps, the kinetic traces fitted perfectly to a first-order 
exponential function to generate the observed pseudo-first-order rate 
constants, 𝑘𝑜𝑏𝑠 (1/2), according to equation (5.1):30  
𝐴t =  𝐴o + (𝐴o −  𝐴∞)exp [−𝑘𝑜𝑏𝑠(1/2)𝑡]                           (5.1)                               
where 𝐴o,  𝐴t and 𝐴∞ represent the absorbance of the reaction mixture at the onset of 
the reaction, at time (t) and at the end of the reaction, respectively. The observed 
pseudo-first rate constants, 𝑘𝑜𝑏𝑠 (1/2), at different nucleophile concentrations and 
temperatures were determined in the same manner. The second-order rate constants, 
𝑘2 (1st/2nd), for the first and second substitution steps were obtained from the slopes 
of the linear regression plots of 𝑘𝑜𝑏𝑠 (1/2) against the concentration of the entering 
nucleophile, according to the rate laws described in equation (5.2):31  
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𝑘𝑜𝑏𝑠 (1/2) =  𝑘2 (1st/2nd) [Nu] + 𝑘−1 (1st/2nd) ≅  𝑘2 (1st/2nd) [Nu]        (5.2)         
where Nu = TU, DMTU and TMTU. Representative plots displaying a linear 
dependence of 𝑘𝑜𝑏𝑠 (1/2) on the concentration of the entering nucleophiles are shown 
in Figure 5.6 (also see Figures SI 5.4).  
 
Figure 5.6.   Pseudo-first-order rate constants, 𝑘obs 1/2, plotted as a function of 
nucleophile concentration for the substitution of the first (a) and second (b) labile 
aqua ligand from Pt(dCF3Qn) at pH = 2.0, T = 298 K and I = 0.1 M (HClO4/ NaClO4). 
No observable intercepts were recorded for all linear regression plots, suggesting the 
absence of the solvolytic pathway or insignificance of the reverse reaction. Thus, the 
first-order rate constant, 𝑘−1 (1st/2nd), is too small to be measured accurately. The 
values of the second-order rate constants for the reactions of the complexes are 









Table 5.3.   Summary of the second-order rate constants for the stepwise substitution 





















Complex Nu  𝒌𝟐 (𝟏𝐬𝐭) 
(M−1s−1) 








100 ± 1 
 




72.6 ± 0.7 
 




20.2 ± 0.2 
 







5.08 ± 0.05 
 




4.72  ± 0.08 
 




0.803  ± 0.02 
 







30.7 ± 0.6 
 




15.5 ± 0.3 
 




4.46 ± 0.06 
 







147 ± 1 
 




87.9 ± 2 
 




18.8  ± 0.1 
 
0.259 ± 0.003 
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The temperature dependence of the second-order rate constants, 𝑘2 (1st/2nd), was 
studied at a fixed nucleophile concentration, to determine the activation parameters 
of each substitution step. The enthalpy (∆𝐻1/2
≠ ) and entropy (∆𝑆1/2
≠ ) of activation were 
calculated using the Erying equation:32  
ln[𝑘2(1st/2nd) /𝑇] =  −(∆𝐻1/2
≠  /𝑅) . 1/𝑇 + [23.8 + (∆𝑆1/2
≠ /𝑅)]         (5.3)    
where 𝑅 and 𝑇 represent the  ideal gas constant and temperature, respectively. 
Typical Erying plots are shown in Figure 5.7 (also see Figure SI 5.5).  
 
Figure 5.7: Plots of ln(k2/T) versus (1/T) for the substitution of the first (a) and 
second (b) aqua ligand from Pt(dCF3Qn) by thiourea nucleophiles at varying 
temperatures.  
A summary of the activation parameters for the first (∆𝐻1
≠ and ∆𝑆1
≠) and second (∆𝐻2
≠ 
and ∆𝑆2









Table 5.4.   Summary of the activation parameters for the stepwise substitution of 
labile aqua ligands by thioures from the diaqua Pt(II) complexes 
 
5.4 Discussion 
5.4.1 Acid-base equilibrium of diaqua Pt(II) complexes  
By comparing the pKa values in Table 5.1, an increasing order in the pKa1 values of: 
Pt(dCH3Qn) (4.88) < Pt(H2Qn) (4.56) < Pt(dCF3Qn) (4.07) is established for 
quinoline-bearing Pt(II) complexes. It is well-known that the pKa values of the 
coordinated aqua ligands serve as an indicator of the electrophilicity of the metal 
centre.10,32,33 The results clearly show a correlation between the pKa values and the 
electrophilicity of the Pt(II) centre as already pointed in Section 5.3.2. The 
introduction of the electron-withdrawing trifluomethyl (−CF3) substituents on the 
pyrazole ring decrease the electron density on the metal centre (vide infra). 
Consequently, the pKa1 value of Pt(dCF3Qn) is lower than that recorded for 
Pt(H2Qn).  As expected, Pt(dCH3Qn)  a complex with  electron donating substituents 
on the pyrazole ring records a higher pKa1 value due to σ-inductive donation of 
eletron density towards the Pt centre. 
The pKa2 values for the second deprotonation of the aqua ligand from aqua/hydroxo 
to dihydroxo species occurred at a higher pH than pKa1. This is ascribed to a 


















( 𝐉 𝐦𝐨𝐥−𝟏𝐊−𝟏) 
Pt(H2Qn) TU 42± 1 51 ± 4 - 66 ± 3 - 82 ± 2 
 DMTU 41 ± 1 50 ± 2 - 72 ± 5 - 84 ± 7 
 TMTU 42 ± 2 59 ± 3 -78 ± 8 - 79 ± 1 
Pt(dCH3Qn) TU 38.± 1 51 ± 2 - 103 ± 5 - 131 ± 9 
 DMTU 47 ± 2 54 ± 2 - 74 ± 1 - 97 ± 9 
 TMTU 40 ± 1 57 ±1 -111 ± 4 - 97 ± 1 
Pt(dCF3Qn) TU 52± 3 47 ± 1 - 42 ± 1 - 99 ± 5 
 DMTU 49 ± 1 49 ± 3 - 59 ± 5 - 95 ± 1 
 TMTU 32± 1   48 ± 4 -125 ± 4 - 115 ± 6 
Pt(dCF3Py) TU 41 ± 2 46 ± 2 - 67 ± 3 - 101± 7 
 DMTU 45± 2 48 ± 2 - 58± 6 - 101 ± 7 
 TMTU 36 ± 2 58 ± 3 - 101 ± 7 - 121 ± 1 
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deprotonation of the first aqua ligand to form aqua/hydroxo species. This decreases 
the electrophilicity and the acidity of the Pt(II) complex, leading to higher pKa 
values.34,35         
5.4.2 DFT calculated optimised structures 
In quinoline-bearing complexes, the HOMOs are located mainly on the quinoline 
ring and the metal centre, with an exception of Pt(dCH3Qn) which has an additional 
contribution from 3,5-dimethylpyrazole ring. This signifies that both quinoline and 
3,5-dimethylpyrazole rings donate electron density on the metal centre thereby 
making it less electrophilic. However, in Pt(dCF3Py), the HOMO is localised above 
and below the metal centre with no significant contribution from the pyridine and 
3,5-bis(trifluoromethyl)pyridine rings.  In all complexes, LUMOs are localised on the 
quinoline or pyridine rings with no significant contributions from either the 3,5-
dimethylpyrazole or pyrazole rings. This is consistent with these rings, viz. pyridine 
or 3,5-bis(trifluoromethyl)pyridine being strong π-acceptor ligands. Importantly, the 
location of the HOMO and LUMO electron density maps on the quinoline ring 
indicates that this substructure of the N,N-bidentate has both σ-donor and π-acceptor 
properties, respectively. In addition, the ground state elongation of the Pt−OH2 (2) 
bond length (Table 5.2) of the aqua leaving group trans to the quinoline ring, due to 
an increase in the electron density at the metal centre and along the trans axis, 
reflects an increase in the trans-influence as a result of its stronger σ-donor effect. The 
location of the LUMOs around the metal centre indicates that the π-acceptor ligands 
significantly reduce the electron density on the metal centre, rendering it more 
electrophilic. Furthermore, the location of the frontier molecular orbitals indicate 
that the σ-donor or π-acceptor strength of pyrazole can be controlled by introducing  
electron donating or withdrawing substituents on 3,5-positions of its ring.            
5.4.3 Kinetic studies 
The substitution reactions were carried out at pH 2, where all the Pt(II) complexes 
predominantly existed in their diaqua forms and the protonation of the incoming  
thiourea nucleophiles can be neglected.7 Two consecutive substitution steps were 
observed for all bifunctional Pt(II) complexes, indicating a difference in the trans-
labilization effect of the coordinated rings of the flexible (pyrazolylmethyl)quinoline 
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bidendate ligand. The labilisation of two aqua ligands is distinct and therefore 
occurs at different rates.  Similar to what was observed and described for the Pt(II) 
complexes of Chapter 4,  the first observed  reaction step is ascribed to the 
substitution of the aqua ligand trans to the quinoline ring, while the second 
corresponds to the substitution of the aqua ligand trans to pyrazole. This proposition 
is supported by the metrics of the Pt−OH2 (2) bond trans to the quinoline ring bond 
which is marginally longer compared to the Pt−OH2(1) bond trans to pyrazole (see 
Table  5.2).  
5.4.3.1 First substitution step 
A comparison of the  𝑘2 (1st) values shows a decreasing order in reactivity of 
Pt(H2Qn) > Pt(dCF3Qn) > Pt(dCH3Qn) for all the nucleophiles. When thiourea is the 
incoming nucleophile the rate of substitution decrease in the order: 100 M−1 s−1 
Pt(H2Qn) > 30.7 M−1 s−1 Pt(dCF3Qn) > 5.08 M−1 s−1 Pt(dCH3Qn). This trend 
indicates an interplay between steric and electronic effects, with the dominant factor 
controlling the rate. Since the substitution occurs first at the aqua ligands cis to the 
pyrazole ring carrying substituents of different electronic properties, the absence of 
steric influence at the 3,5-positions of pyrazole overrides the electronic effects of the 
ring  leading to a fast rate of substitution in Pt(H2Qn) compared to its substituted 
analogues.  
Pt(dCF3Qn) reacts about 6 times faster than Pt(dCH3Qn). Considering the 
comparable spatial (steric) sizes of the −CF3 and −CH3 substituents, steric 
considerations alone cannot fully account for the observed large reactivity difference 
between the two complexes. Just as explained for their pyridine analogues (Chapter 
4); a similar reason stands here to account for the observed differences in their 
reactivities.  The electronic properties of the 3,5-substituents of pyrazole dominate 
the substitution of the  aqua coordinated ligand from the complexes. The withdrawal 
of electron density from pyrazole by the −CF3 groups reduces the σ-donation of the 
pyrazole ring towards the Pt centre leading to higher substitution rates. 
Alternatively, the withdrawal of electron density stabilises the π*-molecular orbitals 
in the transition state switching 3,5-bis(trifluoromethyl)pyrazole into a good π-
accepting ring for π-back-donation of electrons from the filled dπ-orbitals of the 
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metal centre. This increases the electrophilicity of the metal centre, leading to an 
acceleration in the rate of substitution. Higher reactivity of Pt(dCF3Qn)  compared to 
Pt(dCH3Qn) is also supported by relatively lower pKa1 value, smaller frontier 
orbitals energy gap and more positive NBO charge of the platinum atom.  
The opposite is true for the 3,5-methyl groups of pyrazole in Pt(dCH3Qn) which 
strengthen electron donation at a cis position leading to  a reduced rate of 
substitution. The 3,5-dimethylpyrazole ring donates the electron density inductively 
towards the metal centre leading to a decreased  electrophilicity.  This enhanced cis 
σ-donor effect destabilizes the electron-rich penta-coordinate transition state and 
repels the approach of an incoming nucleophile, leading to a retarded rate of 
substitution. Also important in slowing down the approach of the nucleophile to 
Pt(dCH3Qn), is the steric effect due to a methyl (–CH3) group in the 3-position of the 
pyrazole ring. This steric effect and the electronic cis σ-donor effect of the two methyl 
groups are cooperative in retarding the rate of aqua ligand substitution. This 
explains why this complex has a significantly smaller second-order rate constant for 
the first substitution step (𝑘2 (1st)) compared to Pt(dCF3Qn).   
5.4.3.2 Second substitution step 
The second substitution step is significantly slower than the first one for all 
complexes. As already alluded (vide supra), this is due to a decrease in the 
electrophilicity of the metal centre upon the coordination of the first TU ligand 
which also confers steric hindrance to the second incoming nucleophile. For the 
substitution of the second aqua ligand (i.e. trans to the pyrazole ring), the same order 
of reactivity as reported for the first aqua leaving group:  Pt(H2Qn) > Pt(dCF3Qn) > 
Pt(dCH3Qn) is observed. This order of reactivity is true for all the nucleophiles. 
Taking the reaction of Pt(dCH3Qn) and TU as a reference, the ratio of reactivity 
decreases in the ratio 18 : 1.2 : 1, respectively for Pt(H2Qn): Pt(dCF3Qn): 
Pt(dCH3Qn). By making structural comparisons between the current complexes and 
those reported in Chapter 4, the lability of the aqua ligand trans to the pyrazole ring 
was expected to follow the order: Pt(dCF3Qn) > Pt(H2Qn) > Pt(dCH3Qn). For this 
substitution step, the 3,5-susbtituents of pyrazole should impart a limited or no steric 
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effect since the aqua leaving ligand is at a trans position. The quinoline substructure 
being more steric-demanding than pyridine, the observed decrease in the rates of 
substitution of the second aqua ligand from both Pt(dCF3Qn) and Pt(dCH3Qn)  
relative to Pt(H2Qn) can possibly be due to an increase in the overall steric constrains 
at an already hindered Pt(II) centre in the transition states of the two substituted 
analogues. This destabilises the transition state leading to a decrease in their rates of 
substitution relative Pt(H2Qn) as already stated. In this regard, the π-acceptor 
stabilising effect of the 3,5-bis(trifluoromethyl)pyrazole ring  relative to 3,5-
dimethylpyrazole ring leads to a slightly increased rate of substitution for the second 
aqua ligand in Pt(dCF3Qn) compared to Pt(dCH3Qn). This is typical for substitution 
reactions proceeding via an associative mode of action that involves bond formation 
in the transition state. The increase in the reactivity of Pt(dCF3Qn) corroborates with 
the NBO charge on its platinum atom, HOMO-LUMO energy gap, and frontier 
molecular orbital diagrams which suggest an increase in the π-backbonding strength 
of the pyrazole ring upon the addition of  –CF3 substituents.   
To pin down on the effect in the rate of substitution upon the replacement of a 
pyridine (which is known to be a strong π-acceptor ring) with a quinoline ring, the 
rate constants, 𝑘2 (1st/2nd), (Table 5.3) of Pt(dCF3Py) and Pt(dCF3Qn) were compared. 
In all cases, Pt(dCF3Py) reacts much faster than Pt(dCF3Qn). The quinoline 
(benzopyridine) ring consists of a σ/π-donating phenyl ring fused to a π-accepting 
pyridine ring.7,36 The  coordinative character of the pyridyl ring of quinoline is 
therefore modulated by σ/π-donor of its phenyl ring. Its capacity to accept electrons 
from the dπ-orbital of the metal to its π*-molecular orbitals is weaker compared to 
pyridine which has lower and stabilised π*-molecular orbitals. This leads to a less 
electrophilic Pt metal centre which repels the electron density of approaching 
nucleophiles. This reduces the rate of substitution.  
The weaker π-accepting character of quinoline relative to pyridine is reflected by the 
relative magnitude of the NBO charges of the platinum atom which decreases from 
Pt(dCF3Py) (0.991) to Pt(dCF3Qn) (0.909). In addition, the LUMO energy in 
Pt(dCF3Py) (-7.61 eV) is significantly lower than the one for Pt(dCF3Qn) (-7.34 eV), 
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making quinoline a less π-acceptor than pyridine. The surprising and anomalous 
increase in the net σ-donor capacity of the quinoline as  a substructure for a chelating  
polypyridyl nitrogen-donor ligand has been reported in the literature.6,7,37 In all 
reported cases, the reduced electrophility of the metal centre is ascribed to the 
weakening of the π-acceptabilty of the coordinated pyridine ring of the 
benzopyridine (quinoline). This makes quinoline an apparent donor of electron 
denstity towards the metal centre rather than it being a π-acceptor if its extended 
molecular orbitals are taken into consideration.   
5.4.4 Activation parameters and reactivity of the nucleophiles 
The data in Table 5.3 show a clear dependence of second-order rate constants for the 
aqua substitutions on the steric hindrance of the incoming nucleophile. The rate of 
substitution decreases as the bulk size of the incoming nucleophiles increases. The 
sensitivity of the complexes on the structural size and hence steric effect of the 
incoming nucleophiles is characteristic of an associative mechanism. The small 
enthalpies of activation (∆𝐻1/2
≠ ) signify an ease in the formation of a bond in the 
transition state. The large and negative entropies of activation (∆𝑆1/2
≠ ) allude to a 
more ordered transition state. All these observations are in support of an 
associatively-activated mechanism of substitution, well documented for d8 square-
planar Pt(II) complexes.10,13,21     
 
5.5 Conclusion 
The 3,5-substituents on the pyrazole ring as well as the replacement of a pyridine 
with a quinoline ring in the N,N-bidentate chelate affects the electrophilicity of the 
Pt(II) centre, which in turn controls the lability of the coordinated aqua ligands. The 
complete order of reactivity for the first substitution was found to be Pt(dCF3Py) > 
Pt(H2Qn) > Pt(dCF3Qn) > Pt(dCH3Qn) and indicates an interplay between steric 
and electronic effects, with the dominant factor controlling the rate. Electron-
withdrawing substituents on the pyrazole ring resulted in lower pKa values while 
the opposite was true for electron-donating substituents.  This study confirms that 
quinoline substructure in the (pyrazolylmethyl)quinoline ligands acts as an apparent 
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donor of electron density towards the metal centre rather than being a strong π-
acceptor. This is contrary to what would be expected given its stabilized extended 
molecular orbitals, which should delocalise electrons better than those of pyridine. 
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5.7 Supporting Information 
 
Table SI 5.1a. Summary of wavelength (nm) used for monitoring the first 
substitution reactions between a series of bifunctional Pt(II) complexes and thiourea 
nucleophiles. 
Complex Nucleophile Wavelength (nm) 
Pt(H2Qn) TU 284 
DMTU 286 
TMTU 340 
Pt(dCH3Qn) TU 298 
DMTU 290 
TMTU 300 
Pt(dCF3Qn) TU 295 
DMTU 295 
TMTU 300 
Pt(dCH3Py) TU 310 
 DMTU 300 
 TMTU 340 
 
Table SI 5.1b. Summary of wavelength (nm) used for monitoring the second 
substitution reactions between a series of bifunctional Pt(II) complexes and thiourea 
nucleophiles 
Complex Nucleophile Wavelength (nm) 
Pt(H2Qn) TU 293 
DMTU 290 
TMTU 385 
Pt(dCH3Qn) TU 290 
DMTU 285 
TMTU 385 
Pt(dCF3Qn) TU 270 
 DMTU 275 
 TMTU 310 










Figure SI 5.1a: 1H NMR spectrum of 2-(pyrazol-1-ylmethyl)quinoline (H2Qn) in CDCl3.  
 
Figure SI 5.1b: 13C NMR spectrum of 2-[3,5-bis(trifluoromethyl)pyrazol-1-













Figure SI 5.1c: Low resolution ESI+ mass spectrum of 2-(pyrazol-1-ylmethyl)quinoline 
(H2Qn).  
 
Figure SI 5.1d: 1H NMR spectrum of [Pt{2-[(3,5-bis(trifluoromethyl)-pyrazol-1-




Figure SI 5.1e: 13C NMR spectrum [Pt{2-[(3,5-bis(trifluoromethyl)-pyrazol-1-
ylmethyl]quinoline}Cl2], [Pt(dCF3Qn)Cl2] in DMSO-d6.  
 
Figure SI 5.1f: 1H NMR spectrum of [Pt{2-[(3,5-bis(trifluoromethyl)pyrazoly-1-




Figure SI 5.1g: 1H NMR spectrum of [Pt{(2-pyrazoly-1-ylmethyl)quinoline}Cl2], 
[Pt(H2Qn)Cl2] in DMSO-d6. 
 
Figure SI 5.2:  UV/visible scan for a trial run of the reaction between Pt(H2Qn) 




Figure SI 5.3:  UV/Visible spectra for the titration of 0.054 mM Pt(dCH3Qn) with 
NaOH in the pH range 2-10 at T = 298.15 K. Insert: Absorbance versus pH plot at 295 
nm for Pt(dCF3Qn) complex. 
Table SI 5.2a. Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(H2Qn) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 M 
(HClO4/NaClO4). 
[TU]/ M kobs1/ s-1 [DMTU]/ M kobs1/ s-1 [TMTU]/ M kobs1/ s-1 
0.002186 0.23007 0.002186 0.1612133 0.002186 0.04969772 
0.004372 0.39936 0.004372 0.3181796 0.004372 0.08848313 
0.006558 0.64926 0.006558 0.4573171 0.006558 0.13115263 
0.008744 0.86254 0.008744 0.6316229 0.008744 0.17503662 
0.01093 1.12344 0.01093 0.8076081 0.01093 0.22193649 
 
Table SI 5.2b. Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCH3Qn) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 
M (HClO4/NaClO4). 
[TU]/ M kobs1/ s-1 [DMTU]/ M kobs1/ s-1 [TMTU]/ M kobs1/ s-1 
0.00149 0.0082105 0.00149 0.00586724 0.00149 0.002336462 
0.00298 0.0155858 0.00298 0.01343998 0.00298 0.003320504 
0.00447 0.0224411 0.00447 0.02044681 0.00447 0.004714193 
0.00596 0.0297551 0.00596 0.02819208 0.00596 0.005895534 
0.00745 0.0381513 0.00745 0.03596169 0.00745 0.007033142 
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Table SI 5.2c. Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCF3Qn) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 
M (HClO4/NaClO4). 
[TU]/ M kobs1/ s-1 [DMTU]/ M kobs1/ s-1 [TMTU]/ M kobs1/ s-1 
0.0009816 0.026531867 0.0009816 0.016562318 0.0009816 0.005065183 
0.0019632 0.053636887 0.0019632 0.027987854 0.0019632 0.009104683 
0.0029448 0.086769674 0.0029448 0.043727462 0.0029448 0.013449955 
0.0039264 0.123355366 0.0039264 0.062799493 0.0039264 0.017200094 
0.004908 0.153634833 0.004908 0.076598717 0.004908 0.021662424 
 
Table SI 5.2d. Average observed rate constants, kobs1, for the displacement of the 
first aqua ligand in Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 
M (HClO4/NaClO4). 
[TU]/ M kobs1/ s-1 [DMTU]/ M kobs1/ s-1 [TMTU]/ M kobs1/ s-1 
0.0013365 0.209136 0.0013365 0.1062663 0.0013365 0.02589553 
0.0026730 0.379717 0.0026730 0.2088192 0.0026730 0.05136792 
0.0040095 0.584138 0.0040095 0.3379142 0.0040095 0.07594849 
0.0053460 0.805353 0.0053460 0.4778034 0.0053460 0.09938629 
0.0066825 0.975599 0.0066825 0.6032466 0.0066825 0.12552738 
 
Table SI 5.2e. Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(H2Qn) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 0.1 
M (HClO4/NaClO4). 
[TU]/ M kobs2/ s-1 [DMTU]/ M kobs2/ s-1 [TMTU]/ M kobs2/ s-1 
0.002186 0.001011554 0.002186 0.000931763 0.001093 1.84058E-05 
0.004372 0.002071891 0.004372 0.002010494 0.002186 4.46553E-05 
0.006558 0.00317183 0.006558 0.003097801 0.003279 7.75336E-05 
0.008744 0.004149731 0.008744 0.004210897 0.004372 0.000106527 
0.01093 0.005128 0.01093 0.005132675 0.005465 0.000132653 
 
Table SI 5.2f. Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCH3Qn) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 
0.1 M (HClO4/NaClO4). 
[TU]/ M kobs2/ s-1 [DMTU]/ M kobs2/ s-1 [TMTU]/ M kobs2/ s-1 
0.00149 3.6016E-05 0.00149 1.86322E-05 0.00149 1.29862E-05 
0.00298 7.85319E-05 0.00298 3.84081E-05 0.00298 2.17823E-05 
0.00447 0.000115767 0.00447 6.20721E-05 0.00447 2.89438E-05 
0.00596 0.000162383 0.00596 8.34018E-05 0.00596 3.71296E-05 
0.00745 0.000200962 0.00745 0.000106976 0.00745 4.69987E-05 
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Table SI 5.2g. Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCF3Qn) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 
0.1 M (HClO4/NaClO4). 
[TU]/ M kobs2/ s-1 [DMTU]/ M kobs2/ s-1 [TMTU]/ M kobs2/ s-1 
0.0009816 0.000298646 0.0009816 0.00019207 0.0009816 2.58571E-05 
0.0019632 0.000557257 0.0019632 0.000452216 0.0019632 4.76812E-05 
0.0029448 0.000858948 0.0029448 0.000647351 0.0029448 7.98776E-05 
0.0039264 0.001249669 0.0039264 0.000901553 0.0039264 0.000109918 
0.004908 0.001537603 0.004908 0.001150635 0.004908 0.000137999 
 
Table SI 5.2h. Average observed rate constants, kobs2, for the displacement of the 
second aqua ligand in Pt(dCF3Py) by thiourea nucleophiles, pH = 2.0, T = 298 K, I = 
0.1 M (HClO4/NaClO4). 
[TU]/ M kobs2/ s-1 [DMTU]/ M kobs2/ s-1 [TMTU]/ M kobs2/ s-1 
0.0006833 0.000166531 0.0006833 8.56831E-05 0.0013665 3.1800E-05 
0.0013666 0.000332366 0.0013666 0.000192329 0.0027330 7.3600E-05 
0.0020499 0.000514252 0.0020499 0.000303338 0.0040995 1.0900E-04 
0.0027332 0.000658979 0.0027332 0.000418477 0.0054660 1.4000E-04 
0.0034165 0.000892367 0.0034165 0.000521954 0.0068325 1.7700E-04 
 
Table SI 5.3a. Temperature dependence of the second-order rate constants, 
𝑘2 (1𝑠𝑡), M
−1 s−1 for the displacement of the first aqua ligand in Pt(H2Qn) by thiourea 
nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -1.785334 0.003470415 -1.893185 0.003470415 -3.21812318 
0.003411223 -1.492685 0.003411223 -1.627207 0.003411223 -2.98658428 
0.003354016 -1.176108 0.003354016 -1.383966 0.003354016 -2.70192064 
0.003298697 -0.935979 0.003298697 -1.055988 0.003298697 -2.40012973 
0.003245173 -0.626953 0.003245173 -0.787489 0.003245173 -2.07924288 
 
Table SI 5.3b. Temperature dependence of the second-order rate constants, 
𝑘2 (1𝑠𝑡), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCH3Qn) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -4.56795 0.003470415 -4.933203 0.003470415 -6.16290124 
0.003411223 -4.36015 0.003411223 -4.510882 0.003411223 -5.87139754 
0.003354016 -4.08409 0.003354016 -4.177158 0.003354016 -5.64440739 
0.003298697 -3.80833 0.003298697 -3.887616 0.003298697 -5.33277591 
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0.003245173 -3.54736 0.003245173 -3.645189 0.003245173 -5.08249946 
 
Table SI 5.3c. Temperature dependence of the second-order rate constants, 
𝑘2 (1𝑠𝑡), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCF3Qn) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -3.1449942 0.003470415 -3.70075165 0.003470415 -4.63628734 
0.003411223 -2.6728291 0.003411223 -3.31899656 0.003411223 -4.42095143 
0.003354016 -2.3148043 0.003354016 -2.99966134 0.003354016 -4.17866185 
0.003298697 -1.9900971 0.003298697 -2.64452973 0.003298697 -3.94267414 
0.003245173 -1.7210378 0.003245173 -2.38378940 0.003245173 -3.79296891 
 
Table SI 5.3d. Temperature dependence of the second-order rate constants, 
𝑘2 (1𝑠𝑡), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCF3Py) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -1.94020813 0.003470415 -1.82993478 0.003470415 -3.33277200 
0.003411223 -1.24929178 0.003411223 -1.52737825 0.003411223 -3.05254003 
0.003354016 -0.71612601 0.003354016 -1.26347124 0.003354016 -2.75620791 
0.003298697 -0.40161104 0.003298697 -0.93898081 0.003298697 -2.55663744 
0.003245173 -0.14142259 0.003245173 -0.60713315 0.003245173 -2.36156920 
 
Table SI 5.3e. Temperature dependence of the second-order rate constants, 
𝑘2 (2𝑛𝑑), M
−1 s−1 for the displacement of the first aqua ligand in Pt(H2Qn) by thiourea 
nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003470415 -7.1529987 0.003470415 -7.15267548 0.003354016 -9.44217912 
0.003411223 -6.7793919 0.003411223 -6.84922886 0.003298697 -9.15832684 
0.003354016 -6.4239739 0.003354016 -6.44758989 0.003245173 -8.76711074 
0.003298697 -6.0971896 0.003298697 -6.17109038 0.003193358 -8.30233588 







Table SI 5.3f. Temperature dependence of the second-order rate constants, 
𝑘2 (2𝑛𝑑), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCH3Qn) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003411223 -9.18549 0.003411223 -10.24122 0.003354016 -10.7373829 
0.003354016 -8.64131 0.003354016 -9.97444 0.003298697 -10.3737568 
0.003298697 -8.01717 0.003298697 -9.56704 0.003245173 -9.92393518 
0.003245173 -7.35479 0.003245173 -9.17496 0.003193358 -9.69017133 
0.003193358 -6.85434 0.003193358 -8.85581 0.003143171 -9.28191049 
 
Table SI 5.3g. Temperature dependence of the second-order rate constants, 
𝑘2 (2𝑛𝑑), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCF3Qn) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003354016 -6.92968499 0.003354016 -7.21250349 0.003354016 -9.3048933 
0.003298697 -6.55842464 0.003298697 -6.75307388 0.003298697 -8.94371596 
0.003245173 -6.29268965 0.003245173 -6.49021734 0.003245173 -8.61731744 
0.003193358 -6.01963565 0.003193358 -6.24274166 0.003193358 -8.34847626 
0.003143171 -5.72083729 0.003143171 -5.93159127 0.003143171 -8.09089331 
 
Table SI 5.3h. Temperature dependence of the second-order rate constants, 
𝑘2 (2𝑛𝑑), M
−1 s−1 for the displacement of the first aqua ligand in Pt(dCF3Py) by 
thiourea nucleophiles, pH = 2.0, I = 0.1 M (HClO4/NaClO4). 
TU DMTU TMTU 
𝟏 𝐓⁄ , 𝐊−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 𝟏 𝐓⁄ , 𝐊
−𝟏 ln(𝒌𝟐/𝐓) 
0.003354016 -7.08042913 0.003354016 -7.60829774 0.003354016 -9.32225342 
0.003298697 -6.82076324 0.003298697 -7.22648780 0.003298697 -8.89819742 
0.003245173 -6.45131890 0.003245173 -6.91286531 0.003245173 -8.57414989 
0.003193358 -6.16827619 0.003193358 -6.65181158 0.003193358 -8.28614497 





Figure SI 5.4:  Concentration dependence plots of kobs1, s-1, for the displacement of 
the first aqua ligand of Pt(H2Qn) (a) and Pt(dCH3Qn) (b) by thiourea nucleophiles, 
pH = 2.0, T = 298 K, and I = 0.1 M (HClO4/NaClO4). 
 
Figure SI 5.5:  Erying plot for the substitution of the first aqua ligand of Pt(H2Qn) 
(a) and Pt(dCH3Qn) (b) by thiourea nucleophiles, pH = 2.0, and I = 0.1 M 
(HClO4/NaClO4). 
 
  
 
